Synthesis of modified oligonucleotides by Will, David W.
Synthesis of Modified Oligonucleotides 
by 
David W. Will 
A thesis presented for the degree of Doctor of Philosophy 







I wish to thank: 
- my supervisor Dr. Tom Brown for his advice and encouragement; 
- John Grzybowski and Duncan Graham for very useful collaborations; 
- Susanne Ebel for support, advice, encouragement, paying the rent, and 
introducing me to the Teutonic work ethic; 
- my colleagues in the Brown group, who almost made working in the lab 
fun; 
- Dr. Rick Randall of the Biochemistry Department of St. Andrews 
University, for his hospitality and advice at St. Andrews University; 
- the Cetus Corporation for hospitality in California; 
- Dr. Stephen Will of Roche Molecular Systems, for many helpful 
discussions; 
- the OSWEL DNA Service for the use of facilities and reagents; 
- SERC for an earmarked studentship; 
- Edinburgh University, for the use of its excellent facilities. 
Proton, Carbon- 13, and a couple of phosphorus NMR spectra were 
recorded by John Miller and Heather Grant. COSY and nOe spectra were 
recorded by Dr. David Reed and Dr. John Parkinson. FAB-Mass spectra 
were recorded by Alan Taylor. 
Abbreviations. 
A Adenosine 
AAAF N-acetoxy-N2-acetylamino fluorene 
1,5 -AEDANS 5-(2-(Iodoacetyl)aminoethyl)-aminonaphthalene- 1- 
suiphonic acid 
AMPPD Adamantyl monopyridinium phosphate dioxetane 
AP Alkaline Phosphatase 
ATP Adenosine triphosphate 
AZT 3'-Azido-3'-deoxythymidine 
BCIP 5-Bromo-4-chloro-3 -indolyl phosphate 
Bio Biotin 
C Cytidine 
CD4 Cell surface receptor recognised by HIV gp 120 
glycoprotein 
Chol Cholesterol 




DCC N,N'-Dicyclohexyl carbodiimide 
dG 2'-Deoxyguanosine 
Dig Digoxigenin 
DMSO Dimethyl suiphoxide 
DMTr 4'-Dimethoxytrityl 
DNFB 2, 4-Dinitrofluorobenzene 
DNP 2, 4-Dinitrophenyl 
dNTP 2'-Deoxynucleoside triphosphate 
D-ODN Normal phosphodiester-linked oligodeoxynucleotide 
DOTMA N-[ 1 -(2,3 -dioleyloxy)propyl] -N,N,N- 
trimethylammonium chloride 
dU 2'-Deoxyuridine 
dUTP 2'-Deoxyuridine triphosphate 
EDC 1 -Ethyl-3-(3 -dimethylaminopropyl) carbodiimide 
hydrochloride 
EDTA Ethylene diamine tetraacetic acid 
EGTA Ethylene glycol bis (3-aminoethyl ether) N,N,N',N'- 
tetraacetic acid 
FAM Applied Biosystems trade name for fluorescent dye 
shown in Figure 3 of Chapter 1. 
FJTC Fluorescein isothiocyanate 
Fmoc 9-Fluorenylmethyloxycarbonyl 
G Guanosine 
gp 120 HIV glycoprotein involved in viral recognition of cells 
heg hexaethyleneglycol 
HDL High-density lipoprotein 
HIV Human immunodeficiency virus 
HPLC High performance liquid chromatography 
HRP Horseradish Peroxidase 
IgG Immunoglobulin G 
JOE Applied Biosystems trade name for fluorescent dye 
shown in Figure 3 of Chapter 1. 
K3 Code name for anti-DNP antibody 
kDa kiloDalton 
LDL Low-density lipoprotein 
Lys-ODN poly-(L-Lysine)-conjugated oligodeoxynucleotide 
MP-ODN Methyiphosphonate oligodeoxynucleotide 
mRNA Messenger ribonucleic acid 
NAP Nucleic Acid Purification (Sephadex G-25) 




p24 HIV glycoprotein 
PAC Phenoxyacetyl 
PBS Phosphate-buffered Saline 
PCR Polymerase Chain Reaction 
Phth Phthaloyl 
PL-ODN Phospholipid oligodeoxynucleotide 
RNase H Ribonuclease H 
ROX Applied Biosystems trade name for fluorescent dye 
shown in Figure 3 of Chapter 1. 
S -ODN Phosphorothioate oligodeoxynucleotide 
T Thymidine 
TAMRA Applied Biosystems trade name for fluorescent dye 
shown in Figure 3 of Chapter 1. 
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Abstract. 
The 2,4-Dinitrophenyl (DNP) group is a hapten with potential use 
as a simple, inexpensive non-radioactive labelling group for 
oligonucleotides. DNP phosphoramidites have been synthesized which 
allow the attachment of multiple spaced and unspaced DNP groups to 
oligonucleotides during solid-phase DNA synthesis. Results of 
Polymerase Chain Reaction and antibody binding experiments are 
reported. 
A phosphoramidite to introduce multiple hydroxyl functions into 
oligonucleotides has been synthesized. Reaction of the multiple hydroxyl 
functions with single-addition biotin and DNP phosphoramidites during 
solid-phase synthesis allows the introduction of multiple biotin or DNP 
labels onto the oligonucleotides in high yield. 
Two single-addition biotin phosphoramidites have been 
synthesized incorporating benzoyl protection of the biotin moiety, and 
different spacer arm lengths. These were used for the synthesis of 
biotinylated oligonucleotides during solid-phase synthesis. 
In an attempt to increase cellular uptake of antisense 
oligonucleotides Vitamin B, cholesterol and adamantane have been 
attached to oligonucleotides during solid-phase synthesis. Results of 
thermal denaturation studies on lipophilic oligonucleotides are reported. 
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General Introduction 
The automated synthesis of oligonucleotides using solid-phase 
methodology has revolutionized many areas of medicine, molecular 
biology and biotechnology. The potential use of modified 
oligonucleotides as highly sensitive tools for the diagnosis of inherited 
and other diseases, and as 'antisense' pharmaceuticals  for the treatment 
of viral diseases and cancer, continues to fuel interest in this field. 
Unlike solution-phase synthesis, the solid-phase approach precludes 
the need to purify intermediates during oligonucleotide assembly. This 
allows the rapid and inexpensive automated synthesis of oligonucleotides 
up to Ca. 150 nucleotides long. Oligonucleotides which would have taken 
several months to synthesize by solution-phase methods can be 
synthesized in 24 hours by solid-phase methodology. Unlike enzymatic 
synthesis, chemical synthesis allows specific modifications to be made to 
the oligonucleotide at specific sites in a very controlled manner. Such 
modifications include: the insertion of unnatural and rare bases at specific 
sites; modification of the phosphodiester backbone; and the attachment of 
non-nucleosidic residues, such as non-radioactive labels, to the 
oligonucleotide. 
A full review of the development of oligonucleotide synthesis is 
given in a recent review by Beaucage and Iyer2. The organic chemistry 
underlying oligonucleotide synthesis is described in an excellent review 
by Sonveaux3. 
By far the most widely used method of solid-phase oligonucleotide 
synthesis at present is the phosphoramidite method. This allows the very 
rapid synthesis of oligonucleotides (ca. 7 minutes per synthesis cycle) in 
exceptionally high yields (>98.5% per synthesis cycle) on a controlled-
pore glass or polystyrene solid phase. Standard oligonucleotide synthesis 
and purification procedures using the phosphoramidite method are 
described in detail by Brown and Brown4. 
The work described in this thesis had the following general aims: 
To introduce modifications to oligonucleotides using solid-phase 
phophoramidite methodology. 
To design and synthesize compounds of practical and potential 
commercial use to introduce these modifications. This entails the use of 
inexpensive, commercially available starting materials and as few 
synthetic steps as possible to reach the target compounds. 
The introduction of the modifications should require little or no 
change to standard oligonucleotide synthesis and purification conditions. 
The practicality and commercial viability of any potentially useful 
compound is severely impaired if the end-user must make major 
alterations to standard DNA synthesis and purification procedures. 
This thesis is divided into two chapters: 
-Chapter One describes work carried out on the non-radioactive labelling 
of oligonucleotides during solid-phase synthesis. 
-Chapter Two describes the modification of oligonucleotides with 
lipophilic groups in an attempt to enhance cellular uptake of 'antisens& 
oligonucleotides. 
The general approach - the attachment of hydrophobic, non-
nucleosidic groups to the ends of oligonucleotides during solid-phase 
synthesis - is essentially the same in both areas. To enhance readability 
each chapter has its own introduction, results and discussion, 
experimental section and references, 
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The Non-radioactive Labelling of Oligonucleotides during Solid-
Phase Synthesis. 
A. INTRODUCTION 
Non-radioactive labelling of oligonucleotides has attracted much 
interest in recent years as the number of biological and biomedical 
techniques requiring labelled oligonucleotides has increased. The use of 
non-isotopic labels is especially desirable in applications where a large 
number of similar experiments are carried out on a routine basis. Such 
applications include; screening of clinical samples for viral infections or 
genetic diseases, and large-scale automated DNA sequencing. The latter 
application has increased in importance recently with the advent of the 
'Human Genome Project'.1  
The most common technique used for the labelling of 
oligonucleotides is the introduction of a 32p  radiolabel by the action of 
polynucleotide kinase and 'y-32P-dATP. Other radioisotopes such as 
14C, 3H and 1251  can also be used.2 The radiolabelled DNA is detected 
using autoradiography. This technique is extremely sensitive, but has 
several major disadvantages. 
(i) The 32P radioisotope has a half-life of 14.2 days. This requires 
experiments to be carried out very soon after the DNA is labelled. Thus 
repeated labelling of DNA is necessary for long-term experiments. This 
makes this type of labelling time consuming, expensive and hazardous 
due to repeated exposure of the experimentalist to ionising radiation. It 
4 
also introduces an element of variability into experiments, as the specific 
activity of the radiolabelled DNA varies with time and batch. 
(ii) The cost and time required to ensure statutory shielding, monitoring, 
containment, storage, waste disposal and training is often high. 
For these reasons several methods for the non-radioactive labelling of 
oligonucleotides have been developed. 
TIIiRTl I[Th JTllflT 
There are two basic strategies for the non-radioactive labelling of 
oligonucleotides: 
I.I. Directly detectable labelling. 
This involves the covalent attachment of a detectable molecule 
(such as a fluorescent dye), or an enzyme (such as alkaline phosphatase 
or horseradish peroxidase), to the oligonucleotide (Figure 1). Fluorescent 
groups can be detected visually by means of a fluorescence microscopy 
or fluorimetry. Enzymes can be detected by addition of an enzyme 
substrate which produces either a coloured product (which can be 
detected visually or spectrophotometrically), or a light signal via a 
chemiluminescent reaction (which is detected photographically or by a 
charge-coupled device). 
The enzymes which are most commonly used at present are 
alkaline phosphatase (AP) and horseradish peroxidase (HRP). There are a 
variety of substrates commercially available for both enzymes. 
5 
Immobilise Target DNA or RNA on Membrane 
Nitrocellulose or Nylon 




111111 III III III III 111111 III III 
Wash away Non-specifically Bound Oligonucleotide Probe 
Label 
wmm/ 
II 	II til III 	II III III III ill III 	liii 
WmWWWNWW 
Detect 
If Label is a Fluorophore 
-detect by irradiation with light of the appropriate frequency 
If Label is an Enzyme 
-add enzyme substrate to the membrane to produce a 
coloured precipitate or chemiluminescence 
Figure 1: Schematic diagram of a typical hybridisation experiment 
using a directly detectable labelled oligonucleotide probe. 
(not to scale) 
1.2. Indirectly detectable labelling. 
This involves the attachment of a molecule (such as a hapten), which is 
not directly detectable, to the oligonucleotide. Incubation of the hapten-
labelled oligonucleotide with an enzyme-linked antibody to the hapten 
results in the attachment of the enzyme to the oligonucleotide (Figure 
2a). Subsequent addition of an enzyme substrate gives rise to the signal, 
as described in section 1.1. above. It is desirable to attach the labelling 
molecule to the oligonucleotide by means of a spacer arm to minimise 
steric hindrance to antibody-hapten binding.3'4 Figure 2b shows the 
relative sizes (approximately to scale) of an IgG antibody and a 20mer 
oligonucleotide. A variety of methods for increasing the number of 
enzymes bound to the oligonucleotide, and thus the signal intensity and 
sensitivity of detection, are possible using indirect labelling. One such 
method is the use of a primary antibody which binds to the labelling 
molecule, followed by incubation with a secondary antibody-enzyme 
conjugate which binds to the primary antibody. The secondary antibody 
can bind to several sites on the primary antibody, resulting in the indirect 
attachment of several enzyme molecules to the o ligonucleotide. (Figure 
2) 
2.0. Types of labelling grouns and methods of detection 
2.1. Directly Detectable Labelling Groups. 
2.1.1. Fluorescent dyes. 
Oligonucleotides can be covalently labelled with a range of 
fluorescent dyes such as fluorescein, tetramethyirhodamine, Texas Red, 
FAM, ROX, TAMRA, JOE, dansyl and acridine derivatives(Figure 3). 
These dyes are usually attached by reaction of the dye active ester or 
isothiocyanate with an amino-modified oligonucleotide, or by reaction of 
7 
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Figure 2a: Schematic diagram of a typical hybridisation experiment using 
a hapten labelled oligonucleotide probe and a secondary antibody. 
(not to scale). 
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Figure 2b: Relative sizes of a 20mer oligonucleotide and 
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Figure 3: Amine- and Thiol-Reactive Derivatives 
of Fluorescent Dyes. 
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the dye iodoacetamide with a thiol-modified oligonucleotide (described in 
detail in section 3.1.2. of this chapter). Dyes can be chosen which 
fluoresce at different wavelengths, allowing simultaneous detection of 
different oligonucleotides labelled with different fluorophores. This is the 
basis of one type of automated DNA sequencing.59 The use of a single 
fluorophore in automated DNA sequencing is also possible. 10 Fluorescent 
oligonucleotides are also used for in situ hybridisation experiments,11  
where fluorescence microscopy is used to detect the position of the 
hybridised fluorescent oligonucleotide. Cellular uptake of fluorescently 
labelled antisense oligonucleotides can be verified and quantified 
(described in Chapter 2 of this thesis). 
2.1.2. Enzymes 
Direct attachment of Alkaline phosphatase (AP) or Horseradish 
peroxidase (HRP) to oligonucleotides has been achieved by a variety of 
means. 12-15  Colorimetric detection of AP is usually carried out using a 
mixture of 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitro blue 
tetrazolium (NBT), resulting in the production of a blue/purple 
precipitate. 16-19  A much wider choice of substrates is available for the 
colorimetric detection of HRP. Substrates which produce an insoluble 
coloured precipitate, such as 3,3'-diaminobenzidine (DAB), are of use 
where a semi-permanent record of the result is required, such as in in situ 
hybridization. 20  Substrates which produce a soluble coloured product are 
useful where quantitation of the signal is required as the colour can be 
measured spectrophotometrically. 
11 
Chemilumines cent detection has several advantages over 
colorimetric detection: 
The background is theoretically zero. 
Detection is very rapid, typically involving a 20 second exposure to 
photographic film or a charge-coupled device. 
Quantitation of the observed signal is relatively easy using a charge-
coupled device, unlike colorimetric detection where quantitation by 
densitometer is very unreliable. 
The labelled probe can be washed off, allowing several 
hybridisations to be carried out on the same filter-bound sample, unlike 
colorimetric detection where the coloured precipitate cannot normally be 
washed off. 
The oxidation of 3-aminophthalhydrazide (luminol),2124 (Figure 
4) by HRP in the presence of hydrogen peroxide results in 
chemiluminescence. The intensity of this chemiluminescence can be 
increased by the use of certain enhancers (eg. para- hydroxycinnamic 
acid orpara- iodophenol). 
An alternative chemiluminescent reaction is that between the 
dioxetane produced by photooxygenation of 3-phosphate-9H-xanthen-9-
ylideneadamantane, monopyridinium salt (AMPPD) and AP (Figure 
4).25  
This direct approach to labelling has the advantage of speed and 
convenience of detection. The disadvantages are: 
The synthesis and purification of the enzyme-oligonucleotide 
conjugate is expensive and time consuming. 
Only one enzyme can be attached per oligonucleotide 
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(iv)The hybridisation properties of the enzyme-labelled probe may be 
affected. Jablonski et al. found that the melting temperature of an AP-
linked oligonucleotide was 10°C lower than that of an underivatized 
oligonucleotide. 12 
(v) HRP cannot be used in hybridisation experiments requiring incubation 
at >420C, as it loses activity rapidly on heating above this temperature.21  
2.2 Indirectly Detectable Labelling Groups. 
2.2.1. Biotin 
Biotin (Figure 5) forms a high affinity complex with the egg-white 
glycoprotein avidin and with the non-glycosylated bacterially-derived 
protein streptavidin both of which have four biotin binding sites.25 The 
method of detection involves incubation of the biotinylated 
oligonucleotide with an avidin (or streptavidin)-enzyme conjugate. This 
results in the formation of an oligonucleotide-biotin-avidin-enzyme 
complex which is then incubated with the appropriate enzyme substrate to 
give a colorimetric or chemiluminescent signal. Anti-biotin antibodies can 
also be used for detection. 3,20,27  Although these antibodies have a lower 
affinity for biotin than (strept)avidin (Kd10 12 M compared to 10 15M 
for streptavidin), the use of a secondary antibody-enzyme conjugate 
allows enhancement in sensitivity. However, biotin is a very expensive 
hapten and much simpler and less expensive haptens could be used. The 
synthesis of derivatives of biotin is made difficult by its insolubility in 
most solvents. Biotin is unsuitable for use in certain in situ hybridization 
applications due to the high level of endogenous biotin found in some 
tissues and samples of biological origin. 
14 
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Figure 5: The three most common groups for indirectly detectable 
labelling of oligonucleolides 
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2.2.2. Digoxigenin. 
Digoxigenin28'29 (Figure 5) has become the leading alternative to 
biotin for use in in situ hybridization experiments where high levels of 
endogenous biotin cause high background signal problems. It does not 
occur naturally in clinical samples and therefore does not give rise to an 
undesirable background. It is detected immunogenically, using anti-
digoxigenin polyclonal antibodies conjugated to AP. The sensitivity of 
detection of digoxigenin is comparable to that of biotin in DNA 
containing multiple digoxigenin groups. Digoxigenin is expensive, and 
the synthetic routes to its derivatives are complex due to the 
multifunctionality of the molecule.4  
2.2.3. The 2,4-Dinitrophenyl (DNP) Group. 
The 2,4-Dinitrophenyl (DNP) group (Figure 5) is an attractive 
labelling group for the following reasons: 
It is small. This minimises the possibility of interference with 
oligonucleotide hybridization. 
It is inexpensive (unlike biotin and digoxigenin). 
It is chemically simple (unlike digoxigenin). 
It is extremely immunogenic. Very high affinity anti-DNP antibodies 
are commercially available from a number of sources. 
The DNP group is not found in vivo. 
So far the practical and commercial applications of this labelling group 
have not been fully investigated. The methods used previously for 
introduction of the DNP group are: 
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Reaction of 1 -(2,4-dinitrophenylamino)-6-aminohexane with DNA 
which had been treated with N-bromosuccinimide. The bromine atoms on 
the modified bases generated in this way were displaced by the free 
amine resulting in a spaced DNP adduct.30 
Enzymatic incorporation of 8-aminohexyl adenosine triphosphate 
follow by reaction of the amino-modified DNA with 2,4-
dinitrofluorobenzene, or enzymatic incorporation of 8-(2,4-
dinitrophenylamino)hexyl adenosine triphosphate.31  
Photochemical attachment of a DNP-aryl azide.32 
2.2.4. N-Acetoxy-N2acetyl amino fluorene. (AAAF) 
This group and it's 7-iodo derivative have been incorporated into 
DNA by direct reaction with the 8-position of purines and detected using 
an anti-AAAF antibody followed by a secondary antibody-AP 
conjugate.3334  The potential use of this labelling group is limited due to 
the carcinogenicity of AAAF and its derivatives. 
2.2.5.Phosphotyrosine. 
This group has been incorporated into oligonucleotides using a 
phosphotyrosine phosphoramidite.27 It was detected using commercially 
available anti-phosphotyrosine antibody followed by a secondary 
antibody-HRP conjugate. The use of this label for nucleic acid detection 
has only been reported once, and its general applicability has yet to be 
demonstrated. 
2.2-6-Fluorescein. 
As well as its use as a fluorescent reporter group, fluorescein can 
also be detected using anti-fluorescein antibodies.35  
17 
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3.1. Post synthetically. 
Post synthetic methods of introducing non-radioactive labels into 
oligonucleotides are the most commonly used at present. They involve 
the synthesis and purification of the oligonucleotide to be labelled, 
followed by an enzymatic or chemical reaction to link the label to the 
oligonucleotide. The labelled oligonucleotide then has to be purified. The 
post-synthetic reactions are not suitable for automation, making the 
routine synthesis of labelled oligonucleotides a time-consuming task. 
3.1.1 .Enzymatic Labelling of Oligonucleotides. 
Modified nucleoside triphosphates carrying the labelling group can 
be incorporated into oligonucleotides via enzymes such as 
deoxynucleotidyl terminal transferase which attaches a 'tail' of ribo- or 
deoxyribo-nucleotides at the 3'-end of oligonucleotides.35 The most 
commonly used modified nucleoside triphosphates are the commercially 
available 5 -(N-(N-biotinyl-E-aminocaproyl)-3 -amino-allyl) uridine 5'-
triphosphate (Bio-1 l-UTP), and 5-((N-biotinyl)-3-amino-allyl) uridine 5'-
triphosphate (Bio-4-UTP) and their 2'-deoxyuridine analogues3'35-37  
(Figure 6). Biotinylated derivatives of 8-aminohexyl adenosine 5'-
triphosphate are also commercially available. The DNP derivative of 8-
aminohexyl adenosine 5'-triphosphate has been successfully incorporated 
into DNA.31  Digoxigenin can be enzymatically incorporated into DNA 
using Digoxigenin-O-succinyl-E-aminocaproyl- [5- (3 -aminoallyl)-2'-deoxy 
uridine-5' -triphosphate] (Dig- 11 -dUTP), and Digoxigenin-O-succinyl- [5-
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Cosstick et al. introduced a single 2'-deoxycyti dine -5'-phosphate-
3'-thiophosphate coupled to bimane via the thiophosphate into RNA by 
the action of T4 RNA ligase.38  
Other enzymatic methods of introducing modified bases into DNA, 
such as nick translation and random priming are not generally applicable 
to synthetic oligonucleotides and are described in detail by Keller and 
Manak.2 
The enzymatic labelling of oligonucleotides is not feasible on a 
large scale and is expensive and time-consuming. 
3.1 .2.Chemical Labelling of Oligonucleotides. 
Post synthetic chemical labelling of oligonucleotides was, until 
recently, the most widely used technique for the attachment of reporter 
groups to oligonucleotides, and for some labelling groups it is still the 
only method available. The general approach is the attachment of a 
reactive group (usually a nucleophile such as an aliphatic amine or thiol) 
to the oligonucleotide either during or after solid-phase synthesis, and 
subsequent reaction of the reactive group with an activated labelling 
molecule. 39 
3.1.2.1. Amino-modification of oligonucleotides. 
The most common method of chemical labelling is the attachment 
of a linker molecule containing a primary aliphatic amino function to the 
oligonucleotide, followed by reaction with an amino-reactive labelling 
molecule, such as an active ester or isothiocyanate, or with an enzyme. 
Urdea et. al. have reported a variety of useful protocols for the 
attachment of amine reactive labels to amino-modified 
oligonucleotides. 15 
The standard method of introducing a primary amino moiety onto 
the 5'-end of oligonucleotides is via commercially available 
'AMINOLINK 2' (Figure 7a).40 This is the 2-cyanoethyl 
phosphoramidite of 1 -trifluoroacetylaminohexan-6-ol. This can be reacted 
with a huge variety of amine-reactive labelling groups such as fluorescein 
isothiocyanate (FITC), active esters and isothiocyanates of other 
fluorophores, biotin-N-hydroxysuccinimide ester, and digoxigenin N-
hydroxysuccinimide ester.41  A large number of very similar compounds 
based on H2N(CH2)nOH has also been synthesized, including: 
-The methyl phosphoramidite of N-(monomethoxytrityl)-3-amino propan-
1 -ol was prepared and used by Connolly42 to synthesize biotinylated and 
dansylated oligonucleotides. 
-Tanaka et at. synthesized a phosphotriester monomer of N-
(monomethoxytrityl)-2-amino ethanol.43  
-Coull et al. synthesized the 2-cyanoethyl phosphoramidite of N-
(trifluoroacetyl)- 1-amino ethanolA 
-Agrawal et al. synthesized the 2-cyanoethyl phosphoramidite of N-
Fmoc-aminoethanol.45  
-Kaiser et al. synthesized N-Fmoc protected aminoethanol and 6-amino-
hexan- 1-01 phosphoramidites.8  
-Sinha and Cook synthesized phosphoramidites and hydrogen-
phosphonate monomers of N-trityl 6-amino-hexan- 1 -ol.46  
-Bannwarth et at. synthesized the 2-cyanoethyl phosphoramidite of N-
(monomethoxytrityl)-aminopropan-3-ol which was reacted with the NHS 
active ester of a fluorescent bathophenanthroline-ruthenium (II) 
complex.47  
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-Agrawal synthesized a methyiphosphonate monomer of N-Fmoc-6-
amino hexan-1 -ol. This was to be used in the study of cellular uptake of 
methyiphosphonate oligonucleotides.48  
Multiple amino functions have been incorporated into 
oligonucleotides using a simple 1 -amino-propane diol based 
phosphoramidite (Figure 8). 49 This was used to synthesize an 
oligonucleotide probe containing up to five biotins, however no 
comparison between the sensitivity of detection of this probe and a singly 
biotinylated probe is reported. This backbone was also used to produce an 
amino-functionalized controlled-pore glass for the synthesis of 3'-
aminomodified oligonucleotides.50 
Smith et al. used a protected 5'-amino-5'-deoxythymidine 
phosphoramidite to introduce a single amino function at the 5'-end of 
oligonucleotides.5 This was then used to produce sequencing primers 
labelled with four spectrally resolved fluorophores. These were to be used 
in automated DNA sequencing. An analogous approach was used by 
Sproat et al. to synthesize all four 5'-amino-2',5'-dideoxynucleoside 
phosphoramidites for attachment of Iridium complexes and other labels to 
oligonucleotides51  (Figure 8). Manoharan et al. incorporated multiple 
amino functions into oligonucleotides during solid-phase synthesis by 
means of a protected 2'-O-alkylaminoribonucleoside phosphoramidite.52 
These were then used to attach a variety of labelling groups to 
oligonucleotides, as well as cholic acid in an attempt to enhance cellular 
uptake of 'antisense' oligonucleotides. 
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-the carbodiimide coupling of a protected aminoalkyl phosphonate to the 
5'-hydroxyl group of oligonucleotides was carried out by Kansal et al. 53 
-the formation of 5'-phosphorimidazolide of an oligonucleotide by a 
carbodiimide coupling, followed by reaction with an alkyl diamine to 
form a 5'-aminoalkyl phosphoramidate.26' 54  
-oxidative amination of a hydrogen-phosphonate internucleoside linkage 
with N-i -(trifluoroacetyl)-hexane diamine.5557 
-reaction of the 5'-hydroxyl group with the bifunctional reagent 
carbonyldi-imidazole (a phosgene equivalent) followed by reaction with 
hexane diamine gave a carbamate-linked amine. The carbamate linkage 
was found to be stable to ammonia deprotection conditions.58 
The solid-phase synthesis of oligonucleotide-peptide conjugates on 
a controlled-pore glass solid support has been carried out by 
Haralambidis et. al. 59,60  Oligonucleotides labelled with various numbers 
of lysine residues were labelled with multiple biotin and fluorophore 
residues. This approach to labelling requires the use of both a peptide 
synthesizer and a DNA synthesizer, and is thus not of practical use for 
non-radioactive labelling. 
In spite of its expense the introduction of primary amino functions 
into oligonucleotides via modified nucleosides has been used quite 
frequently. Such modified nucleosides include of C-5 aminoalkyl or 
aminoallyl 2'-deoxyuridine derivatives (Figure 9), 61-64  N-4 aminoalkyl 
deoxycytidine derivatives (Figure 9), 15,65,66  C-8 aminoalkyl 
purines31 '35 and N6-aminoalkyl (2'-deoxy)adenosine.35  
One advantage of the use of 5'-non-isotopically labelled 
nucleotides is that it is possible to introduce 5'-radiolabels onto the 
oligonucleotide using polynucleotide kinase. However the efficiency of 
25 
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enzymic radiolabelling is lower in the presence of the modified 5'-
terminal nucleotides.66  
The modified nucleoside approach to the introduction of primary 
amino functions allows the multiple internal labelling of oligonucleotides 
as well as end labelling. However the sensitivity of detection of internal 
biotin labels has been shown to be less than that of biotin attached at the 
3'- or 5'- end of oligonucleotides.64 
The effect on oligonucleotide hybridisation of the modifications to 
the bases is also a problem.64'67'68 Telser et. al. showed that 
oligonucleotides containing N-4 aminoalkyl substituted deoxycytidine 
derivatives gave biphasic melting curves, and those containing C-5 
aminoalkyl 2'-deoxyuridine derivatives were destabilised relative to 
unmodified oligonucleotides.67 In addition, this approach to labelling is 
expensive, mainly due to the cost of the deoxynucleotide precursors. 
3.1.2.2. Thiol-modified oligonucleotides. 
The next most common method of chemical labelling is the 
attachment of a thiol group, a thiophosphate or a phosphorothioate-diester 
intemucleoside linkage to the oligonucleotide, followed by reaction with 
sulphur-reactive labelling molecules, such as maleimides, iodo(or 
bromo)acetamides, y-bromo-a, n-unsaturated carbonyls, and aziridinyl 
sulphonamides (Figure 3), or with disulphide-containing or 
bromoacetylated enzymes. 
The attachment of thiols to the 3'-end of oligonucleotides has been 
achieved during solid-phase synthesis using functionalised solid 
supports.69-72 In all these cases the thiol was protected as a disulphide 
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during oligonucleotide synthesis. After synthesis and deprotection the 
disulphide was cleaved when required using dithiothreitol. Bonfils and 
Thuong69 synthesized oligonucleotides containing a 3'-disulphide-
protected thiol and a 5'-thiophosphate. This allowed the labelling of the 
5'-thiophosphate using 5 -iodoacetamidofluorescein (Figure 3). 
Subsequent treatment of the fluorescent oligonucleotide with 
dithiothreitol gave a free thiol to be used to conjugate the oligonucleotide 
to proteins. Gupta et al. 70  synthesized fluorescent oligonucleotides by 
reacting 5 -(2-(iodoacetyl)aminoethyl) aminonaphthalene- 1 -suiphonic acid 
(1,5-1-AEDANS) (Figure 3) with the 3'-thiol generated using their 
disulphide solid-support. Li et al. 71  synthesized an N-4-aminoethyl-2'-
deoxycytidine derivatized solid support. This was used to synthesize 3'-
amino-modified oligonucleotides. On reaction with dithio-bis-propionyl-
N-hydroxy succinimide and treatment with DTT these were converted to 
3'-thiol modified oligonucleotides which were conjugated to alkaline 
phosphatase which had been bromoacetylated using bromoacetic acid N-
hydroxysuccinimide ester. Zuckermann et al. 72  used 3'-derivatised 
thymidine on a solid support to form 3'-thiol-containing oligonucleotides. 
Enzymatic tailing at the 3'-end with 4-thio-2'-deoxyuridine and reaction 
with sulphur-reactive fluorophores has been carried out by Eshaghpour et 
al. 73 
The synthesis of 5'-thiol modified oligonucleotides has been carried 
out using a protected thiol phosphoramidite (Figure 7b)74 and hydrogen 
phosphonate monomers46 based on S-trityl-mercaptoalkanols. The trityl 
group was removed after synthesis using silver ions to give the free thiol 
which on reaction with biotin maleimide or a variety of sulphur-reactive 
fluorophores gave labelled oligonucleotides. Saiki et al. used the 2-
cyanoethyl phosphoramidite of an S-trityl mercaptan derivative made 
from tetraethylene glycol to introduce a free thiol onto the 5'-end of 
oligonucleotide probes. 14  The thiol was then reacted with maleimido 
derivatised HRP to give HRP labelled oligonucleotides. Sproat et al. 
synthesized all four base protected 5 '-(S -trityl)mercapto-2',5 
dideoxyribonucleoside 3'-O-(2-cyanoethyl) N,N-diisopropyl 
phosphoramidites75 (Figure 8). The 5'-thiol generated on treatment of the 
oligonucleotide with silver nitrate was reacted with 5-
iodoacetamidofluorescein to generate fluorescently labelled 
oligonucleotides. Kumar et al. synthesized 5'-thiol modified 
oligonucleotides by reaction of a 5'-amino modified oligonucleotide with 
N-acetyl -DL-homocysteine-thiolactone.76 The resulting thiol 
oligonucleotides were fluorescently labelled with N-(3 -pyrenyl)-
maleimide. A similar approach was used by Gaur et al., 77  who reacted 
N-succinimidyl-3 -(2-pyridyldithio)-propionate with a 5'-amino modified 
oligonucleotide. Subsequent treatment with DTT liberated the thiol, as 
confirmed by the release of pyridine-2-thione. Murakami et al. 78 
synthesized AP-oligonucleotide conjugates by the carbodiimide coupling 
of a 5'-phosphate oligonucleotide to cystamine. Cleavage of the resulting 
5'-disulphide with DTT and reaction of the thiol with disulphide-modified 
AP gave the desired product. This approach was first used by Chu and 
Orgel to synthesize oligonucleotides conjugated to a number of proteins, 
including peroxidase.54  
The chemical reactivity of phosphorothioate-diester-containing 
oligonucleotides has been exploited by Fidanza and McLaughlin79 to 
give 'backbone labelled' oligonucleotides. The number and position of the 
phosphorothioate moieties can be varied to allow the incorporation of 
multiple labelling groups. Phosphorothioate oligonucleotides were 
labelled with the PROXYL spin-label via its iodoacetamide; with dansyl 
groups by reaction with N-dansyl aziridine or 1 ,5-I-AEDANS (Figure 3) 
and with a y-bromo-a,[3-unsaturated carbonyl-based drug molecule 8O 
Agrawal and Zamecnik56 synthesized oligonucleotides containing two 
different labels by the use of oligonucleotides containing both a 
phosphorothioate-diester intemucleoside link and an aminoalkyl 
phosphoramidate link. Successive reaction of the modified 
oligonucleotide with a sulphur-reactive labelling molecule, such as 
monobromobimane (Figure 3), then with an amine-reactive label, such as 
FITC or biotin-NHS ester, resulted in heterobifunctionally labelled 
oligonucleotides. 3 '-Thiophosphate residues have been incorporated into 
RNA by the action of RNA ligase, and reacted with monobromobimane 
to produce fluorescently labelled RNA.38  
3.1.2.3. Attachment of a 5 '-(5 '-linked ribonucleotide) to oligonucleotides 
This novel approach was carried out by Agrawal et al., who 
introduced a single 5'-(5'-linked ribonucleotide) into oligonucleotides 
during solid-phase synthesis45 (Figure 10). The resulting 2'-3'-cis -diol 
was oxidized to the dialdehyde by sodium periodate. Reaction with biotin 
hydrazide, followed by reduction with sodium borohydride resulted in the 
attachment of a 5'-biotin moiety to the oligonucleotide. 
All the procedures described above suffer from the incompatibility 
between the solubility of the labelling molecule and the oligonucleotide. 
This often results in low yield of the labelled oligonucleotide. In addition, 
the modifications to standard oligonucleotide synthesis and purification 
procedures,81  as well as the post synthetic manipulations involved in the 
labelling reactions, add considerably to the time and cost of routine 
oligonucleotide labelling. 
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3.1.3. Photochemical Labelling of Oligonucleotides 
Another post-synthetic method of introducing labels into an 
oligonucleotide is via photoactivatable aryl azides. UV irradiation of a 
mixture of the label covalently linked to an aryl azide and the 
oligonucleotide results in the formation of a nitrene which reacts with the 
heterocyclic bases thereby attaching the labelling group to the 
oligonucleotide. The major disadvantage of this method is that the 
attachment of such a bulky group to the bases of the DNA in an 
uncontrolled manner is likely to inhibit hybridisation. Biotin can be 
attached to DNA using 'Photobiotin'82, digoxigenin by 
Photodigoxigenin'4 and the DNP group by 'Photo-DNP'32 (Figure 11) 
There is one report of a similar, but non-photochemical method of 
labelling oligonucleotides by the action of a diazonium salt of a biotin 
derivative 83 
3.2. Introduction of Labels during Solid-Phase Oligon ucleotide 
Synthesis. 
The incorporation of the labelling group during the synthesis of the 
oligonucleotide is the quickest and most convenient way of introducing a 
non-radioactive label. After the synthesis is complete the labelled 
oligonucleotide is cleaved from the solid support, deprotected and 
purified. Another advantage of this approach is that the HPLC and gel 
electrophoretic properties of the labelled oligonucleotide are likely to be 
very different from those of unlabelled failure sequences, making 
purification relatively easy. This approach also makes it possible to attach 
multiple labels to the oligonucleotide in a controlled manner, in order to 
increase the signal and thus improve the sensitivity of detection. 
Multiple labels have been introduced to the 3'- and 5'-OH end of 
oligonucleotides, and single labels have been introduced to the 5'-OH 
end. 
3.2.1. Single Labelling 
The 5'-OH end of oligonucleotides has been successfully labelled 
with a single biotin group during solid-phase synthesis using the biotin 
phosphoramidite monomers described below. (Figure 12). 
Alves et al. 85  synthesized methyl-morpholino biotin 
phosphoramidites by reduction of the methyl ester of N-i' dimethoxytrityl 
and N-i '-tetrahydropyranyl biotin, Phosphitylation of the resulting N-i 
protected biotinol gave the pho sphorami dite. (Figure 12). The insolubility 
of biotin derivatives in organic solvents was overcome by the protection 
of N-i' of the ureido ring of biotin to increase the lipophilicity of the 
compound. The yield for the protection reactions were, however, only 
.-40%, making this a rather expensive method of producing a 
phosphoramidite monomer for labelling. In addition the phosphoramidites 
were insoluble in acetonitrile. 
Cocuzza86 synthesized a 2-cyanoethyl- 
diisopropylphosphoramidite of biotin in two steps by reaction of biotin N-
hydroxysuccinimide ester with p-aminophenethyl alcohol followed by 
phosphitylation. The resulting phosphoramidite (Figure 12) is not 
protected at N-i', and was found to be insoluble in acetonitrile. In 
addition, the presence of an aromatic amide in the linker arm necessitated 
care in the ammonia deprotection step of oligonucleotide synthesis. 
Building on the above work, Pon87 synthesized the biotin 
phosphoramidite which has become the standard for introduction of biotin 
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to o ligonucleotides (Figure 12). Biotin was attached to 6-amino-1-tert - 
butyldimethylsi lyihexan- 1-01 using a carbodiimide coupling reaction. The 
resulting compound was reacted with 4,4'-dimethoxytrityl chloride to give 
the N-i' dimethoxytrityl analogue. The silyl ether was cleaved with 
TBAF, and subsequent phosphitylation gave the phosphoramidite. This 
phosphoramidite was soluble in acetonitrile, and was used under standard 
oligonucleotide synthesis conditions. The presence of the dimethoxytrityl 
group allows the coupling efficiency to be monitored. This was found to 
be around 95%, considerably higher than yields obtained by post-
synthetic biotinylation methods described above. This phosphoramidite is 
commercially available (Cambridge Research Biochemicals). 
The 5'-OH end of oligonucleotides has been labelled with a single 
DNP group using a 2-cyanoethyl-diisopropyl phosphoramidite monomer 
synthesized in this group88 (Figure 12). The monomer was soluble in 
acetonitrile, and standard DNA synthesis conditions were used. Coupling 
efficiences were estimated by HPLC to be >97%. The label was found to 
be stable to ammonia deprotection conditions. Ultraviolet-melting studies 
showed that the attachment of this label had no effect on oligonucleotide 
hybridisation. 
A simple fluorescein phosphoramidite has been synthesized by 
Schubert et al. 89  and used for the fluorescent labelling of 
oligonucleo tides during solid-phase synthesis (Figure 12). 
A phosphoramidite of a Bathophenanthroline-Ruthenium (H) 
complex has been successfully used by Bannwarth and Schmidt to 
fluorescently label oligonucleotides.90 The complex was used as solution 
in acetonitrile with a 10 minute coupling time. The complex was found to 
be stable to DNA synthesis conditions. 
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3.2.2. Multiple Labelling. 
Multiple labelling of oligonucleotides with a variety of groups has 
been achieved by Roget et al. 91  using a modified nucleoside 
approach. (Figure 13a). Dansyl, pyrenyl, biotinyl and dinitrophenyl 
derivatives of N-4 aminohexyl deoxycytidine derivatives have been 
synthesized and converted to 2-cyanoethyl-diisopropyl phosphoramidites. 
These were then used in the synthesis of oligonucleotides and gave 
coupling efficiencies of >97%. The DNP-labelled oligonucleotides were 
found to be unstable to the normal base deprotection conditions (5 hours 
at 55°C in NT-140H), liberating 2,4-dinitrophenol. This necessitated the 
use of more base-labile base protecting groups on the DNA synthesis 
monomers.92 The biotin- and dansyl-labelled oligonucleotides were 
found to be stable to normal base deprotection conditions. The biotinyl 
moiety was unprotected and this probably limits the use of this 
phosphoramidite to the introduction of biotin labels at the 5'-end of 
oligonucleotides as side reactions at N-i' are likely to occur on exposure 
to repeated oligonucleotide synthesis cycles.93  
A similar approach has been used by Pieles et al. 93  to introduce 
multiple biotin labels into 2'-O-methyl- and 2'-O-allyl-oligoribo 
nucleotides for use in the capture of RNA binding proteins (Figure 13b). 
The N- 1' of the biotin is protected by a 4-tert-butyl benzoyl group. This 
allowed the synthesis of oligoribonucleotides biotinylated at the 3'-end. 
Attempts to synthesize the same sequences using an unprotected biotin 
phosphoramidite resulted in substantial side reactions and chain 
branching. This side-reaction problem is much worse for 
oligoribonucleotide synthesis than for standard oligodeoxyribonucleotide 
synthesis due to the extended coupling time and the more efficient 



















Figure 13: Nucleoside-based Labelling Phosphoramidites. 
(a) Roget et al. (ref. 91), (b) Pieles et al. (ref. 93). 
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The major drawbacks of both these methods, and of the modified 
nucleoside approach in general, are the expense of the starting materials 
and the large number of steps involved. 
An alternative approach to the synthesis of labelling 
phosphoramidites has been used by Misiura et al. 27  Multiple biotin and 
phosphotyrosine groups were incorporated in oligonucleotides using a 
non-nucleoside phosphoramidite based on a 3-carbon glyceryl backbone 
(Figure 14). The anion of solketal was reacted with acrylonitrile, and the 
resulting 2-cyanoethyl solketal was reduced to 3-aminopropyl solketal 
using NaBH4/CoC12 This amine was then used as the basic framework 
to synthesize both a biotin and a phosphotyrosine phosphoramidite. 
Reaction with Biotin-N-hydroxysuccinimide ester, followed by removal 
of the isopropylidene group with aqueous HC1, dimethoxytritylation of 
the primary hydroxyl, and phosphitylation of the secondary hydroxyl, 
gave the biotin phosphoramidite (Figure 14a). An analogous procedure 
was used to synthesize the phosphotyrosine phosphoramidite (Figure 
14b), however the amine was reacted with the pentaflo rophenyl ester of 
protected L-tyrosine, instead of the biotin active ester. 
Standard streptavidin-AP conjugate detection showed 
disappointingly that oligonucleotides carrying multiple biotin labels gave 
the same detection sensitivity as those carrying a single biotin, even when 
the biotin residues were spaced apart using thyminidyl residues. This was 
attributed to the large size of streptavidin preventing binding of more than 
one streptavidin molecule to the group of biotin labels. Detection using an 
anti-biotin antibody followed by a secondary antibody-AP conjugate gave 
an enhanced signal for multiply biotinylated oligonucleotides. The reason 
for the enhanced signal when using anti-biotin antibody but not 
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Detection of phosphotyrosine labelled oligonucleotides was carried 
out using an anti-phosphotyrosine antibody followed by a secondary 
antibody-AP conjugate. The sensitivity of phophotyrosine detection was 
approximately 10 times lower than that of biotin, and the signal strength 
on increasing the number of labels did not rise as dramatically as for the 
biotin/anti -biotin antibody system. 
Theisen et al. 94  have recently synthesized a multiple addition 5-
carboxyfluorescein phosphoramidite (Figure 14c ) using the same 
backbone as that used by Misiura et al. 27  This monomer is soluble in 
acetonitrile, and requires minimal changes to the oligonucleotide 
synthesis cycle for optimal coupling. 
As with all phosphoramidites based on the 1,2-diol system of 3-
aminopropyl solketal, the oligonucleotides must be synthesized with the 
5-0-dimethoxytrityl group in place (Trityl-ON synthesis) to prevent label 
cleavage by attack of the free primary hydroxyl on the adjacent 
phosphodiester moiety under ammonia deprotection conditions. 
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4.0. Aims. 
It is clear from the work described in this introduction that the 
future of non-radioactive labelling of oligonucleotides lies in the 
introduction of labels as phosphoramidites during automated solid-phase 
synthesis. The aim of the project described in this chapter was to develop 
inexpensive non-nucleoside phosphoramidite monomers for the routine 
synthesis of mono- and poly-labelled oligonucleotides. 
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B. RESULTS AND DISCUSSION. 
5.0. Synthesis of 24-Dinitrophenvi -contain ing Phosphoramidites and 
their Use in Oligonucleotide Synthesis and Detection. 
The basic requirements for a starting material for a 
phosphoramidite monomer suitable for poly-labelling of oligonucleotides 
with DNP groups are: 
It must contain at least one primary or secondary amino group for the 
attachment of the labelling group. 
It must contain two hydroxyl functions, one for the attachment of the 
dimethoxytrityl group, the second for the phosphoramidite. 
A suitable starting material for a DNP labelled monomer was found 
to be bis-(2-hydroxyethyl)-ethylene diamine (Scheme 1). This molecule 
has the following advantages: 
It contains two secondary amino functions, allowing the attachment of 
two DNP groups (or other labelling groups) to the molecule, thus two 
labels are attached to the oligonucleotide per addition during synthesis. 
It is achiral. 
It is inexpensive. 
The hydroxyl groups are at opposite ends of the molecule, 
minimising any possibility of steric interaction between the bulky 
dimethoxytrityl group and the phosphoramidite group which may 
interfere with coupling. 
It is unlike any other molecule previously used to label 
oligonucleotides, and is thus unlikely to infringe existing patents. 
The main disadvantage of this molecule is that it contains two primary 
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and the bis-(dimethoxytrityl) product [2a] is formed in addition to the 
required mono-(dimethoxytrityl) product [2]. It was decided to attempt 
the synthesis of a DNP labelled monomer based on this backbone. 
5.1. Chemical Synthesis. 
The synthetic route used is shown in Scheme]. 2,4-dinitro-
fluorobenzene (DNFB; Caution:Highly Toxic) was added to the starting 
material in the minimum volume of methanol in the presence of 
triethylamine to neutralise the HF generated in the reaction. The reaction 
was complete after 3.5 hours and the product crystallised from the 
reaction mixture. The product [1] was filtered-off and recrystallised from 
methanol. Larger single crystals of [1] were grown from diluted portions 
of the supersaturated hot liquor from the third recrystallisation. These 
crystals were used by Dr. Gordon Leonard to obtain an X-Ray crystal 
structure of [1] (Figure 15). The molecule was found to have an inversion 
centre, with the two DNP groups in an "anti" configuration with respect 
to each other. This increases the chances of antibodies binding to the 
DNP groups as there is no interaction between them. Any interaction 
between the DNP groups would be likely to impare antibody-hapten 
recognition and inhibit antibody binding. 
The tritylation of [1] using 1 equivalent of dimethoxytrityl chloride 
in anhydrous pyridine resulted in a mixture of [1], [2], and the bis-(4,4'-
dimethoxytrityl) adduct [2a], even when a dilute solution of 
dimethoxytrityl chloride in pyridine was added dropwise over several 
minutes. It was decided to add 1.3 equivalents of dimethoxytrityl chloride 
to give a mixture of predominantly [2] and [2a]. These products are 
readily distinguished by tic and are easily separated by flash 
chromatography. It may be possible to carry out a controlled deprotection 
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of [2a] to generate [2] using a mild acid treatment, or alternatively [1] 
could be regenerated from [2a] by treatment with trichioroacetic acid, 
although this was not attempted. 
The phosphitylation of [2] was carried out in anhydrous 
tetrahydrofuran using 2-cyanoethyl N ,N-di-isopropylphosphoramido-
chioridite. The reaction gave one product on tic and after a rapid aqueous 
work-up this was purified by flash chromatography, using an eluent 
containing 1 % triethylamine. The product [3] was obtained as a bright 
yellow foam. Oligonucleotide syntheses carried out using this foam gave 
coupling efficiencies which ranged from 88% to 95%. However, when 
this foam was dissolved in a minimum volume of dichioromethane and 
precipitated from hexane at 780C, the resultant yellow powder gave 
coupling efficiencies of around 97%. This increase in coupling efficiency 
is probably due to the removal of residual triethylamine and other minor 
impurities which are left in solution in the hexane after precipitation. 
5.2. Oligonucleotide Synthesis using Standard DNA Synthesis 
Monomers. 
Compound [3] was found to be insoluble in anhydrous acetonitrile, 
the standard solvent for DNA synthesis monomers. Attempts to use 
anhydrous dimethylformamide as solvent gave low coupling efficiencies, 
and finally anhydrous dichioromethane was found to be the solvent of 
choice. To test for possible adverse effects of using dichioromethane as a 
solvent, a test sequence d(CpCpCpCpT) was synthesized using normal 
dC monomer dissolved in anhydrous dichioromethane. Average coupling 
efficiencies were found to be 98-99%, indicating that the use of 
dichioromethane as a solvent would not adversely affect coupling 
efficiency during DNA synthesis. 
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A series of short test sequences were synthesized to assess the 
coupling efficiency of [3] and to test its stability to standard synthesis and 
deprotection conditions. The synthesis cycle used was the standard ABI 
cycle used for 0.2 imole scale DNA synthesis, with a normal 30 second 
coupling time. The DNP monomer [3] was used as a 0.15M solution in 
anhydrous dichloromethane and its coupling efficiency, determined by 
analysis of released dimethoxytrityl cations, was 97%. After cleavage 
from the solid support and ammonia deprotection the bright yellow 
oligonucleotides were analysed by HPLC. 
5.3. HPLC analysis of DNP-oligonucleotides. 
Oligonucleotides carrying DNP-groups were analysed and purified 
by reversed-phase HPLC. The HPLC characteristics of oligonucleotides 
containing the hydrophobic DNP labels were very different to those of 
unlabelled failure sequences. The DNP oligonucleotides had retention 
times between 5 and 15 minutes longer than unlabelled oligonucleotides, 
depending on the number of DNP groups incorporated. Oligonucleotides 
containing more than two DNP groups failed to elute from the HPLC 
column under normal oligonucleotide HPLC purification conditions (A 
gradient of 0-20% acetonitrile in 0.1 M ammonium acetate). Thus it was 
necessary to increase the final acetonitrile concentration to 65%. The 
labelled oligonucleotides were bright yellow, making identification of the 
product relatively easy. 
5.4. Stability of the DNP label to synthesis and deprotection 
conditions. 
It is clear from the HPLC chromatograms shown in Figure 16 (a), 
(b) that the desired labelled oligonucleotides (labelled [A]) were present 
in low yield. This is inconsistent with the 97% coupling efficiency 
measured for [3] in these syntheses and it was clear that degradation of 
the DNP label had occurred during ammonia deprotection, resulting in the 
formation of a hydrophobic impurity (labelled [H])  and several peaks at 
shorter retention times. To confirm that the ammonia deprotection was 
responsible for the degradation of the label, the product (peak [A]) 
[3]pApGpCpT from Figure 16(a) was collected and subjected to a 17 
hour treatment with concentrated ammonia solution at 550C. The results 
of this experiment are shown in Figure 17 (a)&(b). Obviously severe 
degradation of the DNP label had occurred. The synthesis of a DNP4 
PCR primer 22mer was attempted, but the mixture of failure sequences 
and degradation products made HPLC purification impossible. It appears 
that the use of this DNP monomer [3] is incompatible with the harsh 
ammonia deprotection conditions required to remove the base protecting 
groups on standard DNA synthesis monomers. 
To test the purity of a labelled oligonucleotide in ammonia at room 
temperature, a labelled test sequence [3]pTpTpTpT  was synthesized. As 
T has no base protecting group the only post-synthetic step required is the 
cleavage of the oligonucleotide from the solid support with concentrated 
ammonia for 1.5 hours at room temperature. The HPLC Chromatogram of 
crude [3]pTpTpTpT  is shown in Figure 18. The virtual absence of non-
DNP containing failure sequences shows that the DNP monomer [3] 
couples extremely well and confirms that the only problem is its 
instability to prolonged ammonia treatment at 55°C. 
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(A) 
Figure 16(a): !IPLC Chrornalogram of crude [3]pApGpCpT aftersh at 55°C in 
N[140H. [A]=DNP oligonucteotide; [HI=hydrophobic degradation 
product. 
Figure 16(b): HPLC Chromatogram of crude [3]p[3]pApGpCpT after 5h at 55°C 




Figure 17(a): HPLC Chromatogram of purified [3]pApGpCpT prior to ammonia 
treatment. [A]=DNP oLigonucleotide. 
Figure 17(b): HPLC Chromatogram of purified [3]pApGpCpT after treatment 
with NH40H at 55°C for 17 hours. [A]=DNP oligonucleotide. 
5.5 Oligonucleotide Synthesis using 'PAC'DNA Synthesis Monomers. 
The encouraging result of the synthesis of [3]pTpTpTpT showed 
that the DNP label was stable to ammonia treatment at 20°C. It was 
decided to attempt to synthesize DNP labelled oligonucleotides using [3] 
in conjunction with DNA monomers with base protecting groups which 
are more labile to concentrated ammonia. These commercially available 
"PAC Amidites" 92  are essentially the same as normal DNA monomers, 
except that the base protecting group for dA and dG is the phenoxyacetyl 
group and for dC the isobutyryl group. The conditions required for the 
removal of these protecting groups are either 5 hours in concentrated 
ammonia at 20°C; or 1-2 hour in concentrated ammonia at 550C It was 
hoped that the DNP labels would be stable under these conditions. 
Unfortunately the manufacturer's instructions for the use of the PAC 
monomers were erroneous, and the dG PAC monomer was only partially 
soluble in the anhydrous acetonitrile/anhydrous dimethylformamide 
mixture recommended. However, the dG PAC monomer was found to be 
highly soluble in anhydrous dichioromethane, and this solvent was used 
in all subsequent syntheses. 
HPLC analysis of DNP-oligonucleotides synthesized using PAC 
amidites indicated that the DNP labels were largely stable to the milder 
deprotection conditions used. The HPLC chromatogram of a crude 
oligonucleotide labelled with 6 DNP groups after 1 hour in concentrated 
ammonia at 55°C is shown in Figure 19. The overall yield for this 
synthesis was 83% and the chromatogram shows very little evidence of 
degradation of the DNP label. The sample was passed through a size 
exclusion Sephadex G25 (NAP) column which retains any small 
molecules (eg. degradation products) and allows the passage of larger 
molecules (eg. oligonucleotides). A very faint yellow band was left in 
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Figure 18: HPLC Chromatogram of crude [3]pTpTpTpT. 
Figure 19: HPLC Chromatogram of a crude DNP6 18mer oligonucleotide. 
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Figure 21: Possible Mechanism of DNP Label Degradation 
0 
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the column after elution of the oligonucleotide-containing fraction and 
this was eluted and collected for HPLC analysis. The HPLC 
chromatogram of this impurity collected from the NAP column is shown 
in Figure 20. The degradation of DNP substituted primary amines in 
aqueous ammonia has been reported by Roget et al. who identified 
dinitrophenol as the product of this decomposition91. Peak enhancement 
injections of solutions of 2,4-dinitroaniline and 2,4-dinitrophenol mixed 
with the impurity in solution showed that the major impurity was neither 
of these compounds. The labelled oligonucleotides synthesized using [3] 
contain DNP derivatised secondary amino functions and a possible 
mechanism for label degradation is shown in Figure 21 . To date no 
evidence for this mechanism has been collected. In order to obtain an 
estimate for the rate of degradation in aqueous ammonia at 200C, a PCR 
primer (24mer, DWI, Appendix 1) monolabelled with [3] was 
synthesized and purified by HPLC. A sample of this purified 
oligonucleotide was treated with concentrated ammonia solution for 5 
hours at 220C, removing aliquots every hour for HPLC analysis. The 
HPLC Chromatograms show no evidence of degradation of the label 
under these conditions. 
5.6. Synthesis of a Single Addition DNP phosphoramidite. 
The manner in which the DNP hapten is presented for recognition 
by the antibody may affect the kinetics and thermodynamics of the 
antibody-hapten interaction. It was therefore decided to synthesize a DNP 
phosphoramidite in which the DNP group was separated from the 5'-end 
of the oligonucleotide by a spacer arm. Such a phosphoramidite had 
already been synthesized in this research group by Pritchard.88 The 
synthesis was carried-out largely as described previously(Scheme 2). 2,4- 
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Dinitrofluorobenzene was reacted with 6-amino-hexan- 1 -ol in the 
presence of triethylamine in methanol. The 6-(2,4-dinitrophenylamino)-
hexan- 1-01 [4] was crystallised from diethyl ether /methanol. It tended to 
form an insoluble oil on heating with the crystallisation solvents, but 
eventually analytically pure crystals were obtained. Grzybowski 
(unpublished results) found that recrystallisation from hexane\ethyl 
acetate gave more satisfactory results. Phosphitylation of [4] proceeded 
smoothly in tetrahydrofuran to give the single addition DNP 
phosphoramidite [5]. As reported by Pritchard, the phosphoramidite was 
soluble in acetonitrile, and when used as a 0.1M solution it was found to 
couple with an efficiency of >95% (as estimated by HPLC), under 
standard DNA synthesis conditions. The DNP group on this 
phosphoramidite was found to be stable to ammonia deprotection 
conditions. Oligonucleotides labelled with [5] could be purified under 
standard HPLC conditions81 and eluted approximately 2 minutes after 
unlabelled failure sequences. 
A large number of Polymerase Chain Reaction (PCR) primers and 
in situ hybridisation probes labelled with 1, 2, 6 and 10 DNP groups 
were synthesized using [3] and [5] and purified for the use of 
collaborators in a variety of applications. We await the results of these 
studies. An anti-DNP antibody was supplied by Dr. Rick Randall of the 
Biochemistry Dept. of St. Andrews University. This antibody was raised 
in mice, by immunising with dead E.Coli bacteria which had been reacted 
with 2,4-dinitrofluorobenzene. It was decided to attempt some antibody 
detection experiments during a two week visit to the laboratories of Dr. 
Randall. 
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5.7. Polym erase Chain Reaction using DNP-labelled Primers. 
Amplification of specific sequences in genomic DNA using 
Polymerase Chain Reaction (PCR)9596 has become an important tool in 
many areas of biological and medical research. PCR is particularly useful 
for the detection of single-copy mutations which cause a number of 
inherited diseases, such as Cystic Fibrosis and Sickle Cell Anaemia.1  
Without PCR amplification the detection of such mutations would be 
very difficult or impossible. The use of 'Capture and Detect' experiments 
on PCR products opens the way for large-scale diagnostic testing using 
PCR technology. (Figure 22 (a) and (b) ) The 'Capture and Detect' format 
requires the synthesis of hapten or biotin labelled PCR primers. It is thus 
essential that any new hapten label must not inhibit PCR when it is 
incorporated into a PCR primer. It was therefore essential to test PCR 
primers labelled with single and multiple DNP groups. 
PCR primers labelled with 1, 2, 6, and 10 DNP groups were 
synthesized using [3] and [5] (Figure 23 a primer A) A biotinylated 
(Bio) primer (Figure 23 a primer B) was synthesized by reaction of 
Biotin-N-hydroxysuccinimide ester with the aminomodified primer 
(Aminolink 2). In addition a PCR primer was synthesized which 
incorporated alternating hexaethyleneglycol-[5] units. The 
hexaethyleneglycol (heg) units were introduced using a heg 
phosphoramidite97 (Figure 23 b). (A gift from Susanne Ebel). Using the 
Alchemy II molecular graphics software (Tripos Assoc.; IBM PC) it was 
found that when fully extended the hydrophilic heg units introduce a 
23.3A spacer between the DNP labels. The primers were for the PCR 
amplification of a section of the HN gene of paramyxovirus. This PCR 
system had been optimised using radiolabelled primers in the laboratories 
of Dr. Randall, and was used as a convenient test of the applicability of 
Immobilise avidin on nitrocellulose 
Block membrane with inert protein 
Avidin 
Nitrocellulose 
(3) Incubate wi 
(4) Incubate with anti-DNP antibody, then secondary antibody-enzyme conjugate 
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Figure 22(a): Schematic diagram showing the Capture 
and Detection of a double-stranded PCR product synthesized 
using a biotinylated and a DNP-labelled primer. (not to scale) 
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Figure 22(b): Schematic diagram showing the Reverse Dot Blot 
form at for Capture and Detection of PCR Products. 
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DNP primers to PCR. The PCR reactions were carried out under sterile 
conditions using standard procedures.98 Primer concentrations were 
determined spectrophotometrically at 260rm using the extinction 
coefficients for DNA bases reported in the literature.99 The extinction 
coefficients at 260nm (in methanol) of [1] and [4] (9234M 1cm-1  and 
8872M 1cm-1  respectively) were used to determine the UV absorbance of 
the DNP groups. A single strand hypochromicity factor of 0.9 was 
assumed. The following combination of primers was used: 
PCR Reaction Primer 1 Primer 2 
1 Dl D2 
2 A D2 
3 Dl BioB 
4 DNP1A BioB 
5 DNP2A BioB 
6 DNP6A BioB 
7 DNP10A BioB 
8 ((DNP2)heg)2A BioB 
Where A, B, Dl and D2 are the primers shown in Figure 23 a. The 
sequences of these primers are given in Appendix 1. 
The crude PCR reaction mixtures were analysed by Agarose gel 
electrophoresis, using ethidium bromide staining. The results of the PCR 
reactions are shown in Figure 24 (a). It is clear that the PCR reaction has 
been inhibited by the presence of 6 and 10 DNP groups at the 5'-end of 
the oligonucleotide. This experiment was repeated several times to 
confirm the finding. Doubling the concentration of the DNP primers in 
the reaction had no effect on the result. There are two possible reasons for 
the inhibition of PCR: 
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(a) Agarose gel of PCR reactions using Primers labelled with biotin, [31 or L5J. 
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The multiple DNP groups may inhibit the hybridization of the primer 
to the template strand. 
The steric bulk of the multiple DNP labels may prevent the Taq 
Polymerase from reaching the 5'-end of the template strand, giving rise to 
truncated PCR products. This would eventually lead to termination of 
amplification as the primers would be unable to hybridize to the truncated 
PCR product template in the next PCR cycle. PCR was not inhibited by 
the presence of 4 DNP groups spaced using heg. 
The failure of PCR using multiple DNP labelled primers is a 
serious problem, and rules out the use of [3] as a practical option for the 
introduction of multiple DNP groups into oligonucleotides for use as PCR 
primers. The use of heg units to space the DNP groups away from the 5'-
end of the oligonucleotide may solve this problem, however the 
convenience of using a single DNP phosphoramidite for multiple 
labelling would be removed. 
The problem of inhibition of PCR amplification due to the presence 
of multiple labelling groups at the 5'-end of oligonucleotides has not been 
reported previously. This is probably due to the fact that the use of 
multiply labelled oligonucleotides as PCR primers has seldom been 
reported. It was hoped that the problems encountered using multiple 
additions of [3] were due to the large size and relatively compact nature 
of [3] and that smaller DNP labelling groups incorporating longer spacer 
arms would eliminate the problem. 
5.8. Detection of DNP labelled oligonucleotides. 
Although the use of labelled oligonucleotides in PCR applications 
is undoubtedly important there are many other applications, such as the 
detection of viral diseases in clinical samples by in situ hybridisation of 
labelled probes, where the use of oligonucleotides labelled with [3] could 
be of potential use. In experiments to determine the suitability of the 
oligonucleotides labelled with [3] as probes we attempted to detect the 
DNP labelled PCR primers immobilised on nylon or nitrocellulose 
membranes using mouse monoclonal anti-DNP antibodies. 
Oligonucleotides were fixed onto nylon membranes by UV irradiation for 
5 minutes, and onto nitrocellulose by baking in a vacuum oven at 80°C 
for 2 hours. The experiments were designed to determine the relative 
sensitivity of detection of different numbers of DNP labels and a Biotin 
label, rather than to obtain maximum absolute sensitivity. 
5.8.1. Selection of A nti-DNP antibody. 
Each labelled oligonucleotide was spotted and fixed onto five 
nylon membranes at a loading of lOOng. The filters were blocked with 
ovalbumin and each membrane was incubated with a 1:200 dilution of 
four ascitic fluids containing different anti-DNP antibodies. After 
washing and incubation with goat-anti-mouse IgG antibody-HRP 
conjugate, the DNP primers were detected using o-dianisidine. The 
strongest signal was obtained from the antibody with the designation K3. 
The ascitic fluid containing the K3 antibody was used in all subsequent 
experiments. 
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5.8.2. Comparison of Sensitivity of detection. 
Five-fold dilutions of the labelled oligonucleotides were spotted 
and fixed in duplicate onto nylon membranes starting at 500ng loading. 
After blocking with ovalbumin, one membrane was incubated with 
streptavidin-HRP conjugate, and the other with K3 antibody followed by 
goat-anti-mouse IgG antibody-HRP conjugate. Both membranes were 
then developed with o -dianisidine. Figure 24(b) shows that all the 
multiple DNP labelled oligonucleotides (labelled with [31) gave poorer 
sensitivity than the singly labelled oligonucleotide (labelled with [51), and 
that the single DNP labelled oligonucleotide gives comparable sensitivity 
to the biotin labelled oligonucleotide under the experimental conditions 
used. The probable reason for the drop in sensitivity for the multiple DNP 
oligonucleotides compared to the single DNP oligonucleotide is that the 
antibody does not recognise an unspaced DNP group attached to a 
secondary amine. The oligonucleotide with 10 DNP groups gives only 
slightly higher sensitivity than those with 6 or 4(spaced) DNP groups, but 
gives a much stronger signal than the oligonucleotides with 2 DNP 
groups. This indicates that multiple DNP labelling does give an 
inprovement in sensitivity, however the manner in which the DNP groups 
are presented for antibody binding is of crucial importance. 
The results of the experiments described above show that DNP 
labelling of oligonucleotides using [3] is fundamentally impractical. 
5.9. Conclusions about [3] and [5]. 
The following conclusions may be drawn from the work described 
above: 
(a) The DNP monomer [3] is readily synthesized in reasonable yield from 
inexpensive starting materials in only three steps. This is a considerable 
improvement over the only previous multiple addition DNP 
phosphoramidite91  which required seven-step syntheses using relatively 
expensive starting materials. 
The major disadvantage of the synthetic route to [3] is the lack of 
selectivity during the tritylation, resulting in a low yield for this reaction. 
The coupling efficiency of [3] of 97% is reasonably good and could 
probably be improved by further purification. 
Two DNP labels are introduced per addition of [3].  This cuts down on 
the amount of DNP monomer and machine time required for poly-
labelling as the number of couplings is reduced. 
The degradation of the label during base deprotection has been 
considerably reduced by the use of DNA monomers with base protecting 
groups which are more base-labile, however these DNA monomers are 
prohibitively expensive for routine use. The mechanism for the 
degradation has not been elucidated. 
The insolubility of [3] in acetonitrile is a major drawback to the 
routine use of this phosphoramidite. 
Oligonucleotides which have been poly-labelled with DNP groups are 
very water-soluble in spite of having a large number of hydrophobic 
residues. 
The purification of DNP labelled oligonucleotides is very easy, as the 
HPLC characteristics of oligonucleotides containing the hydrophobic 
DNP labels are very different to unlabelled failure sequences. The 
labelled oligonucleotides are also bright yellow, making identification of 
the product relatively easy. 
The failure of PCR using primers labelled with [3] makes the use of 
[3] for PCR impractical. This effectively destroys the practical value of 
[3] for the many applications involving PCR. 
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) The failure of the anti-DNP antibody to recognise the DNP groups 
introduced by [3] rules out the use of [3] for any practical applications. 
This could not have been foreseen, and could be overcome by raising 
specific antibodies to proteins conjugated to [3].  However this is a major 
undertaking and is outside the scope of the present study. 
6.0. Synthesis and Use of a Multiple-Addition DNP PhosDhoramidite 
JIDKOiUW±ffflhiT7h MINE I 
The results described above help to define more precisely the 
requirements for a suitable backbone for a multiple DNP 
phosphoramidite. These requirements are: 
It must contain at least one primary but not secondary amino group for 
the attachment of the labelling moiety. A DNP group attached to the 
primary amino function of [5] was readily recognised by the antibody. 
There must be a spacer arm between the DNP group and the rest of 
the molecule to facilitate antibody binding and minimise interactions 
between the DNP groups and the oligonucleotide which may inhibit PCR. 
It must contain two hydroxyl functions, preferably one primary 
hydroxyl for the attachment of the dimethoxytrityl group and a secondary 
hydroxyl function for the phosphoramidite. 
The use of the 3-aminopropyl solketal backbone of Misiura et al, 
27 was considered (and is suggested for use with the DNP group in that 
reference) and John Grzybowski of this research group utilised this 
backbone as the basis for two DNP phosphoramidites. Another 
inexpensive starting material suitable as a backbone is 1,2,6-
trihydroxyhexane, and it was decided to synthesize a DNP 
phosphoramidite based on this molecule. 
6.1. Chemical Synthesis. 
The synthetic route to the DNP phosphoramidite based on 1 ,2,6-
trihydroxyhexane is shown in Scheme 3. Thus 1,2,6-trihydroxyhexane 
was converted to its acetonide derivative [6] (following a procedure based 
on that of Fischer and PhthalerlOO) by reaction with anhydrous acetone 
containing anhydrous sodium sulphate and a trace of concentrated 
aqueous HG!. The reaction was quenched by the addition of lead 
carbonate and the product was purified by kugelrohr distillation. It was 
found to be beneficial to add a trace of potassium carbonate to the 
distillation flask to ensure basic conditions to prevent decomposition of 
the product. The acetonide [6] was then tosylated (using a procedure 
based on that of Mori101). The tosylate synthesized by Mori was not 
characterised or purified, but the tosyl acetonide [7] was purified by flash 
chromatography and fully characterised. The tosyl group was displaced 
by potassium phthalimide in DMF, to give the phthalimide [8].  Removal 
of the phthaloyl group group using hydrazine hydrate (Caution:Highly 
Toxic) in methanol, gave after distillation the amine [9] as a clear liquid. 
This amine was then reacted with 2,4-dinitrofluorobenzene in methanol in 
the presence of triethylamine to give, after flash chromatography, the 
DNP-acetonide [10]. Previous work on related compounds by John 
Grzybowski had shown that deprotection of an acetonide and isolation of 
the resulting DNP-diol by flash chromatography resulted in extremely 
low yields due to the irreversible retention of the highly polar DNP-diol 
on the silica gel. Therefore the DNP acetonide [10] was converted to the 
dimethoxytrityl compound [11] in a 'one-pot' reaction. The acetonide 
protection was removed by treatment with aqueous HO in THE After 
exhaustive removal of traces of HO and water by azeotropic evaporation 
with ethanol, toluene and anhydrous pyridine, the diol was reacted with 
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4,4'-dimethoxytrityl chloride in pyridine to give the phosphoramidite 
precursor [11]. Phosphitylation of [11] in anhydrous THF, using 2-
cyanoethyl N ,N-diisopropylphosphoramidochloridite in the presence of 
N,N-diisopropylethylamine, proceeded smoothly to give the multiple-
addition DNP phosphoramidite [12] as an orange oil, 
6.2. Oligonucleotide synthesis using [12]. 
Multiple DNP phosphoramidite [12] which was readily soluble in 
anhydrous acetonitrile, was used as a 0.15M solution for oligonucleotide 
synthesis. The coupling efficiency was found to be 97.5% when [12] was 
used with a standard 0.2j.tmol or 1imol scale DNA synthesis cycle. This 
could be improved to 98.5% by increasing the wait time for the coupling 
reaction to 2 minutes. Oligonucleotides labelled at the 3'-end were 
synthesized by coupling one or more additions of [12] onto normal T 
solid support followed by the synthesis of the desired oligonucleotide. 
6.3. HPLC analysis and purification of oligonucleotides DNP-labelled 
using [12]. 
As only one DNP group is introduced per synthesis cycle when 
using [12],  the lipophilicity of DNP oligonucleotides labelled with [12] is 
less than that of oligonucleotides labelled with the same number of 
additions of [3]. However the DNP oligonucleotides were still found to 
elute on HPLC several minutes later than unlabelled failure sequences. 
The full HPLC conditions for purification of DNP-labelled 
oligonucleotides are given in the experimental section. A suitable buffer 
system for use with all DNP labelled oligonucleotides (either Trityl On, 
or Trityl Off syntheses) was found to be a gradient of 0-50% acetonitrile 
in 0.1 M ammonium acetate. 
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6.4. Stability of the DNP label to DNA Synthesis and Deprotection 
Conditions. 
Misiura et al. 27  reported that labelled oligonucleotides synthesized 
using the 3-aminopropyl solketal backbone had to be synthesized with the 
5'-terminal dimethoxytrityl group in place (Trityl-On synthesis). This was 
necessary to prevent attack of the free terminal primary hydroxyl function 
on the adjacent phosphodiester linkage under the strongly basic 
conditions used for oligonucleotide deprotection. As [12] contains the 
same vicinal diol arrangement found in the 3-aminopropyl solketal 
backbone it was thought necessary to confirm this finding by synthesizing 
the test sequence [12]pTpTpTpTpT  both Trityl On and Trityl Off and 
monitoring any degradation in aqueous ammonia by HPLC. Figure 25 
shows the HPLC chromatograms of (a) Trityl Off and (b) Trityl On test 
sequence after heating at 55°C in NH40H for 2 hours. As expected the 
Trityl Off synthesis resulted in degradation of the label. Peak 
enhancement injections with pure TpTpTpTpT confirmed that the result 
of the degradation was loss of the labelling group to form the 
underivatized oligonucleotide (Figure 25, Peak (I)). There was no loss of 
label for the Trityl Off synthesis of internally labelled 
Tp[12]pTpTpTpTpT, in which both hydroxyl functions of the vicinal diol 
are protected' by the phosphodiester linkage. The probable mechanism 
of degradation is shown in Figure 26. This problem is easily overcome 
by synthesizing oligonucleotides Trityl On and the presence of the very 
lipophilic 5'-terminal dimethoxytrityl group makes the purification of the 
DNP-labelled oligonucleotide from its failure sequences even easier. 
As with the single addition DNP phosphoramidite [5],  the DNP 
group of [12] was found to be stable to ammonia deprotection conditions. 
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(I) (II) 
(a) [12]pTpTpTpTpT, Trityl Off after 2 hours in NH40H at 55 0C. 





(b) [12]pTpTpTpTpT, Trityl On after 2 hours in NH40H at 55 0C. 






DNP1 DNIP3 DNP5 
(c) Mixed injection of a PCR primer (24mer) labelled with 1,3 and 5 DNP groups 
(using [12]), after trityl on purification and subsequent detritylation. 
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Figure 26: Possible mechanism of degradation of 1,2-diol-linked 
labels under ammonia deprotection conditions. 
-
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Figure 25c shows HPLC chromatograms of 24mer 
oligonucleotides (GW1; Appendix 1) labelled with 1, 3 and 5 DNP 
groups. Increasing the number of DNP groups attached to the 
oligonucleotide causes the oligonucleotide to elute later on reversed-
phase HPLC. 
6.5. Synthesis of Hybridisation Probes and PCR primers. 
Probes (40mer; HC 1; Appendix 1) for use in in situ hybridisation 
experiments for the detection of Epstein-Barr virus in clinical samples 
were synthesized with 1,3 and 5 DNP groups. Epstein-Barr virus causes 
mononucleosis (glandular fever), and has been linked with Burkitt's 
lymphoma and nasopharyngeal carcinoma, two common forms of cancer 
in Africa and China. 102  These oligonucleotides have been supplied to Dr. 
Heather Cubie at the Regional Virology Laboratory at the City Hospital 
in Edinburgh. The detection limits of these DNP labelled probes will be 
compared to those of more expensive Digoxigenin labelled probes. 
6.6. Antibody Purification. 
In order to allow the capture of DNP oligonucleotides or PCR 
products with an anti-DNP antibody immobilised on a solid support it is 
essential that the antibody is pure and free from plasma proteins. In order 
to allow such experiments to be carried out a pure sample of K3 anti-
DNP antibody was obtained by Protein A column chromatography of 
ascitic fluid using a commercially available kit (Pierce). The ascitic fluid 
was found to have an antibody concentration of approximately 7mg ml-1  
as measured spectrophotometrically at 280nm. The antibody was 
assumed to have an extinction coefficient at 280nm of 1.45L g 1 cm. 103 
The anti-DNP activity of the purified antibody was confirmed by the 
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detection of DNP oligonucleotides which were fixed by UV irradiation 
onto nylon filters. Samples of the purified antibody have been supplied to 
collaborators for use in 'Capture and Detect' experiments. 
6.7. Capture and Detect Experiments on Biotinylated DNP 
Oligonucleotides. 
In a preliminary experiment to determine the feasibility of the 
capture of PCR products containing both DNP groups and biotin on 
immobilised avidin, oligonucleotides (24mer PCR primers; GW1; 
Appendix 1) were labelled with 1 or 3 DNP groups at the 3'-end and a 
single biotin moiety (Bio) at the 5'-end.87 The experimental design is 
summarised in Figure 27. A solution of avidin was spotted onto a 
nitrocellulose filter to give a 0. lj.tg loading per spot. After incubation at 
4°C for 4 hours the filter was blocked with a 10% solution of fat-free 
skimmed milk in phosphate-buffered saline (PBS). The filter was then cut 
into strips and each strip was incubated with a 0.175iM solution of 
different 24mer oligonucleotides. 
The strips were washed and incubated with K3 anti-DNP antibody 
followed by goat-anti-mouse IgG-HRP conjugate. The strips were then 
incubated with diaminobenzidine (DAB) to give the colour reaction. The 
results are shown in Figure 28(a) . The experiment has clearly worked 
well. The increased signal from the 5 Bio ----------- DNP33' oligonucleotide 
compared with the 5tBio ----------- DNP13' oligonucleotide indicates that 
multiple DNP groups do indeed give an enhanced signal compared to 
single DNP groups. One minor problem was the appearance of a faint 
background signal at the positions where avidin was spotted in the 
negative control experiments. This signal only appeared after prolonged 
incubation with DAB and was present even in the strip where no 
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Immobilise avidin on nitrocellulose 
Block membrane with inert protein 
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ADNP 
Avidin 
(3) Incubate with anti-DNP antibody, then secondary antibody-enzyme conjugate 




Figure 27: Capture and Detection of a biotinylated DNP oligonucleotide 
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oligonucleotide was added. The most likely cause of this signal is the 
presence in the polyclonal mixture which comprises the goat-anti-mouse 
IgG-HRP conjugate of an antibody which binds weakly to avidin. This 
slight problem could probably be overcome by the use of streptavidin 
which should exhibit fewer non-specific interactions. 
These experiments have proven the feasibility of carrying out 
capture and detect experiments on biotin/DNP PCR products. Such 
experiments are now being carried out by collaborators. 
6.8. Comparison of the Detection Sensitivity of DNP and Biotinylated 
Oligonucleotides. 
In order to compare the sensitivity of detection of oligonucleotides 
labelled with different numbers of DNP groups with biotinylated 
oligonucleotides a simple assay was developed. The DNP or biotin 
labelled oligonucleotides (GW1, Appendix 1) were immobilised on nylon 
membranes by UV irradiation for 5 minutes. The DNP groups were 
detected by incubation with K3 antibody followed by secondary 
antibody-HRP conjugate. Biotin was detected by incubation with avidin-
HRP conjugate and colour development was carried out with DAB. In 
order to ensure that the presence of multiple DNP groups did not affect 
the binding of the oligonucleotides to the nylon membrane, 
oligonucleotides containing both biotin and DNP groups were 
synthesized and fixed to nylon, if multiple DNP groups increased 
oligonucleotide binding then an enhanced signal would be expected for 
detection of the biotin residue at the other end of the oligonucleotide. 
The experiments were carried out as follows: 
Five-fold dilutions of the labelled 24mer oligonucleotides were 
spotted and fixed in duplicate onto nylon membranes starting at lpmol 
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loading. After blocking with non-fat skimmed milk solution, one 
membrane was incubated with avidin-HRP conjugate, and the other with 
K3 antibody followed by goat-anti-mouse IgG antibody-HRP conjugate. 
Both membranes were then developed with DAB. The results of this 
experiment are shown in Figure 28(b) 
Conclusions: 
There is a five-fold increase in sensitivity between the DNP, the 
DNP3 labelled oligonucleotides. There is no increase in sensitivity 
between the DNP3 and DNP5 labelled oligonucleotides. This would 
suggest that 3 DNP groups is the optimum number to maximise the 
sensitivity: cost ratio. The reason for the increase in sensitivity is unlikely 
to be due to the binding of more than one antibody as the antibody is 
much larger than both the labelling groups and the oligonucleotide. The 
distance between the two hapten binding sites of an IgG is approximately 
200A.104 An increase in antibody binding affinity due to the presence of 
multiple haptens is a more likely explanation. 
There is no difference in sensitivity between oligonucleotides labelled 
at their 3'- and 5'-ends with a single DNP group. 
The presence of the DNP groups does not affect the binding of the 
oligonucleotides to the nylon as the biotin signal is identical for 
oligonucleotides with and without DNP groups. 
DNP3  and DNP5 labelled oligonucleotides give comparable 
sensitivity to biotinylated oligonucleotides. The limit of detection using 
this simple assay was 8 fmol of oligonucleotide. 
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6.9. Effect of length of spacer arm on sensitivity of detection. 
Two DNP phosphoramidites based on the backbone of Misiura et 
al. were synthesized and used by John Grzybowski of this group to 
synthesize DNP oligonucleotides. These two phosphoramidites are shown 
in Figure 29(a) . It was thought that the longer spacer arms of [JG1] and 
especially [JG2] would enhance the accessibility of the DNP groups to 
the antibody and minimise steric crowding. The same assay conditions as 
described above (Section 6.8.) were used. The results of this experiment 
are shown in Figure 29(b). (Sequence OWl, Appendix 1) 
Conclusion: The length of the spacer arm has no effect on the sensitivity 
of detection in this assay system. 
7.0. Overall Conclusions on DNP phosphoramidites. 
The DNP phosphoramidite [12] is easy to synthesize using simple 
reactions which are amenable to scale-up. 
Single or multiple DNP groups can be incorporated into 
oligonucleotides at the 3'- or 5'-end during standard DNA synthesis 
conditions. 
Trityl On synthesis is essential for 5'-end labelling with [12]. 
The DNP oligonucleotides are readily purified by reverse-phase 
HPLC due to their lipophilicity. 
The DNP label is suitable for use in 'Capture and Detect' experiments. 
Three DNP groups is the optimum number for detection. 
The length of the spacer arm connecting the DNP group to the rest of 
the backbone has no effect on sensitivity under the assay conditions used. 
8.0. Synthesis and Uses of a Multiple Addition Hydroxyl 
Phosphoramidite. 
The introduction of multiple hydroxyl functions to the 5'-end of 
oligonucleotides during solid-phase synthesis and the subsequent 
coupling of a simple single addition labelling phosphoramidite should 
allow the attachment of multiple labelling groups to the oligonucleotide. 
This circumvents the need for the lengthy synthetic routes necessary for 
the synthesis of multiple addition labelling phosphoramidites. 
The introduction of multiple hydroxyl functions into 
oligonucleotides has been carried out previously using a modified 
nucleoside phosphoramidite. 105,106  and also a glycerol 
phosphoramidite.107 The aim in those studies was to synthesize 'fork and 
comb-shaped' oligonucleotides. Hybridisation to a target sequence by the 
'handle' of the fork or comb, and subsequent hybridisation of multiple 
labelled oligonucleotides to the 'teeth' of the fork or comb, allowed the 
detection of very low levels of the target sequence. 
8.1. Chemical Synthesis. 
The simplest method of introducing multiple hydroxyl functions is 
via a protected triol phosphoramidite. This approach was used by Horn et 
al. to synthesize branched oligonucleotides. In that study glycerol was 
used as a triol starting material. The multiple hydroxyl phosphoramidite 
was not used for multiple non-radioactive labelling of oligonucleotides. 
A suitable triol starting material for a multiple hydroxyl 
phosphoramidite is 1 ,2,6-trihydroxyhexane. Although this molecule is 
asymmetric, the tetramethylene spacer between one of the primary 
hydroxyl functions and the backbone is likely to improve both the 
coupling characteristics of the phosphoramidite, and the antibody or 
streptavidin mediated recognition of labelling groups attached to it. The 
synthetic route is outlined in Scheme 4. The two primary hydroxyl 
functions were selectively protected as their 4, 4'-dimethoxytrityl ethers, 
by reaction with 4, 4'-dimethoxytrityl chloride in pyridine to give 
compound [13]. Subsequent phosphitylation of the secondary hydroxyl 
function proceeded smoothly using 2-cyanoethyl N,N-diisopropyl-
phosphoramidochloridite in the presence of N,N-diisopropylethylamine, 
to give [14] as an oil. 
8.2. 0 ligonucleotide Synthesis using multiple hydroxyl phosphoramidite 
[14]. 
8.2.1. Solubility. 
In spite of its high lipophilicity, [14] was found to be soluble in 
anhydrous acetonitrile and was used as a 0.15M solution in this solvent 
for DNA synthesis. 
8.2.2. Coupling Efficiency. 
The coupling of n additions of [14] results in the introduction of 2 
hydroxyl functions onto the 5t-end of the oligonucleotide. For example, 
this means that the coupling of 2 additions of [14] during a 0.2mo1 
synthesis introduces 0.8llmol of hydroxyl functions. These hydroxyl 
functions are then available for the coupling of any phosphoramidite (eg. 
a biotin phosphoramidite; single addition DNP phosphoramidite [5]; 
further additions of [14]; or normal DNA synthesis monomers). During a 
normal 0.2imol scale synthesis the phosphoramidite is added in a 10-fold 
excess over the solid-support bound 5'-hydroxyl functions. The 
introduction of 4 hydroxyl functions effectively changes a 0.2j.tmol scale 
synthesis into a 0.8tmol scale synthesis and the normal phosphoramidite 
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has repercussions on the kinetics and efficiency of the coupling reaction. 
It was thus necessary to modify the synthesis cycle to allow a double 
delivery of phosphoramidite + tetrazole for the coupling of [14] and the 
subsequent labelling phosphoramidite. This double delivery of 
phosphoramidite does not fully compensate for the increase in number of 
pmoles of primary hydroxyl groups bound to the solid support, so a 5 
minute wait time for the coupling of [14] and the subsequent labelling 
phosphoramidite was also included in the synthesis cycle. A schematic 
representation of the sequence of events using [14] and [5] for multiple 
DNP labelling is shown in Figure 30. 
In order to test coupling efficiencies a sequence 
5 Bio[14][14]pTpTpTpTpT3' was synthesized. After two successive 
couplings of [14] to the 5'-end of the oligonucleotide the biotin residues 
were introduced by a single coupling with the biotin phosphoramidite of 
Pon.87 This biotin phosphoramidite contains a dimethoxytrityl group and 
so its coupling efficiency can be measured. During detritylation the 
amount of dimethoxytrityl cation released doubles for every addition of 
[14]. The coupling efficiencies were therefore corrected to allow for this 
effect. The coupling efficiencies for the test sequence under different 
synthesis conditions are shown below. 
Coupling efficiency 
Coupling 	Coupling wait 	1141-T 11414141 	Bio-1141 
Normal 	30 seconds 	83% 	86% 	70% 
Normal 	5 minutes 	91% 	90% 	75% 
Double delivery 5 minutes 	91% 	89% 	92% 
Although the coupling efficiencies are not >98.5% typical of 
normal DNA synthesis, they are high enough for reasonable yields of the 
desired product. The 92% coupling efficiency of the biotin 
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Figure 30: Multiple DNP labelling using [14] and [5]. 
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phosphoramidite to the multiple hydroxyl functions means that only a 
very small proportion of the multiple-hydroxyl oligonucleotides will have 
no biotins attached. The coupling efficiency of the biotin 
phosphoramidite under normal DNA synthesis conditions was 97%. 
The synthesis cycle incorporating the double delivery of phosphoramidite 
+ tetrazole and the 5 min wait step for coupling was used in all 
subsequent syntheses using [14]. 
8.3. Synthesis and Purification of Multiply Biotinylated 
Oligonucleotides using [14]. 
PCR primers (24mers, GW1, Appendix 1) were synthesized with 
either 1 or 2 additions of [14] at the 5'-end, followed by a single coupling 
of biotin phosphoramidite. This gave primers with either 2 or 4 biotin 
residues at the 5'-end. The HPLC chromatogram of crude 
tetrabiotinylated primer is shown in Figure 31a. The first peak to elute (I) 
is unbiotinylated failure sequences. The smaller peaks (II) contain either 
1, 2 or 3 biotins. The presence of biotin in these oligonucleotides was 
confirmed by spraying with p-dimethylamino-cinnamaldehyde 
solution. 108,109  The desired product is the second large peak to elute 
(Ill), and is obviously well separated from unlabelled failure sequences. 
The identity of peak (IV) is not known. The HPLC chromatogram of 
crude di-biotinylated primer was very similar, however the separation 
between failure sequences and product was smaller. The HPLC 
chromatogram of a mixed injection of the same purified PCR primer 
bearing 1, 2, and 4 biotins is shown in Figure 31b to illustrate the 
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Mixed injection of a 24mer oligonucleotide bearing 1, 2 and 4 biotin 
groups. 
Figure 31 
8.4. Synthesis and Purification  of Multiple DNP Oligonucleotides 
using [14] and [5]. 
The same procedure as described in section 8.3. above was used 
for the synthesis of multiple DNP oligonucleotides (24mer, GW1, 
Appendix 1), however DNP phosphoramidite [5] as a 0.15M solution in 
acetonitrile was used instead of biotin phosphoramidite. The HPLC 
chromatogram of crude DNP4 primer is shown in Figure 32a. Peak (I) is 
a mixture of failure sequences. The smaller peaks (II) are 
oligonucleotides with 1,2 and 3 DNP groups, and are yellow. The 
extremely lipophilic product is the last peak to elute (III), and is bright 
yellow. A mixed injection of the same PCR primer bearing 1, 2, and 4 
DNP groups is shown in Figure 32b to illustrate the increase in 
lipophilicity as the number of DNP groups is increased. Probes for the 
detection of Epstein-Barr virus were synthesized (40mer, HC1, Appendix 
1) with 2 and 4 DNP groups using [14] and [5] and are now being 
evaluated by collaborators. 
8.5. Detection of Multiply Biotinylated Oligonucleotides. 
To determine if the attachment of multiple biotin moieties to 
oligonucleotides using [14] gave enhanced detection sensitivity, a series 
of three-fold dilutions of oligonucleotides (24mer, GW1, Appendix 1) 
bearing 1, 2, and 4 biotins were spotted onto nylon and fixed by UV 
irradiation. The biotin was detected using avidin-HRP conjugate followed 
by colour development with DAB. 
The results of this experiment are shown in Figure 33a. It is clear 
that there is only slight enhancement in sensitivity using multiply 
biotinylated oligonucleotides and an avidin-based detection system. This 
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Mixed injection of a 24mer oligonucleotide bearing 1, 2 and 4 DNP 
groups, labelled using [14] and [5]. 
Figure 32 
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Detection of biotinylated oligonucleotides fixed on nylon (using 
Avidin-HRP conjugate). 
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Detection using anti-biotin antibodies has not yet been attempted, 
however a detection system using avidin or streptavidin is preferable due 
to the commercial availability of a wide variety of derivatives of these 
proteins and the high affinity they have for biotin. 
8.6. Detection of Multiple DNP Oligonucleotides. 
The same procedure as that in section 6.8. above was carried out 
using five-fold dilutions of oligonucleotides (24mer, GW1, Appendix 1) 
labelled with 2 and 4 DNP groups using [14] and [5] to compare with 
oligonucleotides labelled with a single DNP group using [12]. The results 
are shown in Figure 33b. 
The oligonucleotide labelled with 2 DNP groups (using[141 and 
[5]) gives comparable sensitivity to those labelled with a single DNP 
group (using [5]).  The oligonucleotide labelled with 4 DNP groups 
(using[14] and [51) gives comparable sensitivity to those labelled with 3 
or 5 DNP groups using multiple addition DNP phosphoramidite [12]. 
(Figure 29). 
8.7. Conclusions. 
The chemical synthesis of multiple hydroxyl phosphoramidite [14] is 
readily achieved in 2 steps from an inexpensive starting material. 
The phosphoramidite [14] is soluble in acetonitrile, the solvent of 
choice for DNA synthesis. 
The introduction of multiple hydroxyl functions onto the 5-end of 
oligonucleotides during solid-phase synthesis is readily achieved in high 
yield using [14]. 
The use of a slightly modified synthesis cycle is necessary to increase 
the yield of the product. These minor modifications do not add 
significantly to the time and cost of DNA synthesis. 
Multiple labelling groups can be attached in high yield to 
oligonucleotides by a single coupling reaction after the desired number of 
additions of [14]. 
Reversed-phase HPLC purification of the labelled oligonucleotides is 
easy due to their enhanced lipophilicity. 
There is little (<3461d) enhancement in sensitivity on labelling with 
multiple biotins compared to single biotin labelling when avidin detection 
is used. 
An approximately five-fold increase in sensitivity is observed for 
labelling with 4 DNP groups compared to single DNP labelling. 
8.8. Work in Progress and Future Work. 
8.8.1. Synthesis of Branched Oligonucleotides. 
The simultaneous synthesis of two identical oligonucleotides 
joined at the 3'-ends may produce oligonucleotides with interesting 
hybridisation properties, as a complementary strand would be antiparallel 
to both strands of the branched oligonucleotide on hybridisation. This 
work is being carried out at present. 
8.8.2. Synthesis of RNA with multiple biotin labels. 
Multiple hydroxyl phosphoramidite [14] has been used 
successfully by Susanne Ebel of this research group for the synthesis of 
oligoribonucleotides carrying four biotin residues. These are being used 
by collaborative researchers for the affinity purification of small nuclear 
ribonucleoproteins. 
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9.0. Synthesis of Benzovl Protected Biotin Phosphoramidites. 
In spite of its disadvantages, biotin remains the non-radioactive 
label of choice for oligonucleotides in many biological and medical 
applications. The traditional method for biotinylation of oligonucleotides, 
by reaction of biotin-N-hydroxysuccinimide ester with an amino modified 
oligonucleotide has largely been superceded by the use of biotin 
phosphoramidite monomers. These allow rapid one-step automated 
biotinylation during solid-phase synthesis. Some biotin phosphoramidites, 
designed to introduce single or multiple biotins to the 5'-end of 
oligonucleotides (Figure 12)27,85,86 have the disadvantages of a short 
spacer arm85 or an unprotected biotin ring27' 86 which has been shown to 
lead to side-reactions during oligonucleotide synthesis.93 Other 
phosphoramidites, based on modified nucleosides91'93 (Figure 13) allow 
biotinylation at any position but require lengthy and expensive syntheses. 
The phosphoramidite of Pon87 has none of the above disadvantages but 
uses the rather bulky and relatively expensive dimethoxytrityl group for 
protection of the biotin ring. This phosphoramidite became commercially 
available as the work described below was being carried out. 
According to Misiura et al. 27  the attachment of multiple biotin 
residues does not give rise to an increase in sensitivity when a 
streptavidin-based detection system is used (Section 3.2.2.). Pieles et al. 
93 demonstrated the necessity of protection of N1' of the biotin ring to 
prevent side-reactions (Section 3.2.2.). Based on these observations it 
was decided to attempt the synthesis of single addition protected biotin 
phosphoramidites. 
9.1. Chemical Synthesis of a 3-oxa-penlyl spaced biotin 
phosphoramidite. [17] 
A base-labile acyl protecting group for N1' of biotin was 
considered to be the most appropriate approach for the synthesis of a 
biotin phosphoramidite. The 4-tert-butyl benzoyl protecting group had 
been successfully used by Pieles et al. 93  for the protection of their 
multiple addition biotin phosphoramidite (Figure 13), although a rather 
lengthy synthetic route was chosen. It was decided to synthesize the N1'-
benzoyl derivative of a biotin active ester. This would allow the 
introduction of a protected biotin unit onto any amino function in the 
presence of unprotected hydroxyl functions. 
Biotin-2-nitrophenyl ester (Scheme 5) was synthesized in high 
yield by the procedure of Pieles et a! 93  and was reacted with benzoyl 
chloride in anhydrous pyridine to give N1t-benzoylbiotin-2-nitrophenyl 
ester [15] in 70% yield. The product was readily identified on t.1.c., 
giving a yellow colour on treatment with conc. aqueous ammonia then a 
pink colour on heating with p -dimethylamino-cinnamaldehyde. 108,109 
As a first attempt at the synthesis of a benzoyl biotin 
phosphoramidite it was decided to use inexpensive 1 -amino-3-oxa-
pentan-1-ol as a spacer group. Thus N1'-benzoylbiotin-2-nitrophenyl ester 
[15] was reacted with 1-amino-3-oxa-pentan-1-ol in the presence of 
triethylamine to give the benzoyl biotin alcohol [16] in excellent yield. 
Phosphitylation of [16] using 2-cyanoethyl N,N-diisopropyl 
phosphoramidochioridite in the presence of N,N-diisopropylethylamine 
gave the short chain biotin phosphoramidite [17] as a foam. This 
compound was found to be rather too polar for easy handling and 
purification and 31P-NMR indicated that this phosphoramidite was 
contaminated by Ca. 10% phosphonate impurities due to hydrolysis 
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during aqueous work-up. This did not appear to interfere with the 
coupling of [17]. 
9.2. Oligonucleotide Synthesis using Biotin Phosphoramidite [17]. 
Phosphoramidite [17], as a 0.1 M solution in anhydrous acetonitrile, 
was used to synthesize oligonucleotides under standard DNA synthesis 
conditions. The coupling efficiency was >95% (estimated by HPLC). In 
order to ascertain if the benzoyl group was fully removed under normal 
base deprotection conditions a test sequence [17]pTpTpTpTpTpT  was 
synthesized. HPLC analysis of aliquots removed at one hour intervals 
from a solution of this oligonucleotide in NH40H heated to 55°C, 
indicated that the benzoyl group was completely removed under the 
conditions required to cleave the oligonucleotide from the solid support 
(1.5 hours in NH40H at room temperature). Figure 34a shows an HPLC 
chromatogram of a crude 26mer oligonucleotide (A; Appendix 1). 
Biotinylated PCR primers were synthesized using either [17] or by 
conventional reaction of an Aminolink 2 (Figure 7a) oligonucleotide with 
biotin-NHS ester (to give a hexamethylene-spaced biotin). The presence 
of the unprotected biotin ring was confirmed by the generation of a pink 
colour after applying an aqueous solution of the oligonucleotide to a tic 
plate and spraying with p-dimethylamino-cinnamaldehyde. 108,109  It was 
found that due to the more polar spacer aim incorporated using [17] gave 
poorer resolution of the biotinylated oligonucleotide from failure 
sequences by reversed-phase HPLC than the aminolink-biotinylated 
oligonucleotides (Which have an hexainethylene spacer arm). The 
separation of the failure sequences from the biotinylated oligonucleotide 
labelled with [17] was dependent upon the sequence and length of the 
i] 
oligonucleotide. Clearly a longer, more lipophilic spacer arm would 
overcome this problem. 
9.3. Chemical Synthesis of an octamethylene spaced biotin 
phosphoramidite. [22]. 
In order to improve upon the resolution of failure sequences from 
biotinylated oligonucleotide obtained from either the 3-oxa-pentyl spacer 
(introduced using [17]) or the hexamethylene spaced biotin (introduced 
using Aminolink-2, or the phosphoramidite of Pon87), it was decided to 
synthesize a benzoyl biotin phosphoramidite incorporating an 
octamethylene spacer arm. 
THP protected aminooctanol was synthesized in two steps from 
commercially available 1 -Bromo-8-tetrahydropyranyloxyoctane by the 
Gabriel method. (Scheme 6) The tetrahydropyranyl group, although not 
crucial to the synthetic strategy, was found to be convenient as this 
compound [19] was used in other applications (described in Chapter 2 of 
this thesis.) Thus 1 -B romo-8 -tetrahydropyranyloxy -octane was reacted 
with potassium phthalimide in anhydrous dimethylformamide to give 1-
phthalimido-8-tetrahydropyranyloxyoctane [18] in 91% yield. The 
phthaloyl group was removed by hydrazine hydrate in methanol to give, 
after distillation, 1 -amino-8-tetrahydropyranyl-oxyoctane [19] in 69% 
yield. 
The benzoylated active ester [15] was then reacted with amine [19] 
in anhydrous tetrahydrofuran in the presence of triethylamine to give the 
amide [20] in 96% yield which, on treatment with DOWEX H in 
methanol gave [21] (93%). Finally compound [21] was reacted with 2-
cyanoethyl N,N-diisopropylphosphoramidochloridite in anhydrous 






































(a) HPLC chromatogram (preparative) of a crude 26mer oligonucleotide 
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(b) HPLC chromatogram of a crude 24mer oligonucleotide biotinylated 
with the octamethylene phosphoramidite [22]. 
Figure 34 
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8 -(N-(N1 '-benzoylbiotinyl)- 1 -aminooctyl)-2-cyanoethyl-N,N-
diisopropylamino phosphoramidite [22] as a white powder in 44% yield 
after silica-gel chromatography. This phosphoramidite was sufficiently 
lipophilic to allow easy handling and purification. 
9.4. Oligonucleotide Synthesis using Biotin Phosphoramidite [22]. 
A 0.1 M solution of [22] in anhydrous acetonitrile was used for 
standard 0.2 pmol and 1.0 p.mol scale oligonucleotide synthesis on an 
Applied Biosystems 380B DNA synthesizer. The coupling efficiency of 
[22] was estimated to be >95% by HPLC. The benzoyl group was 
completely removed from N1' of the biotin moiety on the oligonucleotide 
after lh at 200C in conc. NH40H (HPLC monitoring) and the presence 
of the unprotected biotin ring on the oligonucleotide was confirmed by 
the generation of a pink colour after applying an aqueous solution of the 
oligonucleotide to a tic plate and spraying with p -dimethylamino-
cinnamaldehyde. Reversed-phase HPLC analysis of aliquots of 
[22]p(Tp)4T heated in conc. NH40H at 550C for periods of 2 to 24h 
confirmed the aliphatic amide link to be stable to standard deprotection 
conditions. The octamethylene linker arm gave baseline resolution of 
product from failure sequences, which elute approximately 5 minutes 
earlier, for oligonucleotides up to Ca. 35 bases long (Figure 34b). Such 
separation is not always possible with the hexamethylene spacer and 
never possible with the 3-oxa-pentyl linker. The relative retention times 
of a series of biotinylated 23mers (OSWEL 1, Appendix 1) with various 
linker arms were determined by HPLC. (Figure 35). 
A PCR primer (27mer, OSWEL 2, Appendix 1) biotinylated with 
[22] was synthesized and supplied to a customer of the OSWEL DNA 
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Service. It was reported that this primer worked well in PCR 
amplification. 
To confirm the presence of the biotin ring and spacer, 10 mg of 
biotinylated (Tp)4T were synthesized and purified and analysed by 
600MHz 'H NMR using COSY techniques to assign the spectrum. The 
assignment of the spectrum is given in the experimental section. 
1 
(a) (b) (c) 
Figure 35 : HPLC chromatogram of biotinylated oligonucleotides 
(23mers) with different linkers (a) 3-oxa-pentyl; (b) hexamethylene; (c) 
octamethylene. 
9.5. Conclusions about Biotin Phosphoramidites [17] and [ 22]. 
The use of the benzoyl biotin active ester [15] is a convenient method 
of introducing a protected biotin unit onto an amine-containing backbone 
in one step and in high yield. 
Both benzoyl biotin phosphoramidites were soluble in acetonitrile and 
coupled at >95%. 
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The N1'-benzoyl protecting group is removed from the biotin moiety 
very rapidly by NH40H at room temperature. 
The aliphatic amide link between the biotin and the spacer is stable to 
ammonia deprotection conditions. 
The 3-oxa-pentyl spacer arm introduced using [17] gives biotinylated 
oligonucleotides which are more lipophilic than failure sequences, 
however the differences in HPLC retention time are too short to allow 
convenient purification of oligonucleotides biotinylated using [17]. 
The octamethylene spacer confers excellent physical properties to 
phosphoramidite [22] in terms of lipophilicity and solubility in 
acetonitrile. 
Due to its increased lipophilicity the octamethylene spacer gives 
excellent separation of biotinylated oligonucleotides, making them easier 
to purify by reversed-phase HPLC than unmodified oligonucleotides 
under identical conditions. 
PCR experiments carried out using primers biotinylated using [22] 
were successful. 
The synthesis of multiple addition biotin phosphoramidites using the 
benzoyl biotin active ester [15] has yet to be attempted, but should be 
feasible. 
This work was presented as a poster at the San Diego Conference on 
Nucleic Acids 1991. 
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C. EXPERIMENTAL. 
Solvents and Reagents. 
Solvents were of laboratory grade, except those used for the extraction 
and chromatography of phosphoramidites, which were of HPLC grade. 
Pyrogen-free, reverse osmosis-purified water was used during 
oligonucleotide synthesis, analysis and purification. 
Anhydrous solvents and reagents 
Dichioromethane was distilled over CaH2; tetrahydrofuran and diethyl 
ether were distilled over sodium/benzophenone; N,N-dimethylformarnide 
was fractionally distilled under reduced pressure over 4A molecular 
sieve; pyridine was distilled over CaH2; acetone was distilled over 
anhydrous CaSO4 (Sikkon Fluka Universal Dessicant); hexane was dried 
over Na wire; triethylamine and N,N-diisopropylethylamine were dried 
over CaH2; anhydrous N,N-dimethylacetamide was purchased from 
Aldrich; anhydrous acetonitrile was purchased from Applied Biosystems 
Inc. (ABI). 
Other reagents. 
2-cyanoethyl N,N-di-isopropyl phosphoramidochloridite was synthesized 
and purified by the procedure of Booth. 110 1 -Bromo-8-tetrahydropyranyl-
oxyoctane and potassium phthalimide were supplied by Lancaster 
Synthesis. 4,4'-Dimethoxytrityl chloride was purchased from Fluka and 
recrystallised from hexane containing 1% acetyl chloride. para -Toluene 
suiphonyl chloride was purchased from Aldrich and recrystallised from 
petroleum ether/chloroform. All other chemicals were supplied by 
Aldrich or Fluka. 
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1H.NMR spectra were recorded on a Brucker WP-80 spectrometer 
(80MHz) and a Brucker WP-200 spectrometer (200.130MHz); 13C-NMR 
spectra were recorded on a Brucker WP-200 spectrometer (50.32MHz); 
and some 31P-NMR spectra were recorded on a Brucker WP-200 
spectrometer (81MHz). Other 31P-NMR spectra were recorded on a Jeol 
FX90Q spectrometer (90MHz). Correlated Spectroscopy (COSY) 
experiments were carried out on a Varian Instruments VXR-600 (599.945 
MHz). Nuclear Overhauser Effect experiments were carried out on a 
Bruker WH-360 (360MHz). 
Mass Spectra. 
Positive ion Fast Atom Bombardment (f,a.b.) mass spectra were recorded 
on a Kratos MS50 TC spectrometer using a thioglycerol or 3-nitrobenzyl 
alcohol (3-NOBA) matrix. 
IR spectra. 
IR spectra were recorded on a Perkin-Elmer 781 IR spectrophotometer 
using KBr plates and a polystyrene reference (1603 cm-1 and 1029cm 1). 
Melting Points. 
Melting points were determined on a Koffler Hot Stage Microscope 
apparatus and are uncorrected. 
Wel 
Oligonucleotide synthesis. 
Oligonucleotide synthesis was performed on an Applied Biosystems 
380B DNA synthesizer. All DNA synthesis reagents and cyanoethyl-
phosphoramidite monomers were supplied by ABI or Cruachem. 
Measurement of phosphoramidite coupling efficiencies. 
Coupling efficiencies of phosphoramidites were measured by comparison 
of the absorbance at 498nm of the dimethoxytrityl cations produced in the 
detritylation steps of successive synthesis cycles. The coupling efficiency 
was calculated as follows: 
[A498(cycle n+1 )/A498(cycle n)}x 100 
The absorbances were measured by dilution of the detritylation product 
fractions to 25m1 with 0.1M Toluene-4-sulphonic acid in acetonitrile. 
Coupling efficiencies of phosphoramidites with more than one 
dimethoxytrityl group were calculated by division of the absorbance at 
498nm by the number of dimethoxytrityl groups present. Coupling 
efficiencies of phosphoramidites (X) without a dimethoxytrityl group 
were estimated by comparison of the integrals of the HPLC peaks for a 
test sequence XT5 and the failure sequence T5. 
Oligonucleotide analysis and purification. 
Reversed-phase HPLC analysis and purification were carried out on a 
Gilson model 306 HPLC system using ABI Brownlee Aquapore Octyl 
reverse phase columns. Oligonucleotides >12 bases long were desalted on 
NAP-10 columns (Sephadex G25) (Pharmacia) following manufacturers 
instructions. Shorter oligonucleotides were desalted on a Sephadex G-10 
column (35cm x 2cm) using a 1 ml mm -1 flow rate. 
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Buffer systems: 
Buffer A-0.1M NH40Ac; Buffer B-O.1M NH40Ac/X% acetonitrile, 
where 20<X<65%, depending upon the lipophilicity of the 
oligonucleotide. (Exact buffer systems are reported in each case.) 
Gradients: 
Gradient A. 
Time/mm Flow/mlmiw1  %Buffer B 
0 3 0 
3 3 0 
4 3 15 
23 3 70 
25 3 100 
28 3 100 
29 3 0 
30 3 0 
Gradient B. 
Time/mm Flow/mlmin-1  %Buffer B 
0 3 0 
3 3 0 
4 3 15 
23 3 100 
27 3 100 
28 3 0 
30 3 0 
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Gradient C. 
Time/mm Flow/mlmin-1  %Buffer B 
0 3 0 
3 3 0 
4 3 15 
19 3 100 
28 3 100 
29 3 0 
35 3 0 
Detritylation of "trityl-on" oligonucleotides. 
After HPLC purification "trityl-on" oligonucleotides were evaporated to 
dryness and taken-up in 3% aqueous acetic acid (4m1). After lh at 20°C 
the solutions were evaporated to dryness then desalted on Sephadex G-
25. Removal of the dimethoxytrityl group was confirmed by HPLC. 
Chromatography. 
Flash chromatography was carried out using silica gel 60 (Fluka). Thin 
layer chromatography (tic) was carried out on aluminium sheets, silica 60 
F254, 0.2mm layer (Merck) using the following solvent systems: 
Toluene-ethyl acetate (50:50, v/v) 
Toluene-ethyl acetate (80:20, v/v) 
Dichloromethane-methanol (90:10, v/v) 
Dichioromethane-methanol (99:1, v/v) 
Dichioromethane-isopropanol (95:5, v/v) 
Dichioromethane-methanol (80:20, v/v) 
n-Butanol-acetic acid-water (60:20:20, v/v/v) 
Dichioromethane-ethyl acetate (50:50, v/v) 
Dichioromethane-methanol (95:5, v/v) 
Hexane-ethyl acetate (50:50, v/v) 
Ethyl acetate-methanol-NH40H (5:1:1, v/v/v) 
Ethyl acetate-acetonitrile (50:50, v/v) 
Dichioromethane-acetonitrile (50:50, v/v) 
Hexane-ethyl acetate (80:20, v/v). 
Products were visualised on tic using the following techniques: 
UV absorbtion at 264nm where appropriate. 
Spraying with a 10% solution of phosphomolybdic acid in ethanol. 
Gives a dark blue colour for oxidisable compounds. 
Spraying with a 0.2% solution of p -dimethylaminocinnamaldehyde 
and 2% sulphuric acid in ethanol. 108,109  Gives a pink colour for biotin 
containing compounds and biotin containing oligonucleotides. 
Compounds with a -protecting group on biotin require prolonged 
heating to develop the colour. 
Spraying with a solution of para - methoxybenzaldehyde:acetic 
acid:H2SO4: ethanol (5:1:1:100, v/v/v/v). Compounds with a protected or 
unprotected 1 ,2-diol function give a dark blue colour on heating. 
Spraying with a 1% solution of ninhydrin in ethanol. Amines give a 
strong purple/brown colour on heating. Amides and phthalimides give a 
brown colour on strong heating. 
Dinitrophenyl-containing compounds can be seen directly due to their 




N,N'-Bis(2-hydroxyethyl)-ethylene diamine (1 eq; 1 .5g; 1 Ommol) was 
dissolved in methanol (30m1) and to this solution was added triethylamine 
(2.5eq; 2.53g; 3.48m1; 25mmol) and 2,4-dinitrofluorobenzene (2eq; 
3.72g; 20mmol). After 2h the product appeared as an orange precipitate. 
After 3.5h the flask was cooled to 0°C in an ice bath and the precipitate 
was filtered-off and washed with methanol (30m1) and diethyl ether 
(300m1). After drying in vacuo the product was recrystallized from 
methanol to give the title compound [1] as dark orange crystals (3.89g; 
81%). m.p. 149-150°C; (Found C,44.8; H, 4.18; N, 17.4. 
C18H20N6010 requires C,45.0; H, 4.16; N, 17.5%); Rf 0.38 (Solvent Q. 
V(nujol)/cm 1 3490 (m, OH), 2850 (s, aliphatic), 1600 (s, aromatic), 
1580 (m), 1525 (s), 1495 (s), 1470 (s), 1420 (w), 1395 (w), 1360 (m), 
1330 (s), 1270 (s), 1230 (w), 1205 (m), 1165 (w), 1145 (m), 1125 (w), 
1080 (w), 1070 (w), 1045 (w), 995 (w), 930 (w), 915 (w), 900 (w), 850 
(w), 830 (w), 770 (w), 745 (m), 725 (w), 655 (w), 630 (w). oH 
(80.13 MHz, CDC13) 3.0-4.0 (12H, in, CH2), 4.7 (2H, t, OH, OH-
CH25HZ), 7.33 (2H, d, DNP 6-H,J5..6 =9.5Hz), 8.13 (2H, dd, DNP 5-H, 
J5H6H=9.5Hz, 3-H-5H =2.8Hz), 8.47 (2H, d, DNP 3-H, 3-H-5-
H=2.8Hz). f.a.b. ms, mlz 481 (M+H). 
8-(4,4' .Dimethoxytrityloxy)-3,6-bis(2,4-dinitrophenyl)-3,6-
diazaoctan-1-oJ [2] 
3 ,6-Bis (2,4-dinitrophenyl)-3 ,6-diazaoctane- 1 ,8-diol [1] (1 eq;3 . 30g; 
6.88mmol) was dried by evaporation of anhydrous pyridine (3 x 30m1) 
and dissolved in anhydrous pyridine (60m1). To this solution was added 
dropwise over 30 mm, a solution of 4,4'-dimethoxytrityl chloride (1 .3eq; 
111 
3.03g; 8.94mmol) in anhydrous pyridine (100m!). After 2hr a second 
aliquot of 4,4'-dimethoxytrityl chloride (0.2eq; 0.47g; 1.38mmol) in 
anhydrous pyridine (20m1) was added dropwise over 20 min and after a 
further 30 min the reaction was quenched with methanol (20m1) and the 
solvent was evaporated in vacuo. The residue was dissolved in 
dichioromethane (250m1) and washed with saturated aqueous NaHCO3 
(50m1), and water (3 x 50m1). The organic phase was dried (Na2SO4), 
filtered and the solvent removed in vacuo. The residue was dissolved in 
the minimum volume of toluene-ethyl acetate (1:1, v/v)+ I% triethylamine 
and applied to a silica gel chromatography column, eluting with the same 
solvent system, to give the title compound [2] as an orange foam (1.68g; 
31%). Rf 0.29 (solvent D); Rf 0.58 (solvent E); Rf 0.35 (solvent A). 
Vmax(nujol)/cm 1  3560 (w, OH), 1605 (s, aromatic), 1590 (s), 1500 (s), 
1330 (s), 1245 (s), 1170 (m), 1145 (m), 1125 (w), 1060 (w), 1030 (m), 
990 (w), 930 (w), 910 (w), 830 (m), 790 (w), 745 (m), 720 (m). 
H(80.13MHz; CDC13) 2.0-2.25 (1H, bs, OH), 3.25-3.72 (12H, m, 
CH2), 3.73 (6H, s, OCH3), 6.65-7.23 (15H, in, DMT, DNP 6-H), 8.06 
(1H, dd, DNP 5-H, J5H6H=9.3Hz, 44J5...H 2.7HZ), 8.13 (1H, dd, 
DNP 5-H, J5H6H 9.3HZ, J3H5H=2.3Hz), 8.52 (d, 1H, DNP 3-H, 
J3H5H=2.7HZ), 8.55 (1H, d, DNP 3-H, J3H5H=2.7Hz). f.a.b. ms, 
m/z 783.26259. [(M+H)+, C39H39N6012 requires 783.262571. 
2-Cyanoethyl -[8-(4,4' -dimethoxytrityloxy)-3,6-bis(2,4-dinitrophenyl).. 
3,6-d iazaoctyl] N,N-di-isopropylphosphoramidjte [3] 
8-(4,4'-Dimethoxytrityloxy)-3 ,6-bis(2,4-dinitrophenyl)-3 ,6-diazaoctan- 1-
ol [2] (leq;0.643g; 0.822mmo1) was dried by evaporation of anhydrous 
tetrahydrofuran (3 x 20ml) and dissolved in anhydrous tetrahydrofuran 
(30m1). To this solution was added N,N-diisopropylethylamine(4eq; 
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3.29mmol; 0.425g; 0.573m1) and 2-cyanoethyl N,N-di-isopropyl-
phosphoramidochioridite (1.5 eq; 1.23mmoi; 0.291g; 0.276ml). The 
solution was stirred at 200C and the reaction was complete by tic after 15 
mm. The reaction was diluted with ethyl acetate (30m1) and the resulting 
solution was washed with brine (4 x lOOml). The organic layer was dried 
(Na2SO4), filtered and the solvent was removed in vacuo. The residue 
was dissolved in the minimum volume of toluene-ethyl acetate (80:20, 
v/v)+ 1 % triethylamine, and applied to a silica gel chromatography 
column, eluting with the same solvent system, to give [3] as an orange 
foam. The foam was dissolved in the minimum volume of anhydrous 
dichioromethane and the solution was added dropwise to rapidly stirred 
anhydrous hexane at -78°C. The precipitated product was collected by 
filtration under a stream of argon, to give the title compound [3] as an 
orange powder (0,678g; 84%). Rf 0.50 (solvent B). op (81.020 MHz; 
CDC13) 149.12 (s). f.a.b. ms m/z 983.37044 [(M+H),C48H56N8013P 
requires 983.370421. 
6-aminohexan-1-ol derivatives. 
6-(2,4-Dinitrophenylamino) hexan-1-oI [4]. 
6-Aminohexan-1-ol,(leq; 0.8g; 6.8mmol) was dissolved in methanol 
(20m1). To this solution was added 2,4-dinitrofluorobenzene (leq; 1.3g). 
After 1 2hr the solvent was evaporated in vacuo and the resulting oil was 
washed with diethyl ether. Crude yield of [4] was 70% (1.3g). 
Recrystallisation from diethyl ether/ methanol gave the title compound [4] 
as waxy yellow crystals(1.04g; 54%). m.p. 750C; (Found C, 50.65; H, 
5.83; N, 14.78. C12H17N305 requires C, 50.88; H, 6.01; N, 14.84%); Rf 
0.52 (solvent C); v(nujol)!cml 3530 (m, OH), 3380 (m, NH), 3110 
(w, NH), 2850 (s, aliphatic), 1605 (s, aromatic), 1520 (s), 1490 (s), 1460 
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(s), 1415 (m), 1375 (s), 1335 (s), 1305 (s), 1265 (s), 1240 (s), 1225 (s), 
1165 (m), 1140 (s), 1125 (m), 1100 (m), 1070 (s), 1060 (m), 1035 (m), 
980 (m), 935 (m), 920 (s), 870 (w), 860 (w), 835 (s), 765 (m), 745 (s), 
700 (s), 645 (w), 610 (s). 8H(200.13OMHz; CDC13) 1.1-2.0 (9H, m, CH2, 
OH), 3.25-3.5 (2H, m, C1H2), 3.64 (2H, t, C6H2, J=6.2Hz), 6.9 (1H, d, 
Ar H-6, J01.tj10=9.56Hz), 8.25 (1H, ddd, Ar H-5, J01-tj10=9.53Hz, 
Jmeta=2.69Hz, Jpara=0.75Hz), 8.5 (1H,br s, NH), 9.1 (1H, d, Ar H-3, 
Jmeta=2.66Hz); c(50.320MHz, CDC13) 25.24 (CH2),26.55 (CH2), 
28.48 (CH2), 32.25 (CH2), 43.35 (CH2), 62.42 (CH2), 113.82 (CH), 
124.15 (CH), 130.17 (CH+C), 135.68 (C), 148.23 (C); f.a.b. ms m/z 
284.12462 [(M+H)+, C1 2Hl 8N305 requires 284.12463]. 
1-(2-Cyanoethyl-6-(2,4-dinitrophenylamino)hexyl)-N,N 
diisopropylphosphoramidite [5]. 
6-(2,4-Dinitrophenylamjno) hexan-1-ol [4] (1eq;0.14g; 0.495mmo1) was 
dissolved in anhydrous tetrahydrofuran (5m1) and to this solution was 
added anhydrous diisopropylethylamine (leq;0. imi) and 2-cyanoethyl 
N,N-di-isopropyl phosphoramidochioridite (1 .2eq;0. 1 4g; 0.13 2m1). After 
lh the reaction was diluted with ethyl acetate (20m1) and washed with 
NaHCO3 (2x5m1) and brine (2x5m1). The organic phase was dried 
(Na2SO4), filtered and evaporated in vacuo. The resulting oil was 
dissolved in the minimum volume of dichloromethane: ethyl acetate, 1:1, 
and applied to a flash chromatography column, eluting with the same 
solvent system, to give [5] as an oil. This was dissolved in 
dichloromethane and precipitated from anhydrous hexane to give the title 
compound [5] as an red-orange oil (0.1g; 80%). Rf 0.8 (solvent F); 
8p(81 MHz; CDC13)147.54 (s); f.a.b. ms m/z 484.23247 [(M+H)+, 
C21H35N506P requires 484.23248]. 
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HPLC analysis and Purification of Oligonucleotides DNP-labelled 








Phosphoramidite Gradient %MeCN 
used. 	 used 	in Buffer B. 
[5] 	 A 	20 
[3] 	 B 	20 
[3] 	 B 	40 
[3] 	 B 	50 
[3] 	 B 	65 
Multiple Addition DNP Phosphoramidite based on a 1.2.6-
Trihydrpxyhexan e Backbone. 
5,6-Isopropylidenedioxyhexan- 1-01 [6]. 
1,2,6-Trihydroxyhexane (37g; 0.27mo1) was dissolved in anhydrous 
acetone (250m1) and to this solution was added anhydrous sodium 
sulphate (lOOg) and cone, aqueous HC1 (5m!). After stirring overnight at 
200C, lead (II) carbonate (basic form) (lOOg) and Na2CO3 (ig) were 
added and the reaction was left for a further 48h. Solids were removed by 
filtration and the solvent was evaporated in vacuo to give a pale yellow 
liquid. Na2CO3 (ig) was added to the liquid to maintain basic conditions 
and the residue was purified by kugelrohr distillation to give the title 
compound [6] as a clear liquid (39.92g, 85%). b.p. 1200C (at 0.05mbar). 
vm (fihTl)/cm 1 3410 (s, OH), 2985 (s, CH), 2930 (s, CH), 2860 (s, CH), 
1455 (m), 1380 (s), 1370 (s), 1250 (s), 1215 (s), 1155 (s), 1050 (s), 915 
(w), 855 (m), 815 (w), 790 (w), 735 (w). Rf 0.46 (solvent C); 
8H(200. 130MHz; CDC13) 1.24 (3H,s,CH3), 1.29 (3H,s,CH3), 1,244.60 
(6H,m,CH2), 2.91 (1H,brs,OH), 3.36-3.52 (3H,m,CH,CH2), 3.89-4.01 
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(2H,m,CH2); c(50.32MHz; CDC13) 21 .73(CH2), 25.39 (CH3), 26.59 
(CH3), 32.21 (CH2), 32.93 (CH2), 61.89 (CH2), 69.06 (CH2), 75.71 
(CH), 108.41 (C). f.a.b. ms m/z 175.133411 [(M+H)+, C91-11903 
requires 175.13341]. 
5,64sopropylidenedioxyhex-1-yl p-toluenesulphonate [7]. 
To a solution of compound [6] (leq; 2.3g; 0.014mol) in anhydrous 
pyridine (50m1) cooled to 0°C, was added 4-toluene suiphonyl chloride 
(leq; 0.014mol; 2.74g). After 2h at 200C the solution was evaporated to 
an oil which was coevaporated with toluene three times. The residue was 
taken-up in dichioromethane and washed with water (50m1) and sat. aq. 
KC1 (3 x 50m1). The organic phase was dried (Na2SO4), filtered and the 
solvent removed by evaporation in vacuo. The product was purified by 
wet-flash silica gel chromatography, eluting with 10% ethyl acetate in 
toluene, to give the title compound [7] as a pale yellow clear oil (2.874g; 
61%). Rf 0.40 (solvent B); vmax(film)1cm 1  2980 (s, CH), 2930 (s, CH), 
2870 (s, CH), 1600 (m, aromatic), 1495 (w), 1455 (m), 1360 (s, 
sulphonyl), 1308 (w), 1295 (w), 1250 (m), 1210 (s), 1190 (s), 1175 (s, 
suiphonyl), 1095 (s), 1055 (s), 960 (s), 930 (s), 835 (m), 815 (m), 775 
(m), 730 (m), 705 (w), 690 (w), 665 (s). H(200.130MHz; CDC13) 1.24 
(3H,s,CH3), 1.29 (3H,s,CH3), 1.24-1.63 (6H,m,CH2), 2.36 (3H,s, Ar-
CH3), 3.36-3.41 (1H,m,CH), 3.87-3.97 (4H,m,CH2), 7.26 (2H,d, Ar 3-H, 
Ar 5-H, J01.tj10=7.84Hz), 7.69 (2H,m,Ar 2-H, Ar 6-H); 8c(50.32MHz; 
CDC13) 21.26 (CH3), 21.41 (CH2), 25.34 (CH3), 26.58 (CH3), 28.40 
(CH2), 32.48 (CH2), 68.93 (CH2), 69.99 (CH2), 75.31 (CH), 108.32 (C), 
127.49 (2xAr CH), 129.54 (2xAr CH), 132.72 (C), 144.44 (C); f.a.b. ms 
m/z 329.14224 [(M+H)+, C16H2505S requires 329.14226]. 
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N-Phthaloyl-5,6-isopropylidenedioxyhexylamine [8]. 
To a solution of compound [7] (leq; 3.446g; 0.0105mol) in anhydrous 
N,N-dimethylformamide (15m1) was added potassium phthalimide 
(1.leq; 0.01l6mol; 2.14g). The reaction was stirred for 16h at 200C then 
heated to 600C for 2h after which time the reaction was found to be 
complete by tic. The solvent was removed by evaporation to dryness and 
the residue was coevaporated once with toluene, dissolved in 
dichioromethane and washed with water (3 x 50m1). The organic phase 
was dried (MgSO4), filtered and the solvent removed by evaporation in 
vacuo to give a pale brown solid. The product was purified by wet-flash 
silica gel chromatography, eluting with 10% ethyl acetate in toluene, to 
give the title compound [8] as a waxy white solid (3.037g; 96%). Rf 0.37 
(solvent B). v(nujoI)/cml 1720 (s, cyclic imide CO), 1700 (s, cyclic 
imide CO), 1400 (m), 1335(m), 1285(w), 1245(w), 1230(m), 1205(w), 
1160(m), 1085(m), 1055(m), 1040(s), 985(w), 915(w), 890(w), 855(m), 
790(w), 720(s). 8H(200.13OMHz; CDC13) 1.24 (3H,s,CH3), 1.29 
(3H,s,CH3), 1.30-1.71 (6H,m,CH2), 3.37-3.46 (1H,m,CH), 3.60 (2H, t, 
N-CH2, 3J=7.13Hz), 3.89-4.01 (2H,m,CH2), 7.60-7.78 (4H,m,Ar CH); 
c(50.32MHz; CDCI3) 22.78(CH2), 25.40 (CH3), 26.61(CH3), 28.25 
(CH2), 32.80 (CH2), 37.42 (CH2), 69.05 (CH2), 75.47 (CH), 108.34 (C), 
122.83 (2xAr CH), 131.79 (2xAr C), 133.56 (2xAr CH), 168.01 (2xCO); 
f.a.b. ms m/z 304.15488[(M+H), C17H22N04 requires 304.15487]. 
5, 6-Isopropylidenedioxyhexylamine [9]. 
To a solution of compound [8] (leq; 2.501g; 8.25mmol) in methanol 
(lOml) was added hydrazine hydrate (1. leq; 9.08mrnol; 0.454g; 0.44ml). 
The mixture was stirred for 16h at 200C, during which time a white 
precipitate formed. The solvent was removed by evaporation in vacuo, 
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and the residue was dissolved in diethyl ether and washed with 2M 
NaOH. The aqueous phase was extracted three times with diethyl ether 
and the combined organic phase was dried (MgSO4), filtered and 
evaporated in vacuo to give a white solid which was purified by 
kugelrohr distillation to give the title compound [9] as a clear liquid 
(0.720g; 51%). b.p. 100°C (at 0.01mbar). Rf 0.36 (solvent K); 
vm (film)/cm 1 3360 (s), 2985 (s), 2930 (s), 2860 (s), 1570 (s), 1485 (s), 
1380 (s), 1370 (s), 1320 (s), 1245 (s), 1210 (s), 1160 (s), 1055 (s), 850 
(s), 820 (m), 790 (w). 8H(200.13OMHz; CDC13) 1.27 (3H,s,CH3), 1.32 
(3H,s,CH3), 1.17-1.63 (6H,m,CH2), 1.49 (2H,s,NH2), 2.62 (2H, t, N-
CH2, 3J=6.6Hz), 3.32-3.46 (1H,m,CH), , 3.92-4.03 (2H,m,CH2); 
c(50.32MHz; CDC13) 22.88(CH2), 25.47 (CH3), 26.69(CH3), 33.18 
(CH2), 33.39 (CH2), 41.73 (CH2), 69.19 (CH2), 75.74 (CH), 108.37 (C); 
f.a.b. ms mlz 174.149392[(M+H), C91-120NO2 requires 174.14939]. 
1-(2,4-Dinitrophenylamino)-5, 6-isopropylidenedioxyhexane [10]. 
To a solution of compound [9] (leq; 0.5g; 2.89mmol) in methanol (lOmi) 
was added triethylamine (4eq; 0.012mol; 1.169g; 1.61m1) and a solution 
of 2,4-dinitrofluorobenzene (leq; 2.89nimol; 0.538g) in methanol (5m1). 
The mixture was stirred at 200C for 16h. Solvents were removed by 
evaporation in vacuo, and the residue was coevaporated 3 times with 
toluene. The residue was purified by wet-flash silica gel chromatography, 
eluting with a gradient of 5-10% ethyl acetate in toluene, to give the title 
compound [10] as an orange oil (1.101g; 100%). vm (fi1m)/cm 1  
3360(m, NH), 3100(w, NH), 2980(m, CH), 2930(m, CH), 2840(m, CH), 
1615(s, NO2), 1590(s, aromatic), 1520(s), 1500(m), 1420(m), 1365(m), 
1335(s, NO2), 13 10(s), 1240(m), 1150(m), 1130(m), 1055(m), 920(w), 
850(w), 830(w), 820(w), 740(m), 710(w). Rf 0.33 (solvent B); 
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H(200.130MHz; CDC13) 1.32 (3H,s,CH3), 1.38 (3H,s,CH3), 1.21-1.88 
(6H,m,CH2), 3.37-3.55 (3H,m,CH,CH2), 3.98-4.12 (2H,m,CH2) 6.89 
(1H,d, DNP 6-H,J5.H.6H=9.5Hz),  8.22 (1H,dd, DNP 5-H, 5-H-6 
H9.5HZ, 3-H-5H26),  8.54 (1H, bt, NH), 9.07 (1H,d, DNP 3-H, J3.. 
H5H=2.6HZ). c(50.32MHz; CDCI3) 23.11 (CH2), 25.45 (CH3), 
26.75(CH3), 28.47 (CH2), 32.88 (CH2), 43.25 (CH2), 69.11 (CH2), 
75.44 (CH), 108.69 (C), 113.72 (DNP-CH), 124.12 (DNP-CH), 130.14 
(DNP-CH+C), 135.69 (DNP-C), 148.14 (DNP-C); f.a.b. ms m/z 
340.15088 [(M+H), C1 5H22N306 requires 340.15085]. 
1-(4, 4'-Dimethoxytrityloxy)-6-(2, 4-dinitrophenylamino) hexan-2-ol 
[11]. 
To a solution of compound [10] (leq; 1.00g; 2.95mmol) in 
tetrahydrofuran (lOmi) was added water (4m1) and cone. aqueous HC1 
(imi). The reaction, to give the diol, was complete after 45mm. Rf (diol) 
0.39 (solvent Q. The solvents were removed by evaporation in vacuo and 
the residue was coevaporated with anhydrous pyridine (4 x lOmi), then 
dissolved in anhydrous pyridine (20ml). To this solution was added 4,4'-
dimethoxytrityl chloride (1.1eq; 3.25mmol; 1.1g). The mixture was 
stirred at 200C for 16h then quenched with methanol (imi). The solvent 
was removed by evaporated in vacuo. The residue was coevaporated with 
toluene (3 x lOmi), dissolved in dichioromethane and washed with sat. 
NaHCO3(50m1) then sat. KC1 (3 x 50ml). The organic phase was dried 
(MgSO4), filtered and the solvent was removed by evaporation in vacuo. 
The residue was dissolved in hexane:ethyl acetate! 1:1 and applied to a 
wet-flash silica gel chromatography column which had been equilibrated 
with hexane containing 20% ethyl acetate and 1% triethylamine. The 
column was then eluted with a gradient of 20-50% ethyl acetate in 
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hexane, to give the title compound [11] as a yellow foam (1.274g; 72%). 
Rf 0.26 (solvent J), Rf 0.71 (solvent H); v(nujol)/cml 3560 (w, OH), 
3360(m, NH), 3160(w, NH), 2720(m), 1720 (w), 1620 (m, NO2), 
1590(m, aromatic), 1335(s, NO2), 1300(s), 1245(s), 1170(m) 1150(m), 
1115(w), 1075(w), 1030 (m), 970 (w), 920(w), 830(m), 790(w), 740(m), 
720(s). 6H(200.13OMHz; CDC13) 1.45-1.74 (6H,m,CH2), 2.44 (1H, 
bs,OH), 2.99-3.21 (2H,m,CH2), 3.37 (2H, dt, CH2-N, JCH2CH2=6.95HZ, 
JCH2NH=5.3Hz) , 3.71-3.78 (7H,m,CH+OCH3), 6.79-6.89 (4H, m, 
DMT-CH), 7.14-7.45 (10H,m, DNP 6-H, DMT-CH), 8.24 (1H,dd, DNP 
5-H, J5H6H=9.3HZ, J3.H5H=2.5HZ), 8.53 (111, bt, NH), 9.12 (1H,d, 
DNP 3H, J345jj2.7HZ). c(50.32MHz; CDC13) 22.83 (CH2), 28.51 
(CH2), 32.54 (CH2), 43.34 (CH2), 55.08 (2xDMT-CH3), 67.34 (CH2), 
70.48 (CH), 86.04 (DMT-C), 113.02 (4xDMT-CH), 113.73 (DNP-CH), 
124.21 (DNP-CH), 126.74 (DMT-CH), 127.73 (2xDMT-CH), 127.96 
(2xDMT-CH), 129.18 (4xDMT-CH), 130.18 (DNP-CH+C), 135.79 
(DNP-C, 2xDMT-C), 144.61 (DMT-C), 148.14 (DNP-Q, 158.40 
(2xDMT-C). f.a.b. ms m/z 601.24243 [Mt, C33H35N308 requires 
601.24240]. 
2-Cyanoethyl [1-(4, 4' -dimethoxytrityloxy)-6-(2, 4-
dinitrophenylamino) hex-2-yl] N,N-diisopropylamino 
phosphoramidite [12]. 
To a solution of compound [11] (leq; 0.718g; 1.19mmol) in anhydrous 
tetrahydrofuran (1 Omi) was added N,N-diisopropylethylamine (4eq; 
4.78mmol; 0.62g; 0.83m1) and 2-cyanoethyl N,N-di-isopropyl-
phosphoramidochioridite (leq; 1.19mmol; 0.283g; 0.266m1). After lh the 
reaction was diluted with ethyl acetate (lOOmI) and the resulting solution 
was washed with sat. aqueous KCI(4 x 50m!). The organic phase was 
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dried (MgSO4), filtered and solvents removed by evaporation in vacuo. 
A silica gel column was pre-equilibrated with hexane containing 40% 
ethyl acetate and 1% triethylamine and the residue was then purified on 
this column, eluting with 40% ethyl acetate in hexane, to give the title 
compound [12] as an orange gum (0.851g; 89%). Rf 0.54 (solvent J), Rf 
0.60 (solvent B); 6p(80MHz; CH3CN solvent; (CD3)2C0 int) 147.57(s), 
147.74 (s). f.a.b. ms m/z 803.36588 [(M+2H)+, C42H54N509P requires 
803.365891. 
Oligonucleotide Synthesis using DNP Phosphoramidite [12]. 
A 0.1 5M solution of [12] in anhydrous acetonitrile was used for 
oligonucleotide synthesis. Standard synthesis cycles for 0.2 tmo1 and 1.0 
j.tmol scale syntheses were used. All syntheses were carried out Trityl-
ON to prevent cleavage of the labelling group from the oligonucleotide. 
HPLC Analysis and Purification of Oligonucleotides DNP-labelled 
using [12]. 
Buffer A: 0.1M NH40Ac; Buffer B: 0.1M NH40Ac/50% acetonitrile. 
For oligonucleotides containing one DNP group: Gradient A. 
For oligonucleotides containing more than one DNP group: Gradient B. 
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Polymerase Chain Reaction (PCR) Experiments. 
PCR reaction mixture: 
Solution 	 Volume 
Primer 1 (10mM) 	101.11 
Primer 2 (10mM) 	101.11 
dNTP's (2mM) 	101.11 
1OxPCR buffer 	lOpi 
1-2ng Template DNA 2pi 
Water 	 57.5p1 
2.5U Taq Polymerase 	0.5p.l 
The components of the reaction mixture were added, in the above order, 
to a 0.5m1 sterile, siliconized eppendorf tube, and covered with 1001.tl of 
sterile mineral oil. 
PCR Temperature Cycle: 
The following cycle was run on a Techne PHC-3 Thermal Cycler. 
Denature at 940C for 1.5mm 
Anneal at 550C for 1.5mm 
Extend at 720C for 2.0mm 
The PCR reaction mix was subjected to 30 such cycles, with a final 
extension at 720C for 3 mm. 
Agarose Gel Electrophoresis analysis of PCR products. 
Solutions: 
1OxTBE = 0.9M tris-borate, 25mM EDTA, pH 8. 
TNE = 10mM Tris.HC1, 100mM NaCl, 1mM EDTA, pH 8. 
Ethidium bromide solution = 10mgml 1  ethidium 
bromide. [Caution: Carcinogenic] 
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Loading buffer = 0.25% bromophenol blue, 0.25% xylene cyanol, 15% 
Ficoll (type 400) in H20. 
PCR products were analysed on flat-bed 1% Agarose gels, visualising the 
product by Ethidium Bromide staining. The gels were cast using the 
following mixture: 
0.25g Agarose 
2.5m1 1OxTBE buffer 
22.25m1 water. 
The above mixture was boiled, then after cooling to Ca. 900C, 2.5i1 
ethidium bromide solution was added and the gel cast using the hot 
liquid. 
The gels were loaded with a mixture of 5tl of the crude PCR product and 
2jil of loading buffer, and run at 100V/6OmA for 15 mm. Double stranded 
DNA is visualised as bright pink fluorescent bands in the gel when 
viewed on a UV trans illuminator. Primers are not resolved into bands and 
appear as a faintly fluorescent continuum near the bottom of the gel. 
Purification of PCR products. 
Crude PCR product (30p1) and loading buffer (3il) were loaded onto a 
1% agarose gel. The gel was run at 120V (60mA) for 10 mm, then 
viewed on a UV transilluminator. Wells were cut in the gel just ahead of 
the position of the PCR product band, and filled with 60j.tl of TBE. The 
gel was then run for 1mm. and the buffer in the well was collected. This 
was repeated 4 times. The relative amounts of PCR product in the 
fractions were determined by ethidium bromide fluorescence. The 
combined fractions were concentrated to lOOj.il, and run down Sephadex 
G-50 spun columns (imi) to remove the marker dyes. Ethidium bromide 
was removed by five butan-2-ol extractions. Presence of pure PCR 
product was confirmed by agarose gel electrophoresis. 
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Purification of Anti-DNP Monoclonal Antibody. 
Pure Anti-DNP monoclonal antibody was obtained from mouse ascitic 
fluid using a Pierce ImmunoPure IgG Purification Kit (Protein A 
columns), following manufacturer's instructions. The amount of pure 
antibody obtained from imi of ascitic fluid was determined 
spectrophotometrically to be approximately 6.9 mg, assuming an 
extinction coefficient at 280nm of 1.5 Lg-1cm 1. 
Dot Blot Experiments. 
Solutions used: 
PBS! EDTA/ EGTA: Phosphate-buffered saline solution (Sigma) 
containing 1mM EDTA and 1mM EGTA. 
PBS! EDTA! EGTAITween: Phosphate-buffered saline solution 
(Sigma) containing 1mM EDTA and 1mM EGTA and 0.5% Tween-20. 
Blocking solution: 10% solution of fat-free skimmed milk in 
PBS/EDTA/EGTA. 
K3 antibody ascitic fluid: contains approx. 7mgmFi of monoclonal 
anti-DNP antibody. 
Avidin-HRP conjugate solution: a 0.2mgml4 solution of avidin-
horseradish peroxidase conjugate (Sigma) in PBS. 
DAB solution: a 0.5mgml4 solution of 3,3'-diaminobenzidine 
tetrahydrochloride (Sigma) in 50mM Tris-HC1, pH 7.6. Hydrogen 
peroxide (0.06% final conc.) was added just before use. 
Five-fold dilutions of labelled oligonucleotides were made and 0.5tl of 
each solution was spotted onto nylon (Hybond N) filters (Amersham). 
The oligonucleotides were fixed to the membrane by UV irradiation for 5 
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mm. The filters were blocked by incubation with blocking solution for lh. 
The filters were washed with PBS/EDTA/EGTA/Tween (3x2min) and 
PBS/EDTA/EGTA (1 x2min). 
For DNP detection : The filters were incubated for lh with a 1:200 
dilution of K3 antibody ascitic fluid in PBS/EDTA/EGTA. then washed 
with PBS/EDTA/EGTA/Tween (3x2min) and PBS/EDTA/EGTA 
(1 x2min). The filters were then incubated with a 1:1000 dilution of goat-
anti-mouse IgG solution (SIGMA) for lh, then washed with 
PBS/EDTA/EGTA/Tween (3x2min) and PBS/EDTA/EGTA (1x2min). 
For Biotin detection :The filters were incubated for lh with a 1:1000 
dilution of avidin-HRP conjugate solution in PBS/EDTA/EGTA then 
washed with PBS/EDTA/EGTA/Tween (3x2min) and PBS/EDTA/EGTA 
(lx2min). 
Colour reaction: The filters were incubated with DAB solution for 10-30 
mm. The reaction was stopped by washing the filter several times with 
water. 
Capture and Detection of DNP-Biotin Labelled Oligonucleotides. 
Solutions used as for Dot Blot Experiments. 
Fixing of Avidin to Nitrocellulose and blocking : A nitrocellulose 
membrane (Amersham Hybond-C) was pre-wetted with PBS. A solution 
of avidin (0.lmgml4) in PBS was spotted onto the membrane in imi 
aliquots (gives 0. 1tg of avidin/spot). The membrane was incubated at 
40C for 4h, then washed once with blocking solution. The membrane was 
incubated with blocking solution for lh, then washed with PBS/Tween 
(3x5min). 
Oligonucleotide capture : The membrane was cut into strips and each 
strip was placed in a sealed polythene bag containing 3.3m1 
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PBS/EDTA/EGTA and 0.7ml of a 1mM solution of oligonucleotide in 
PBS/EDTA/EGTA (gives an oligonucleotide conc. of 0.175jiM). The 
strips were incubated in these bags for lh, then washed successively with 
PBS/EDTA/EGTA (3x5min), PBSiTween (3x5min) and PBS (3x5min). 
Oligonucleotide detection :The strips were incubated with a 1:200 
dilution of K3 antibody ascitic fluid in PBS/EDTA/EGTA for lh. then 
washed with PBS/EDTA/EGTA (3x5min). The filters were then 
incubated with a 1:1000 dilution of goat-anti-mouse IgG solution (Sigma) 
for lh, then washed with PBS/EDTA/EGTA (3x5min). 
Colour reaction : The filters were incubated with DAB solution for 30 
mm. The reaction was stopped by washing the filter several times with 
water. 
Multiple Hvdroxvl Phosphoramidite. 
1,6-bis(4,4'-Dimethoxytrityloxy)hexan-2-oI [13]. 
1,2,6-Trihydroxyhexane (leq; 1.00g; 7.45mmol) was dissolved in 
anhydrous pyridine (25m1) and to this solution was added 4,4'-
dimethoxytrityl chloride (2.2eq; 0.016mol; 5.56g). After stirring for 24h 
at 200C the reaction was quenched with methanol (2m1) and solvents 
removed by evaporation in vacuo. The residue was dissolved in 
dichioromethane and washed with sat NaHCO3 (50m1) and sat. KC1 (3 x 
50ml). The organic phase was dried (Na2SO4), filtered and solvents 
removed by evaporation in vacuo . The residue was purified by wet-flash 
silica gel chromatography on a column which had been equilibrated with 
hexane containing 10% ethyl acetate and 1% triethylamine eluting with a 
gradient of 10-50% ethyl acetate in hexane, to give the title compound 
[13] as a white foam (1.920g; 35%). Rf 0.55 (solvents J and B), Rf 0.83 
(solvent H); v(nujol)/cml 3550 (m, OH), 2720(m), 2020 (w), 1720 
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(m), 1610 (m, aromatic), 1580(m, aromatic), 1300(s), 1250(s), 1170(m) 
1155(w), 1115(w), 1075(w), 1035 (w), 970 (w), 915(w), 825(m), 790(w), 
770(w), 750 (m), 720(s). 11(200.130MHz; CDC13) 1.31-1.75 
(6H,m,CH2), 2.25-2.45 (1H, brs,OH), 2.98-3.22 (5H, m, CH, CH2), 3.77 
(6H, s, OCH3), 3.78 (6H, s, OCH3), 6.78-6.87 (8H, m, DMT-CH), 7.19-
7.48 (18H, m, DMT-CH); 5c(50.32MHz; CDC13) 22.14 (CH2), 29.87 
(CH2), 33.07 (CH2), 55.00 (4xDMT-CH3), 63.02 (CH2), 67.39 (CH2), 
70.76 (CH), 85.47 (DMT-C), 85.87 (DMT-C), 112.79 (4xDMT-CH), 
112.96 (4xDMT-CH), 126.38 (DMT-CH), 126.64 (DMT-CH), 127.52 
(2xDMT-CH), 127.67 (2xDMT-CH), 127.99 (4xDMT-CH), 129.85 
(8xDMT-CH), 135.89 (2xDMT-C), 136.51 (2xDMT-C), 144.71 (DMT- 
C), 145.22 (DMT-C), 158.12 (2xDMT-C), 158.31 (2xDMT-C). f.a.b. ms 
m/z 738.35561 [Mt, C48H5007 requires 738.35563]. 
2-Cyanoethyl [1,6-bis(4,4' -d imethoxytrityloxy) hex-2-yI] N,N-
diisopropylamino phosphoramidite [14]. 
To a solution of compound [13] (leq; 1.084g; 1.47mmol) in anhydrous 
tetrahydrofuran (lOmi) was added N,N-diisopropylethylamine (4eq; 
5.88mmol; 0.76g; 1.02m1) and 2-cyanoethyl N,N-di-isopropyl-
phosphoramidochioridite (leq; 1 .47mmol; 0.348g; 0.33m1). After lh the 
reaction was diluted with ethyl acetate (lOOmi). The resulting solution 
was washed with sat. aqueous KC1 (4 x 50m1). The organic phase was 
dried (MgSO4), filtered and solvents were removed by evaporation in 
vacuo. A silica gel column was pre-equilibrated with hexane containing 
20% ethyl acetate and I% triethylamine and the residue was then purified 
on this column, eluting with a gradient of 20-30% ethyl acetate in hexane, 
to give the title compound [14] as a clear oil (1.217g; 89%). Rf 0.21 
(solvent N), Rf 0.65 (solvent B); 8p(81.02 MHz; CH3CN solvent; 
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(CD3)2C0 int) 147.57(s), 147.74 (s). f.a.b. ms m/z 939.47135 [(M+H)+, 
C57H68N208P requires 939.4713]. 
Oligonucleotide synthesis using [14]. 
A 0.15M solution of [14] in anhydrous acetonitrile was used for 
oligonucleotide synthesis. Single addition biotin and DNP 
phosphoramidites were used as 0.15M solutions in anhydrous 
acetonitrile. Modifications to the standard synthesis cycle for 0.2 j.imol 
syntheses were as follows: 
Double delivery of Base and Base+tetrazole to column during 
coupling step for both [14] and biotin or DNP phosphoramidites. 
Coupling wait step increased to 5mm. for additions of both [14] and 
biotin or DNP phosphoramidites. 
HPLC Analysis and Purification. 
Buffer A: 0.1M NH40Ac; Buffer B: 0.1M NH40Ac/50% acetonitrile. 
Gradient B. 
Biotin Derivatives. 
N1' -Ben zoylbiotin-2-nitrophenyl ester [15] 
Biotin-2-nitrophenyl ester (leq; 1.5g; 4.1 immol) was dried by 
evaporation of anhydrous pyridine (3 x l5ml), then dissolved in 
anhydrous pyridine (20m1), and cooled to 0°C. Benzoyl chloride (2eq; 
8.22mmol; 1.15g; 0.95m1) was added dropwise with stirring. The reaction 
was allowed to warm to room temperature and tic indicated that all the 
starting material was consumed after 90 mm. The reaction mixture was 
poured into sat, aqueous NaHCO3, extracted with dichloromethane and 
the organic phase was washed twice with sat, aqueous KC1, then dried 
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(Na2SO4), filtered and the solvent was removed by evaporation in vacuo 
to give a yellow foam. The product was purified by wet-flash column 
chromatography, eluting with a gradient of 0-20% ethyl acetate in 
dichioromethane, to give the title compound [15] as a white foam (1.36g; 
70%). Rf 0.63 (solvent C), 0.43 (solvent H); 8H(200.13OMHz; DMSO-
d6) 1.45-1.79 (6H, in, 6-, 7-, 8-H), 2.68 (2H, t, 9-H, J89=7.2Hz), 2.89-
3.12 (2H, m, 2-H), 3.24-3.30 (1H, m, 5-H), 4.25 (1H, dd, H-4, J3... 
47.7HZ, J45=4.5Hz), 5.07 (1H, in, H-3),7.34-7.60 (8H, m, H-3', Bz 
CH, nitrophenyl 4-H, 6H), 7.80-7.88 (1H, dt, nitrophenyl 5-H, J3 
5=1.6Hz, J54,6=7.7Hz), 8.13-8.18 (1H, dd, nitrophenyl 3-H, J3.. 
=1.6Hz, J34=8.lHz); 8c(50.32 MHz; CDC13) 23.87 (CH2), 27.59 
(CH2), 27.96 (CH2), 33.46 (CH2), 38.10 (CH2), 54.98 (CH), 57.52 (CH), 
62.17 (CH), 125.04 (CH), 125.65 (CH), 126.54 (CH), 127.34 (CH), 
128.66 (CH), 131.28 (CH), 134.62 (CH), 134.72 (CH), 141.64(C), 
143.87(C), 156.56(C), 169.69(C), 170.96(C). f.a.b. ms m/z 470.13855 
[(M+H)+, C23H24N306S requires 470.138571. 
(N5-(N1' -Benzoylbiotinyl)) -5-amino-i -hydroxy-3-oxa-pentane [16] 
N1'-Benzoylbiotin-2-nitrophenyl ester [15] (leq; 0.7g; 1.49mmol) was 
dissolved in dichioromethane (20m1) and to this solution was added 
triethylamine (0.2m1) and 2-(2-aminoethoxy)ethanol (leq; 1 .49mmol; 
0.15g). The solution immediately turned bright yellow due to the 
liberated 2-nitrophenol. The reaction was complete after 2hr at 200C 
whereupon the solution was evaporated to dryness and coevaporated with 
toluene (2x7m1) then ethanol (7ml). The product was purified by wet-
flash chromatography eluting with a gradient of 1-2% methanol in 
dichioromethane, to give the title compound [16] as a white solid (0.586g; 
90%). Rf 0.25 (solvent C); 5H(200.13OMHz; DMSO-d6/D20) 1.26-1.59 
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(6H, in, 6-, 7-, 8-H), 2.09 (2H, t, 9-H, J8..9=7.2Hz), 2.87-2.96 (2H, in, 2-
H), 3.15-3.26 (3H, in, 5-11, CH2), 3.37-3.54 (6H, in, CH2), 4.22 (1H, dd, 
H-4, J3..47.8Hz, J4..5=4.6Hz), 5.01-5.06 (1H, in, H-3),7.27-7.47 (5H, 
in, Ar). f.a.b. ms m/z 436.19062 [(M+H)+, C21H30N305S  requires 
436.190601. 
1-[(N5-(Nl '-Benzoylbiotinyl))-5-amino-3-oxa-pentyl] -2-cyanoethyl-
N,N-diisopropylamino phosphoramidite [17] 
(N5-(N 1 '-Benzoylbiotinyl))-5-amino- 1 -hydroxy-3 -oxa-pentane [16] (1 eq; 
0.54g; 1 .24mmol) was dissolved in anhydrous tetrahydrofuran (lSml). To 
this solution was added N, N-diisopropylethylamine (4eq; 4.97mmol; 
0.64g; 0.86m1) and 2-cyanoethyl N,N-di-isopropylphosphoramido-
chioridite (leq; 1.24mmol; 0.29g; 0.28m1). The reaction was incomplete 
after lhr and a further 0.3 eq (0.09m1) of 2-cyanoethyl N,N-di-isopropyl-
phosphoramidochioridite was added. After a further hour the reaction was 
quenched with anhydrous ethanol (5m1), and the solution was evaporated 
to an oil which was dissolved in dichloromethane and washed once with 
sat. aqueous NaHCO3 and twice with sat. aqueous KC1. The organic 
phase was dried (Na2SO4), filtered and the solvent evaporated in vacuo. 
The product was purified by wet flash chromatography eluting with 
dichloromethane containing 0-5% methanol and 1% triethylamine. The 
purified product was dissolved in dichloromethane and precipitated from 
anhydrous hexane at 200C. The precipitate was allowed to settle and the 
supernatant was removed via a double ended needle. The solid residue 
was dissolved in dichloromethane and evaporated in vacuo to give the 
title compound [17] as a white foam (0.346g; 43%). The product was 
found by 31P-NMR to be contaminated with ca. 10% of the 
corresponding phosphonate. This did not appear to interfere with 
130 
coupling during oligonucleotide synthesis. Rf 0.48 (solvent C); 
8p(80MHz; CH202solvent; (CD3)2C0 mt.) 148.347, 9.019. f.a.b. ms 
mlz 63 6.29846 [(M+H)+, C30H47N506PS requires 636.29845] 
1-Phthalimido-8-tetrahydropyranyloxyoctane [18] 
1 -Bromo-8 -tetrahydropyranyloxyoctane (1 eq; lOg; 34mmol) was 
dissolved in anhydrous dimethylformamide (50m1) and to this solution 
was added potassium phthalimide (1.1eq; 37.5mmol; 6.95g). The reaction 
was stirred at 200C for 24h, then evaporated to dryness. The residue was 
dissolved in ethyl acetate and the precipitate of KBr and excess 
potassium phthalimide was filtered off. The resulting solution was 
washed once with water, dried (Na2SO4), filtered and the solvent was 
removed by evaporation in vacuo . The product was purified by wet-flash 
chromatography, eluting with a gradient of 10-20% ethyl acetate in 
hexane, to give the title compound [18] as a clear oil, which solidified on 
standing (1 1.07g;91 %). Rf 0.74 (solvent I), 0.67 (solvent J); 
v(nujo1)/cm 1  1770 (m, cyclic imide), 1715 (s, cyclic imide), 1390 
(s), 1255 (w), 1200 (w), 1185 (w), 1170 (w), 1135 (m), 1120 (m), 1075 
(s), 1065 (s), 1030 (s), 990 (w), 965 (w), 940 (w), 905 (w), 865 (m), 815 
(w), 790 (w), 715 (s), 690 (w). 5H(200.13OMHz; CDC13) 1.25-1.76 (18H, 
m, CH2), 3.23-3.83 (6H, in, NCH2, OCH2), 4.49 (1H, t, THP-CH, 
J=3.lHz), 7.61-7.78 (4H, m, Ar-H); c(50.32MJ-1z; CDC13) 19.46 (CH2), 
25.29 (CH2), 25.95 (CH2), 26.59 (CH2), 28.37 (CH2), 28.92 (CH2), 
29.10 (CH2), 29.48 (CH2), 30.55 (CH2), 37.81 (CH2), 62.05 (CH2), 
67.36 (CH2), 98.57 (THP-CH), 122.92 (2xAr CH), 131.95 (2xAr C), 
133.62 (2xAr CH), 168.20 (2xCO). f.a.b. ms mlz 360.21745 [(M+H), 
C21H30NO4 requires 360.217471. 
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1-Amino-8-tetrahydropyranyloxyoctane [19] 
1 -Phthalimido-8 -tetrahydropyranyloxyoctane [18] (1 eq; 5g; 0.01 4mol) 
was dissolved in methanol (20m1). To this solution was added hydrazine 
hydrate (1.1eq; 0.015mol; 0.77g; 0.74m1). After 5h the reaction was 
evaporated to dryness and the residue was dissolved in diethyl ether and 
extracted once with 2M aqueous NaOH. The organic phase was dried 
(Na2SO4), filtered and the solvent evaporated to give an oil which 
solidified on standing. The product was purified by kugelrohr distillation, 
to give the title compound [19] as a clear liquid (2.2g; 69%). b.p. 1800C 
(at 0.5mbar); Rf 0.45 (solvent K); vm (film)/cm 1 3360 (m, NH2), 3295 
(m, NH2), 2920 (s, aliphatic), 2845 (s, aliphatic), 1575 (m), 1460 (m), 
1440 (m), 1380 (m), 1360 (m), 1350 (m), 1320 (m), 1280 (w), 1260 (w), 
1200 (m), 1180 (m), 1160 (m), 1135 (s), 1120 (s), 1075 (s), 1030 (s), 985 
(m), 970 (m), 905 (m), 865 (m), 815 (m), 720 (w); 5H(200.13OMHz; 
CDC13) 1.20-1.73 (18H, in, CH2), 2.56 (2H, t, NCH2, J=6.7Hz), 3.20-
3.81 (4H, in, OCH2), 4.46 (1H, t, THP-CH, J=3.2Hz); 5c(50.320MHz; 
CDC13) 19.33, 25.15, 25.85, 26.49, 29.09(2xCH2), 29.38, 30.42, 33.48, 
41.88, 61.93, 67.26, , 76.25, 76.89, 77.53, 98.45 (CH). f.a.b. ms m/z 
230.21197 [(M+H)+, C13H27NO2 requires 230.21199]. 
N-(N1 '-Benzoylbiotinyl)-1-amino-8-tetrahydropyranyloxyoctane [20]. 
Compound [19] (leq; 0.94g; 2mmol) was dissolved in anhydrous 
tetrahydrofuran (20m1). To this solution was added compound [15] (leq; 
2mmol; 0.46g) and triethylamine (leq; 2mmol; 0.20g; 0.28ml). After 
30min the reaction was evaporated to dryness, then coevaporated with 
ethanol (lOml) then toluene (lOml). The residue was dissolved in 
dichloromethane and this solution was washed with sat. aqueous 
NaHCO3(50m1) then sat. aqueous KC1 (50m1). The aqueous washings 
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were extracted twice with dichioromethane, and the combined organic 
phase was dried (Na2SO4), filtered and the solvent evaporated in vacuo. 
The product was purified by wet-flash chromatography, eluting with 
dichioromethane containing 2-10% methanol. The title compound [20] 
was obtained as a white solid (1.069g; 96%). Rf 0.60 (solvent C); 
H(200.130MHz; CDC13)  1.25-1.76 (24H, m, 6-, 7-, 8-H, octyl CH2), 
2.05 (2H, m, 9-H), 2.91-3.14 (5H, m, 2-H, 5-H, NCH2), 3.26-3.87 (4H, 
m, OCH2), 4.10 (1H, dd, 4-H, J3=7.6Hz, J4...5=4.6Hz), 4.50 (1H, m, 
THP-CH), 5.10 (1H, in, 3-H), 5.78 (1H, m, CONH), 7.00 (1H, s, 3'-H), 
7.25-7.55 (5H, m, Ar-H); 5c(50.32MHz; CDC13) 19.57(CH2), 
25. 16(CH2), 25.30(CH2), 25.98(CH2), 26.69(CH2), 27.39(CH2), 
27.68(CH2), 29.05(CH2), 29.19(CH2), 29.41(CH2), 29.53(CH2), 
30.62(CH2), 35.54(CH2), 38.02(CH2), 39.35(CH2), 54.98(5-C), 57.32(4-
C), 62.15(3-C), 62.26(THP-CH2), 67.46(THP-CH2), 98 ,76(THP-CH), 
127.31 (benzoyl 3-&5-C), 128.61 (benzoyl 2-&6-C), 131 .24(benzoyl 4-C), 
134.59 (benzoyl 1-C), 156.20(benzoyl CO), 169.76 (2'-C), 172.55(10-C). 
f.a.b. ms m/z 560.3 1579 [(M+H)+, C30H46N305S requires 560.31580] 
N1-(N1' -Benzoylbiotinyl)-1-aminooctan-8-ol [21]. 
To a solution of compound [20] (leq; 0.9g; 1.61mmol) in methanol 
(25m1) was added DOWEX H form (30g). After 3h the DOWEX was 
filtered-off and washed with methanol (150m1). The combined filtrate 
was evaporated to dryness and the residue was purified by wet-flash 
column chromatography, eluting with 10% methanol in dichloromethane, 
to give the title compound [21] as a white solid (0.712g; 93%). Rf 0.36 
(solvent C); 6H(200.13OMHz; CDC13) 1.03-1.55 (18H, in, 6-, 7-, 8-H, 
octyl CH2), 1.88 (2H, t, 9-H, J=7.OHz), 2.69-3.00 (5H, in, 2-H, 5-H, 
CH20H), 3.21-3.29 (2H, m, NCH2), 3.45-3.47 (1H, m, OH), 3.89-3.95 
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(1H, m, H-4),4.83-4.90 (1H, m, 3-H), 6.66 (1H, t, CONH, J=5.3Hz), 
7.04-7.40 (6H, m, Ar-H, 3'-H); 8c(50.32MHz; CDC13) 25.22(CH2), 
25.39(CH2), 26.48(CH2), 27.54(CH2), 27.85(CH2), 28.86(CH2), 
28 .96(CH2), 29.13 (CH2), 3 2.37(CH2), 35 .34(CH2), 37.69(CH2), 
38.96(CH2), 55.04(5-CH), 57.18(4-CH), 61 .73(CH2), 61 .74(CH), 
1 27.09(benzoyl 3-&5-C), 128 .30(benzoyl 2-&6-C), 1 30.82(benzoyl 4-C), 
134.75 (benzoyl 1-C), 155.65(benzoyl CO), 169.55 (2'-C), 172.76(10-C). 
f.a.b. ms m/z 476.25828 [(M+H), C25H38N304S  requires 476.25829]. 
8-[N1 -(N" -Benzoylbiotinyi)-1-aminooctyl] -2-cyanoethyl-N,N-
diisopropylamino phosphoramidite [22]. 
Compound [21] (leq; 0.40g; 0.842mmol) was dissolved in anhydrous 
tetrahydrofuran (5m!). To this solution was added N, N-
diisopropylethylamine (4eq; 3. 37mmol; 0.44g; 0. 59m1) and 2-cyanoethyl 
N,N-di-isopropylphosphoramidochloridite (1 eq; 0. 84mmol; 0.19g; 
0.1 9m1). The reaction which was complete after 5min was quenched by 
the addition of anhydrous ethanol (imi). Dichioromethane was added and 
the resulting solution was washed sat. aqueous NaHCO3 (50m1) and sat. 
aqueous KC1 (2x50m1). The organic phase was dried (Na2SO4), filtered 
and the solvent was removed by evaporation in vacuo . A silica gel 
column was pre-equilibrated with ethyl acetate containing 20% 
acetonitrile and 1% triethylamine and the product was purified on this 
column, eluting with ethyl acetate containing 20-50% acetonitrile, to 
give the title compound [22] as a white solid (0.251g; 44%). Rf 0.53 
(solvent L); 6p(80MHz; ethyl acetate solvent; (CD3)2C0 int) 146.866 (s). 
f.a.b. ms m/z 676.36612 [(M+H), C34H55N505PS requires 676.36613]. 
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Large scale synthesis and characterisation of [22]p(T)4T. 
This sequence was synthesised in order to fully characterise the group 
which was introduced onto the 5'-end of the oligonucleotide by [22], and 
to demonstrate that full deprotection of the biotin ring had occurred. A 
total of six 1.0 pmol scale syntheses were carried out and the desired 
product was purified by HPLC and desalted on a Sephadex G-10 column. 
After lyophilization the biotinylated oligonucleotide was obtained in 
10.1mg yield. The entire sample was dissolved in 0.5ml of H20:D20 I 
9:1 (vlv) and analysed by 600MHz 1H-NMR using Correlated 
Spectroscopy (COSY). 
J-]1(599.945MHz; H20:D20/9:1) 1.15-1.22 (814, m, octyl 3-,4-,5-,6-H), 
1.33-1.43 (4H, m, octyl 2-H, biotin 7-H), 1.51-1.72 (6H, m, octyl 7-H, 
biotin 6-,8-H), 1.85-1.93 (m, thymidine 5-H, acetate), 2.22-2.37 (8H, m, 
biotin 9-H, thymidine 2'-,2t1-H), 2.49-2.54 (4H, m, thymidine 2'-,2"-H), 
2.76 (1H, d, biotin pro-R 2H, Tgem13.lHZ), 2.96 (1H, dd, biotin pro-S 
2H, Jgem13.lHz, J23=5Hz), 3.09-3.17 (214, m, octyl 1-H), 3.26-3.29 
(1H, m, biotin 5-H), 3.79-3.85 (2H, m, octyl 8-H), 4.03-4.15 (11H, m, 
thymidine 4'-,5'-,5"-H), 4.30 (3H, m, thymidine 4'-H), 4.35 (1H, m, 
thymidine 4'-H), 4.39 (114, dd, biotin 4-H, J34=7.9Hz, J4..5=4.6Hz), 
4.57-4.59 (214, m, biotin 3-H, thymidine 3'-H), 4.71-4.84 (thymidine 3'-H 
masked by H20 signal), 6.23-6.31 (514, m, thymidine 1'-H), 7.65 (1H, s, 
thymidine 6-H), 7.66 (114, s, thymidine 6-H), 7.68 (114, s, thymidine 6-
H), 7.71 (1H, s, thymidine 6-H), 7.74 (1H, s, thymidine 6-H), 7.90 (1H, 
t, CONH, J5.7Hz). 
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Chapter Two 
Attachment of LipophHic Molecules to Oligonucleotides during Solid-
Phase Synthesis, 
A. INTRODUCTION. 
10.0. General Principles and Problems of Antisense Therapeutics. 
Since the pioneering work of Zamecnik and Stephenson, 1,2  interest 
in the use of 'antisense' oligodeoxynucleotides (ODNs) as potential 
therapeutic agents has grown rapidly.3-8  Disease states which may be 
treatable with antisense ODNs, include cancer, viral infections, 
autoimmune diseases, endocrinological diseases, neurological disorders 
and parasitic or bacterial infections.7 For a comprehensive review see 
Uhlmann and Peyman.9  The basic concepts for the control of gene 
expression by antisense oligonucleotides are very simple (Figure 36).The 
exogenous antisense ODN is taken up by the cell and hybridises, in a 
sequence specific manner, to the targeted messenger RNA (mRNA). 
This prevents the normal process of translation of this particular mRNA 
into its polypeptide/protein product. The mechanism of translation 
inhibition (Figure 37) may involve prevention of mRNA maturation 
(splicing, capping or polyadenylation); inhibition of niRNA transport to 
ribosomes; inhibition of ribosome binding; inhibition of trans location of 
ribosome along the mRNA; or degradation of the mRNA part of the 
mRNA-ODN hybrid by RNase H. Inhibition of gene transcription is also 
possible if the ODN binds to RNA polymerase. However this is likely to 
be a non-sequence specific process. 
Control of gene transcription by 'triple-helix' forming ODNs is 
another area of great potential for the treatment of cancer and genetic 
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Figure 36: Simple schematic diagram showing the general principle 
of control of gene expression using antisense ODNs. 
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diseases. 10 This approach involves the binding of an ODN to the double-
stranded target sequence in the genome via Hoogsteen base-pairing. The 
resulting triple-helix interferes with the transcription of the target 
sequence, and thus with the expression of the protein encoded by that 
sequence. 
Although use of antisense ODNs is simple in concept, in practice it 
is fraught with difficulties. A major obstacle to the commercial feasibility 
of antisense therapeutics is the high concentration of ODN required to 
elicit antisense effects. In tissue culture reasonable responses are seen 
only in the presence of micromolar concentrations of ODN. A major 
contributor to this low activity is the the poor cellular uptake of ODNs. 
The work to be described in the Results and Discussion section of this 
chapter describes attempts to improve the cellular uptake of antisense 
phosphorothioate oligonucleotides. This introduction will therefore focus 
on cellular uptake of ODNs and previous attempts to improve it. Other 
problems inherent in the antisense approach are outlined below. Detailed 
descriptions of these problems can be found in the review articles already 
cited. 
(i) Enzymic degradation of oligonucleotides in vivo by endo- and 
exonucleases. 
This problem has been overcome by the modification of the normal 
phosphodiester internucleoside linkages to confer resistance to 
nucleases.911  The two most commonly used modified intemucleoside 
linkages at present are phosphorothioates and methylphosphonates, in 
which one of the non-bridging oxygen atoms of the normal 
phosphodiester link is replaced with a sulphur atom or methyl group 
respectively. These modified backbones can be introduced 
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conveniently during solid-phase DNA synthesis at any position in an 
ODN and are largely stable to nuclease activity. 
Poor water solubility. 
The poor water solubility of non-ionic methyl-phosphonate 
oligonucleotides (MP-ODNs) is a major drawback of this class of 
modified ODNs. It can be overcome by the synthesis of ODNs with 
mixed methyl phosphonate and phosphodiester linkages, however this 
may compromise nuclease stability. 12  Phosphorothioate oligonucleotides 
(S-ODNs) are normally readily water soluble due to their ionic nature. 
Choice and accessibility of the target mRNA. 
Non-sequence specific interactions. 
Cost. 
Quality control. 
In spite of the problems encountered in its development, the 
antisense approach to the treatment of viral and other diseases has made 
rapid progress. This progress is due in large part to close cooperation 
between chemists, pharmacologists, clinicians, geneticists, virologists, 
biochemists, engineers and researchers from many other disciplines. This 
multidisciplinary approach, coupled with the potential rewards to the 
pharmaceutical industry of producing effective, non-toxic anti-cancer and 
anti-viral drugs will continue to fuel progress in the antisense field. 
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11.0. Cellular Uptake of Antisense Oligonucleotides. 
11.1. Labelling of Oligon ucleotides. 
In order to follow the uptake of ODNs into cells the ODNs must be 
labelled. The two approaches used so far are the attachment of a 
fluorescent group to the ODN or the incorporation of a radiolabel. 
11.1.1. Fluorescent labelling. 
Labels such as fluorescein 13-15,  tetramethylrhodamine, 13,14,16,17 
and acridine derivatives 18-21  have been covalently linked to ODNs to 
allow visualisation and quantitation of uptake. It should be noted that 
acridine derivatives are also intercalators designed to enhance the duplex 
stability of the ODN-mRNA hybrid. 
Potential complications that arise from the attachment of a 
fluorescent label to an ODN are: 
- The label may be cleaved in vivo. 
- Large, hydrophobic fluorescent groups may affect the rate or 
mechanism of ODN uptake. 
- The label may affect the intracellular distribution of the ODN. 
These complications in the interpretation of results can be partly 
overcome by the use of appropriate control experiments. 
Intracellular distribution can be ascertained directly in living cells 
by fluorescence microscopy. Quantitation of uptake is possible using 
Fluorescence Activated Cytometry 15,19,20  or using 'Multiparameter 
Digitized Video Microscopy.'16 
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11.1.2. Radiolabelling. 
The enzymic 5t-end labelling of ODNs with 32P commonly used 
for the detection of oligonucleotide hybridisation probes is inappropriate 
for in vivo applications due to the presence of endogenous phosphatases 
which cleave off the label. In spite of this obvious drawback many groups 
have used this method of labelling in uptake studies. Internal 32P 
labelling20 can be achieved by 32P end labelling of an ODN followed by 
template directed ligation with another ODN. 35S labelling of S-ODNs is 
readily carried out by ODN assembly using H-phosphonate chemistry 
followed by suiphurization using 35S8.22'23  
Intracellular distribution and quantitation of radiolabelled ODNs is 
measured by fractionation of cellular components followed by 
scintillation counting. 
11.2. Uptake of Unmodified and Phosphorothioate Oligonucleotides. 
There is now considerable evidence that normal phosphodiester-
linked oligonucleotides (D-ODNs) and S-ODNs are taken-up by cells by 
receptor mediated endocytosis.24'25 Loke et al. 19  investigated cellular 
uptake using acridine labelled (Tp) of various lengths. Their findings 
were as follows: 
-Uptake of acridine-oligo T was temperature and ATP dependent. 
-Uptake of acridine-oligo T was inhibited by unlabelled D-ODN, by S-
ODNs and by nucleoside 5'-phosphates (and to a lesser extent nucleoside 
3'-phosphates). 
-Uptake was not inhibited in the presence of MP-ODNs. 
-Uptake was length dependent. Short sequences were taken-up more 
efficiently. 
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These results were strongly indicative of the existence of a 
common cell surface receptor for D-ODNs and S-ODNs. The failure of 
MP-ODNs to competitively inhibit D- and S-ODNs indicates a different 
mechanism for the uptake of this class of modified ODN. The putative 
ODN binding protein was isolated by oligo dT affinity chromatography 
and was found to have a molecular weight of 80kDa. 
Independently, Yakubov et at. 26  obtained very similar results 
using alkylating-ODNs (ODNs linked to a nitrogen mustard moiety). 
They isolated two possible ODN receptor proteins of molecular weight 79 
and 90 kDa. The same group later identified a single 8OkDa protein as the 
putative ODN receptor.27 The temperature and length dependence of 
ODN uptake was confirmed by Boiziau and Toulme.28 
Recently Goodarzi et al. 29  reported the existence of a 34kDa 
membrane protein which had a high affinity for D-ODNs at pH 4-4.5, and 
a low affinity at physiological pH. This is the reverse of the situation 
under normal receptor mediated endocytosis conditions where the 
receptor-ligand complex is dissociated at pH 5 in endosomes.24 The 
extreme non-physiological conditions employed may have caused a 
conformational change in a membrane protein, causing it to bind ODNs. 
11.3. Methyl Phosphonate Oligonu cleotides. 
The poor aqueous solubility, and uncharged nature of MP-ODNs 
has led to the suggestion that they enter cells by passive diffusion. 30  This 
view has now been challenged. 16,17 
Akhtar et al. 17  encapsulated D-, S-, and MP-ODNs in liposomes 
and measured the rates of efflux by passive diffusion. It was found that 
MP-ODNs had an efflux half-life of >4 days but the antisense effects of 
MP-ODNs are observed after a much shorter incubation period with cells. 
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If liposomes are a reasonable model for the plasma membrane of cells it 
is unlikely that passive diffusion is the major mechanism of MP-ODN 
uptake. The water:octanol partition coefficients of MP-ODNs indicated 
that although they are much more lipophilic than D-, or S-ODNs, they are 
still much more soluble in an aqueous environment than in the 
hydrophobic environment that constitutes much of the cell membrane. 
Shoji et al. 16  found that uptake of a 15mer MP-ODN was 
temperature dependent, with a sharp rise in uptake occuring between 15 
and 200C. Lowering of cytoplasmic pH, which inhibits receptor-mediated 
endocytosis, was found to completely prevent uptake of a D-ODN but 
had no effect on MP-ODN uptake. It was suggested by the authors that 
MP-ODNs are taken-up by an 'active fluid-phase endocytotic' route, and 
not by passive diffusion or receptor-mediated endocytosis. 
Spiller and Tidd15 found that uptake of MP-ODNs was not 
saturable and depended only on the extracellular concentration of the MP-
ODN, suggesting passive diffusion. D-ODNs were taken up in a saturable 
manner consistent with receptor-mediated endocytosis. Surprisingly 
chimeric ODNs containing only 4 phosphodiester linkages and 10 
methyiphosphonate linkages were also taken up in a saturable manner. 
The intracellular concentration of D-ODN and MP-ODN was only 0.8% 
and 3% of the extracellular concentration, respectively, underlining the 
extreme inefficiency of cellular uptake of ODNs. 15 
11.4. Intracellular Distribution of Oligonucleotides. 
The intracellular distribution of fluorescently labelled ODNs can be 
conveniently monitored by fluorescence microscopy. Leonetti et al. 13,14 
used this technique to determine the distribution of microinjected 
fluorescent cx-anomeric,9 D- and S-ODNs in a variety of cell types. A 
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rapid accumulation of the ODN in the nucleus was observed. The 
transport of the ODN to the nucleus was a passive process as it was not 
temperature or ATP dependent. Nuclear fluorescence persisted for 20 
hours for a-anomeric and S-ODNs, but disappeared after 3 hours for D-
ODNs, presumably due to nuclease degradation. ODNs containing 
photoreactive 5-bromo-2'-deoxyuridine were found to crosslink to a 
variety of proteins, but not histones, on irradiation of the ODN mixed 
with isolated nuclei. The microinjection of ODNs into the cytoplasm does 
not accurately reflect the rather more complex process of endocytosis of 
extracellular ODNs. For example, the packaging of ODNs into 
endosomes after endocytosis would probably prevent any rapid nuclear 
accumulation of ODNs. 
Using fluorescence microscopy Loke et al. 19  observed a punctate 
pattern of intracellular distribution of acridine-labelled D- and S-ODNs 
indicative of the packaging of the ODNs in endocytic vesicles. In 
addition the presence of NaN3 which inhibits internalization of endocytic 
vesicles was found to reduce the uptake of radiolabelled ODNs. A 
punctate intracellular distribution of acri dine -labelled D-ODNs was also 
observed by Saison-Behmoaras et al. 21  A radiolabelled ODN was found 
to have a 2-fold higher incorporation in the nuclear fraction of lysed cells 
than in the cytoplasm. The localisation of fluorescently-labelled S-ODNs 
in endosomes or lysosomes was also observed by Bennett et al.23  
Verspieren et al. 18  showed that acridine labelled ODNs were 
evenly distributed throughout trypanosome parasite cells. 
In a careful study of the uptake of MP-ODNs and chimeric D-MP-
ODNs Spiller and Tidd15 showed by fluorescence microscopy that 
fluorescein labelled D-ODNs and D-MP-ODNs were contained within 
cytoplasmic vesicles, whereas MP-ODNs were evenly distributed 
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throughout the cytoplasm. In contrast, an equally careful study by Shoji et 
al. 16  found a punctate distribution of fluorescently labelled MP-ODNs. A 
partial co-distribution of the MP-ODN and FITC-dextran, a marker of 
endocytic vesicles, was also observed. 
11.5. Summary 
There is considerable variability in the results obtained both for 
cellular uptake of ODNs and also their intracellular distribution. This is 
probably a result of a combination of factors including: different cell 
types; different growth media for cells; the length of the ODN; the 
presence of different hydrophobic fluorescent labels; the positioning of 
the fluorophore at the 3'-, or 5'-end of the ODN; and the type of modified 
backbone used. 
However, the following conclusions may be drawn: 
Cellular uptake of ODNs is highly inefficient, with intracellular 
concentrations reaching only a few percent of the extracellular 
concentration. 
Uptake of MP-ODNs is slightly more efficient than that of D- or S-
ODNs. 
D- and S-ODNs are taken up by cells by receptor mediated 
endocytosis. A putative receptor protein of molecular weight 8OkDa has 
been isolated. The normal function of this protein is not known. 
MP-ODNs are taken up by cells by a non-receptor mediated 
mechanism. This mechanism is either passive diffusion, or active fluid-
phase endocytosis. 
Packaging of intracellular ODNs in endocytic vesicles appears to be a 
common phenomenon. This severely limits the availability of the ODN at 
its sites of action in the cytoplasm and/or nucleus. 
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12.0. Efforts to Increase the Cellular Uptake of Antisense 
Oligonucleotides. 
The inefficient cellular uptake of ODNs is a major reason for the 
limited efficacy of antisense therapeutics. This has led several researchers 
to devise methods to attempt to increase cellular uptake. The approaches 
used so far are: 
Covalent attachment of a hydrophobic group, such as a hydrocarbon 
chain, to the ODN to impart general lipophilicity. 
Covalent attachment of groups, such as cholesterol and 1 ,2-di-O- 
hexadecyl-3-glycerol, designed to interact with cell membranes or 
transmembrane transport mechanisms. 
Covalent and non-covalent attachment of peptides and proteins. 
Non-covalent association of the ODN with cationic lipids. 
Encapsulation of the ODN in antibody-targeted liposomes. 
Each of these approaches will be considered individually. 
12.1. Attachment of Hydrophobic Groups to Oligonucleotides. 
Kabanov et al. 31,32  introduced a single undecyl group onto the 5'-
end of ODNs using an undecanol phosphoramidite (Figure 38), with a 
yield of 90-95%. The same group was also introduced by carbodiimide 
coupling to an ODN 5'-phosphate in lower yield. The lipophilic antisense 
ODNs produced were found to have a considerably greater effect on 
Influenza virus reproduction and protein synthesis than the corresponding 
sequence without the undecyl group. 
Saison-Behmoaras et al. 21  synthesized ODNs with a 3'-dodecyl 
residue using a dodecane diol solid support (Figure 38). It was found that 
the uptake of a 3'-dodecyl 9mer ODN by human T24 bladder carcinoma 
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Figure 38: Examples of methods for introducing hydrocarbon 
chains into ODNs. 
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cells was 4 times greater than the corresponding unmodified 9 mer but 
that the distribution of the ODN between the cytoplasm and the nucleus 
was unaffected. Acridine labelled 3'-dodecyl 9mer ODN was found to be 
trapped in endosomes, however the distribution of the unmodified 
acridine 9mer ODN was not reported so no comparison can be made. The 
dodecyl modified antisense ODNs were considerably more active against 
ras oncogene expression than the corresponding unmodified ODNs. 
In contrast Boiziau and Toulme28 found that the attachment of a 
dodecyl chain to a D-ODN had only a very marginal effect on uptake. 
Abramova et al. 33  found that radiolabelled ODNs bearing an 
octadecyl chain were 'bound to cells' 10 times better than unmodified 
ODNs and had greater anti-HIV activity. 
Guinosso et al. 34  synthesized a series of 2'-0-modified 
ribonucleoside phosphoramidites, including a 2'-0-n-nonyl derivative 
(Figure 38). Cellular uptake of ODNs bearing this derivative was not 
studied, however only modest duplex destabilisation was observed on 
incorporation of multiple 2'-O-n-nonyl adenosine residues into 
oligonucleotides. In addition, incorporation of 2'-0-modified residues at 
the 3'-end of ODNs gave significant protection from exonuclease activity. 
12.2. Attachment of Membrane-Interactive Groups to Oligon ucleotides. 
12.2.1. Cholesterol. 
Cholesterol is a major component of cell membranes and is 
involved in the regulation of membrane fluidity.24 Cholesterol is 
transported in vivo mainly by lipoproteins, which are found in large 
quantities in the circulatory system, and are responsible for the transport 
of hydrophobic molecules. In humans the most important carrier of 
cholesterol is low-density lipoprotein (LDL).3536 LDL is a spherical 
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particle with a mass of Ca. 3MDa. It is composed of a core of 
approximately 1500 molecules of esterified cholesterol enclosed in a coat 
of approximately 800 molecules of phospholipids and 500 molecules of 
unesterified cholesterol, and one 400kDa protein called apolipoprotein B-
100. The unesterified cholesterol in the LDL coat is in equilibrium with 
the cholesterol present in cellular membranes. 
LDL is taken up by cells by receptor-mediated endocytosis.24 All 
cells have high affinity receptors for LDL on their surfaces which are 
clustered in regions known as coated pits. When LDL binds to its 
receptor it triggers the polymerisation of clathrin, a protein which is 
found on the cytoplasmic side of the coated pit. The clathrin 
polymerisation forms a polyhedral 'basket' which causes the invagination 
of the membrane of the coated pit, which continues until a clathrin coated 
vesicle forms. This vesicle, which contains the LDL receptor-ligand 
complex, then uncoats to form an endosome. The pH in the endosome is 
then reduced to pH 5, causing the dissociation of the LDL from its 
receptor. The receptor is then recycled to the cell surface, and the LDL is 
degraded by enzymes on fusion of the endosome with a lysosome. The 
time for one complete cycle of endocytosis is Ca. 10-15 minutes. 
This highly efficient mechanism of cholesterol endocytosis has 
prompted several research groups to attach cholesterol to ODNs in the 
hope that the cholesterol-oligonucleotide conjugate (Chol-ODN) will 
associate with LDL and be endocytosed. It should be noted, however, that 
in most of the literature on Chol-ODNs published so far there is little, or 
no mention of LDL endocytosis as a potential mechanism of uptake of 
Chol-ODNs. The enhanced uptake seen in most cases is attributed to the 
'membrane anchoring properties' of cholesterol. Endosomal membranes 
are thought to contain little or no cholesterol 17  which minimises the 
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potential for entrapment of the Chol-ODN in endosomal membranes by 
cholesterol anchoring. 
Letsinger et al. 37  synthesized D- and S-ODNs with a spaced 
cholesterol attached as a phosphoramidate to the 3'-terminal 
intemucleoside link. This was achieved by oxidative amination of an H-
phosphonate linkage using a derivative of cholesteryl chioroformate 
(Figure 39). The attachment of a single cholesteryl moiety did not have a 
significant effect on the thermodynamic stability of the duplex. The anti-
HIV activity (de novo infection) of a variety of D- and S -ODNs was 
considerably enhanced by the attachment of a single cholesteryl moiety. 
The attachment of a second cholesteryl moiety reduced the activity 
relative to the mono-cholesteryl ODN. The enhanced activity was also 
seen for ODNs which contained mismatches to the HIV mRNA. In 
addition, a 7mer S-ODN with a single cholesterol attached had 
appreciable anti-HP! activity even though hybridisation to the 
complementary strand at 370C was neglible. Clearly a non-sequence 
specific mechanism of HIV inhibition operates for Chol-ODNs. The outer 
membrane of HIV ( and many other viruses) is rich in cholesterol, with a 
cholesterol:phospholipid ratio of —I (cf. 0.5 for most cell membranes).38 
The method used to determine the anti-HIV activity in this study involved 
the simultaneous addition of the Chol-ODN and the virus particles to 
cells. This would allow the association of Chol-ODN with the viral 
membrane, and may interfere with normal interaction of the HIV-
membrane glycoprotein gpl20 with its CD4 receptor on the cell surface, 
or with post-binding membrane fusion. This possible mechanism of 
action is clearly not sequence-dependent. 
Stein et al. 39  later studied the mechanisms of anti-HP! activity of 
phosphorothioate oligo dC sequences either with, or without an attached 
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(i) Synthesize a Support-bound H-Phosphonate dimer. 











(iii) Continue synthesis using Phosphoramidite Chemistry. 
Figure 39: Letsinger's method of synthesizing Cholesteryl ODNs. 
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cholesteryl group. The cholesterol was attached to the 5'-end of ODNs 
during solid-phase synthesis using an unspaced cholesterol H-
phosphonate monomer. The Chol-S-ODNs had much higher anti-I-IIV 
activity than the corresponding unmodified sequences, and were found to 
inhibit the binding of gp 120 to its CD4 receptor and also to inhibit the 
DNA polymerase activity of HIV1-reverse transcriptase. Both of these 
inhibitory effects were strongly dependent on the presence of the 
cholesteryl moiety. 
Farooqui et al. 40  confirmed the non-sequence specific inhibition of 
HIV by a variety of spaced Chol-ODNs. Changing the spacer arm from a 
dimethylene chain to a decamethylene chain had no effect on anti-HIV 
activity. As well as de novo anti-HIV assays, Chol-ODNs were tested on 
cells which had been incubated with HIV alone for 24 hours. Unlike the 
de novo anti-HIV assays, complete inhibition of HIV protein synthesis 
(determined by levels of p17 and p24 proteins) could not be achieved, 
although complete inhibition of syncytia formation was possible. 
(Syncytia are large, non-viable multinuclear cells caused by fusion of 
HIV infected cells). A maximum of 80% inhibition of p17 and p24 
expression could be achieved under these pre-infection conditions. To 
determine if the presence of nucleosides in the oligomer was necessary 
for anti-HIV activity, oligomers were synthesized which were composed 
of multiple propyl groups linked by phosphorothioate groups and attached 
to a cholesteryl group. These cholesteryl-anucleosidic phosphorothioates 
were inactive against HIV, confirming the necessity of the presence of 
nucleosides for anti-HIV activity. 
Ryte et al. 27  synthesized radiolabelled D-ODNs with a 5'-
alkylating group (a nitrogen mustard) and a 3'-cholesteryl group, and used 
these in uptake experiments. It was found that most of the Chol-ODNs 
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were situated in the nucleus or in the cytoplasm (31% and 25% 
respectively). Surprisingly little was found associated with either the 
plasma membrane or the with lysosomes (7% and 0.3% respectively). 
Alkylating D-ODNs were found to associate with, and alkylate an 80kDa 
protein - the putative ODN receptor. The Chol-ODNs also labelled a 
250kDa protein which was not alkylated by unmodified ODNs. It was 
suggested that this Chol-ODN binding protein may be involved in the 
endocytosis of this class of modified ODN. 
Boutorine et al. 41  synthesized radiolabelled alkylating D-ODNs 
carrying a 3'-terminal cholesteryl group. The uptake of the Chol-ODN 
was 30-100 times greater than the control ODN. The distribution of the 
Chol-ODN between the nuclear and cytoplasmic fractions of lysed cells 
was the same as for the control ODN, with 80-85% in the cytoplasmic 
fraction and <20% in the nuclear fraction. A more detailed study of the 
distribution of the ODNs within the cytoplasm and nucleus was not 
carried out. In another publication, Boutorine et al.42 synthesized a 
variety of radiolabelled derivatized ODNs, including cholesteryl ODNs. 
Cystamine derivatized ODNs were reacted with thiocholesterol to give a 
disulphide-linked 5'-cholesteryl ODN. Alkylation of cystamine 
derivatized ODNs by iodocholesterol gave a 5'-thioether-linked Chol-
ODN. The yields for these processes were 58% and 20% respectively. 
The labour-intensive procedures and low yields achieved make these 
methods of linking cholesterol to ODNs feasible only for small-scale 
research purposes. 
Oberhauser and Wagner43 synthesized 3'-disulphide-linked 
cholesteryl-2'-O-methyl-RNA oligonucleotides. The cholesterol was 
attached by reaction of thiocholesterol with a thiol modified 
oligonucleotide. The ODN was converted to a lipophilic salt to allow it to 
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be dissolved in organic solvents. The incorporation of cholesteryl 
oligonucleotides into liposomes was found to be approximately 6 times 
more efficient than that of their unmodified analogues, opening the 
possibility of improved encapsulation of ODNs in antibody targetted 
liposomes (to be discussed in section 12.5. below). The cholesteryl 
oligonucleotides were found associated with the outside of liposomes as 
well as in the internal fluid phase, suggesting insertion of the cholesteryl 
moiety into the lipid bilayer. The binding of cholesteryl oligonucleotides 
to cells in serum-free medium was 15 times higher than that of the control 
oligonucleotide and the internalisation was 8 times higher. In the 
presence of fetal calf serum the rate of uptake of cholesteryl 
oligonucleotides was reduced, presumably due to association with serum 
lipoproteins. The intracellular cleavage of the disulphide linkage between 
the oligonucleotide and the cholesterol was demonstrated. The 
bioreversible nature of the disulphide linker may increase the availability 
of the oligonucleotide at its site of action by releasing it from the 
cholesterol membrane anchor after endocytosis. 
De Smidt et al. 44 investigated the association of radiolabelled 
Chol-ODNs with low-density lipoproteins (LDL) and high-density 
lipoproteins (HDL). Their main findings were: 
-Chol-ODNs were completely incorporated into LDL after a 2 hour 
incubation at 370C. Under the same conditions there was no 
incorporation of unmodified ODN. 
-The LDL: Chol-ODN ratio in the complex ranged from 1:5 to 1:50. 
-When LDL-Chol-ODN complex was incubated with a mixture of LDL, 
HDL, and albumin, the Chol-ODN was found to be distributed between 
the LDL and HDL in a ratio proportional to the ratio of the surface areas 
of LDL and HDL, indicating that the Chol-ODN had no specific affinity 
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for either LDL or HDL. No Chol-ODN was found associated with 
albumin. Unmodified ODN did not associate with any protein. 
-The plasma half-life for Chol-ODN in rats was 10 times that of a control 
ODN. 
-On injection into rats the Chol-ODN was found mainly in association 
with plasma HDL (Rat plasma contains predominantly HDL). 
-The urinary excretion of Chol-ODNs from rats was found to be lower 
than that of unmodified ODNs. This reduced excretion is of considerable 
importance for the potential use of antisense ODNs as therapeutics. The 
expense of ODNs at present would almost certainly necessitate the 
recovery of excreted ODN from the urine of patients. Reducing urinary 
excretion may make this unnecessary. 
The methods used for covalently attaching cholesterol to ODNs in 
the above studies are not readily amenable to routine or large-scale 
synthesis of Chol-ODNs. Two groups have developed simpler methods of 
introducing a cholesteryl moiety into ODNs during solid-phase synthesis. 
Gmeiner et al. 45  synthesised a CPG solid-support based on a 
cholesteryl 6-aminoethyl riboadenosine derivative (Figure 40). This 
solid-support could be used under normal ODN synthesis conditions to 
synthesize 3'-Chol-ODNs. 
Reed et al, 46 synthesized a non-nucleoside-based cholesteryl CPG 
solid support. The synthetic route is shown in Figure 41. Interestingly, 
Chol-ODNs synthesized by this method had a significantly higher 
melting temperature (Tm) than the underivatized ODN on hybridisation to 
a template strand with overhanging ends. This contrasts with the results 
of Letsinger et al. 37 who used a template strand without overhangs. In 
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Figure 41: Synthesis of the Cholesteryl solid support of Reed et al. 
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overhangs of several kilobases. The 'overhanging ends' method of Reed et 
al. 46  is thus a closer approximation to the situation in vivo. 
12.2.2. Cholic Acid. 
Cholic acid, a metabolite of cholesterol, is a bile salt synthesized in 
the liver and excreted into the intestines to emulsify fats. It is then 
reabsorbed and recycled.24  It has been attached to ODNs as a lipophilic 
carrier by reaction of its N-hydroxysuccinimide active ester (Figure 42a) 
with an aminomodified ODN. No details were given of the cellular 
uptake or antisense activity of Cholic acid-ODNs.47  
12.2 .3 .P ho sp holipids. 
There is one report of the synthesis of phospholipid-
oligonucleotide conjugates (PL-ODNs).48  This was achieved by Shea et 
al. using an H-phosphonate monomer of 1 ,2-di-O-hexadecyl-rac-
glycerol during solid-phase synthesis (Figure 42b). The Tm  of an 1 imer 
PL-ODN was reduced to 34°C compared to 42°C for the unmodified 
ODN. Uptake studies showed that 8-10 times more PL-ODN was cell 
associated than the unmodified ODN. De novoinfection assays against 
Vesicular Stomatitis virus showed that PL-ODNs were considerably more 
active than unmodified ODNs or S-ODNs. As with Chol-ODNs the anti-
viral effect of PL-ODNs was found to be non-sequence specific. 
Dr. Calum MacKellar of this research group synthesized a variety 
of phosphoramidites to introduce hydrophobic groups into ODNs during 
solid-phase synthesis. Groups introduced were hydrocarbon chains, a 
phospholipid (the same as that introduced by Shea et al. 48),  and an 
unspaced cholesteryl group. This work is described in the paper 
(MacKellar et al.) in Appendix 3. 
167 
(a) Cholic Acid N-hydroxysuccinimide ester. 
OH 
The Phospholipid H-phosphonate monomer of Shea et al. 
—0
Th o— ç --o HNEt3  
H 




12.3. Association of Oligonucleotides with Peptides and Proteins. 
The effect of poly(L-lysine) on the cellular uptake of nucleic acids 
was investigated as long ago as 1974 by Schell.49 He found that uptake 
of a variety of single-and double-stranded polyribonucleotides was 
stimulated either by the formation of ribopolymer-lysine complexes, or by 
pretreatment of cells with poly(L-Lysine) before addition of the 
ribopolymer. Association of poly(L-lysine) with the cell membrane gives 
a net positive charge to the outside of the membrane, resulting in a strong 
electrostatic attraction for polyanionic nucleic acids. 
Lemaitre et al. 50  synthesized covalently linked poly(L-lysine)-
ODN conjugates (Lys-ODNs). The method used was rather long and 
involved and certainly not amenable to routine, or scaled-up synthesis. A 
3'-ribonucleoside was introduced using pCp and T4 RNA ligase. The 
terminal phosphate was removed by treatment with bacterial alkaline 
phosphatase, and the ODN was coupled to poly(L-lysine) by periodate 
oxidation of the 3'-ribose, followed by reduction with cyanoborohydride. 
Care had to be taken to prevent precipitation of the conjugate. In spite of 
these drawbacks, the Lys-ODNs were extremely active (for antisense 
ODNs) against Vesicular Stomatitis virus protein synthesis, with >95% 
inhibition at a Lys-ODN concentration of 400nM. This concentration is 
one or two orders of magnitude lower than for most reported antisense 
ODNs. Incubation with poly(L-lysine) alone, or with a mixture of poly(L-
lysine) and ODN had no effect on viral protein expression, indicating the 
requirement for covalent linkage of the polypeptide and the ODN. The 
same group later investigated the antiviral activity of Lys-ODNs which 
were synthesized by essentially the same method as described above, but 
using a riboadenosine derivatised solid support to introduce the 3'-
terminal ribose moiety.51  
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Stevenson and Iversen52 found that the cytopathic effects of HIV 
were considerably reduced by Lys-ODNs at a concentration of 200nM. 
MP-ODNs were only effective at concentrations of >ljtM. 
Boiziau and Toulme28 found that Lys-ODNs led to non-sequence 
specific inhibition of -g1obin synthesis. 
Another potential drawback of Lys-ODNs is the cytotoxicity of 
poly(L-lysine).9  
Pardridge and Boad053 found that the uptake of a biotinylated D-
ODN was increased from 3% to 15% in the presence of the cationic 
protein avidin. The anionic protein streptavidin did not have this effect, 
although it did bind to the biotinylated ODN. Antisense activity was not 
studied. 
Vestweber and Schatz54 found the covalent attachment of single-
or double-stranded ODNs to a mitochondrial precursor protein resulted in 
the uptake of the ODN into isolated mitochondria. The normal 
mechanism for the uptake of the peptide appeared to able to cope with the 
presence of a covalently attached ODN. 
Wagner et al. 55  investigated the transfection of DNA into cells by 
association of the DNA with polycation derivatized transferrin. 
Transferrin is an iron-transport protein which is taken-up by cells by 
receptor-mediated endocytosis.24 The ODN-polycation-transferrin 
complexes were transported via the normal transferrin endocytosis 
pathway, but with lower efficiency than unmodified transferrin.This 
method of enhancing uptake has not so far been investigated for antisense 
ODNs. 
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12.4. Association of Oligonucleotides with Cationic Lipids. 
The use of cationic lipids to enhance uptake of nucleic acids was 
first applied to the enhancement of transfection of plasmid DNA into 
cells.56'57 This technique is now being applied to enhance cellular uptake 
of antisense ODNs. This approach is especially attractive as the lipid 
functionality is not covalently attached to the ODN and may dissociate 
after endocytosis, thus minimising the possibility of deleterious effects on 
ODN hybridisation and intracellular distribution. The possible toxic 
effects of the cationic lipid must also be considered. 
Bennett et al. 23  found that the potency of an S-ODN-cationic-lipid 
mixture in reducing the cytokine-induced expression of the membrane 
protein Intercellular Adhesion Molecule-1 was >1000 times that of the S-
ODN alone. The presence of the cationic lipid DOTMA57 (Figure 42c) 
enhanced the cell association of S-ODN by between 6 and 18 times 
compared to the control S-ODN alone. The intracellular distribution of 
fluorescently labelled S-ODN was considerably altered in the presence of 
the cationic lipid. S-ODN alone was found associated with endosomes or 
lysosomes. In the presence of cationic lipid the S-ODN was found 
predominantly in association with the nucleus, with some punctate 
distribution in the cytoplasm. The nuclear association was seen as soon as 
15 minutes after administration of the ODN-lipid mixture, in agreement 
with the findings of Leonetti et al. 13  using microinjected ODNs. The 
cationic lipid was found to be cytotoxic at concentrations >211M. 
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12.5. Encapsulation of Oligonucleotides in Antibody-Targelted 
Liposomes. 
Liposomes are attractive candidates as carriers of antisense ODNs. 
ODNs encapsulated within liposomes are protected from nuclease 
digestion. The liposomes can be targetted to specific cell types by 
coupling to antibodies, thus reducing the ODN concentration required for 
efficacy. 
This approach to the delivery of antiviral ODNs has been 
investigated by Leonetti et al. 58  ODNs were encapsulated in liposomes 
with an efficiency of only 3%. The ODN-liposomes were coupled to 
Protein A, and these were incubated with cells in the presence of an 
antibody to a cellular protein. The encapsulated ODN was resistant to 
nuclease digestion. After 4 hours vesicular stomatitis virus was added. 
The ODN-liposome inhibited VSV by >95% at an ODN concentration of 
800nM. The unencapsulated ODN gave 90% inhibition at 40J.M. The 
viral inhibition was dependent upon the correct antibody being present. 
The mechanism of uptake was not investigated. 
12.6. Summary and Aims. 
Many of the methods used to increase cellular uptake of antisense 
ODNs have been successful in increasing the activity of the ODNs. 
However in some cases the increased activity was non-sequence-specific. 
This is especially true of ODNs modified with lipophilic groups, such as 
cholesterol. In spite of this, the potential use of the well-characterised 
receptor-mediated endocytosis pathway of low-density lipoprotein to 
transport ODNs into cells remains an attractive option which warrants 
further investigation. The synthetic routes to ODNs modified with 
lipophilic groups are at present tedious and not amenable to routine 
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synthesis of the large quantities of lipophilic ODNs required for 
biological and clinical testing. 
The aim of the work described in this chapter was to synthesize 
phosphoramidites of lipophilic molecules to allow the routine synthesis of 
ODNs modified with lipophilic groups. 
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B. RESULTS AND DISCUSSION. 
Three types of lipophilic group were attached to ODNs during 
solid-phase synthesis, Vitamin E, cholesterol and adamantane, using 
either phosphoramidites of the lipophilic molecules, or a derivatised 
solid-support. 
13.0. Vitamin E. 
Vitamin E (a-tocopherol) is an attractive candidate as a lipophilic 
carrier. It is inexpensive, essentially non-toxic, and has only one 
functional group for derivatization (Scheme 7). It has not previously been 
attached to ODNs. In vivo it is transported in lipoproteins,59 and in cells 
it is found mainly in association with the membranes of subcellular 
organelles60 such as the endoplasmic reticulum and mitochondria, and 
when linked to ODN analogues, it may transport them to these sites. The 
phytyl chain of the Vitamin E buries itself in the membrane and the 
phenol group protrudes towards the surface.61'62 Thus attachment of the 
ODN to the phenolic hydroxyl group should not adversely affect the 
membrane interaction. Attachment of Vitamin E to ODNs may be 
particularly useful for the antisense inhibition of secreted proteins as 
these are synthesised on ribosomes attached to the endoplasmic 
reticulum. 
The immobilisation of ODNs derivatised with lipophilic groups on 
hydrophobic membranes may have other applications in the areas of 
hybridisation and the capture of PCR products. Samples of the Vitamin B 
phosphoramidites described below have been sent to Dr. Stephen Will 
and Dr. Corey Levenson of Roche Molecular Systems Inc. who will 
investigate this potential application of lipophilic ODNs. 
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Scheme 7: Synthesis of an unspaced Vitamin E phosplwramidite. 
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As the properties of ODNs might differ depending on whether the 
Vitamin E moiety is attached to the 5'- or the 3'-end of the ODN, methods 
were developed for both. 
13.1. Vitamin E Phosphoramidite Synthesis 
In order to attach Vitamin E derivatives to the 5'-end of ODNs two 
phosphoramidite monomers were synthesized for use during normal 
automated solid-phase DNA synthesis. 
An unspaced Vitamin E phosphoramidite [231 was prepared by 
phosphitylation of Vitamin E with 2-cyanoethyl N,N-diisopropyl 
phosphoramidochioridite and diisopropylethylamine in THF (Scheme 7). 
This phosphoramidite is easy to prepare and is ideal for the direct 
attachment of Vitamin E to ODNs. 
For optimum interaction with membranes and LDL, and to 
minimise interference with hybridisation it may be necessary to 
incorporate a spacer between the ODN and Vitamin E. To this end the 
octamethylene-spaced Vitamin E phosphoramidite [26] (Scheme 8) was 
synthesized. Vitamin E was reacted with commercially available 1-
Bromo-8-tetrahydropyranyloxy-octane in DMSO in the presence of 
powdered K0H63 at room temperature to form the ether [24]. This 
method of ether formation is easy and convenient as it does not require 
the use of anhydrous solvents and reagents. Both of the starting materials 
and the product of this reaction ran rather close together on tic. To ensure 
an easy chromatographic purification of the product it was essential to 
use an exact 1:1 ratio of the two starting materials. The THP protecting 
group was removed by treatment with aqueous HC1 in THF and the 
resulting alcohol [25] was phosphitylated in the normal way to give the 






Ku)- O(CH2)8-OToc  
[24] 	73% 
Aqueous HC1 / THE 








Scheme 8: Synthesis of an octamethylene-spaced 
Vitamin E phosphoramidite. 
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13.2. Synthesis of Vitamin E derivatised CPG 
Attachment of Vitamin E to the 3'-end of ODNs requires a different 
approach. For this purpose it was necessary to functionalise Vitamin E 
with two hydroxyl groups, one to link the monomer to the controlled 
pore glass solid support and the other to permit ODN chain extension 
(Scheme 9). Thus, solketal was reacted with 4-toluenesuiphonyl chloride 
in pyridine and the resulting tosyl solketal [27] was reacted with Vitamin 
E in DMSO in the presence of powdered K0H63 to form the ether [27a]. 
This compound was passed down a short silica gel chromatography 
column to remove polar impurities then the isopropylidene protecting 
group was removed by treatment with aqueous HC1 in THF to give the 
diol [28]. Chromatographic purification of this diol was very easy as all 
the impurities present were very much more lipophilic than the product. 
The primary alcohol was reacted with dimethoxytrityl chloride in 
pyridine to give [29]. The secondary alcohol was then reacted with 
succinic anhydride/ DMAP in pyridine and the resulting 
dimethoxytritylated Vitamin E glyceiyl hemisuccinate [30] was reacted 
with 4-nitrophenol and dicyclohexylcarbodi-imide to generate the 4-
nitrophenyl active ester. This was coupled to long-chain alkyl amino CPG 
to give Vitamin E derivatised solid-support with a dimethoxytrityl 
loading of 24 imol.g 1  . CPG functionalization by the procedure of 
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Scheme 9: Synthesis of Vitamin E derivatised controlled-pore glass. 
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13.3. Vitamin E-Oligonucleotide Synthesis. 
Normal and phosphorothioate65 Vitamin E derivatised ODNs were 
synthesized on an Applied Biosystems 380B DNA synthesizer. For 3'-
Vitamin E ODNs, standard DNA and phosphorothioate synthesis cycles 
were used. For the synthesis of 5'-Vitamin E-ODNs, phosphoramidites 
[23] and [26] were used as O.1M solutions in anhydrous 
dichioromethane, as both compounds are insoluble in acetonitrile. Minor 
alterations to the synthesis cycles were necessary to accommodate this 
solvent change. Dichioromethane wash steps were necessary to prevent 
precipitation of the monomer in the reagent lines and column on mixing 
with the tetrazole solution. The coupling efficiencies of [23] and [26] 
were estimated by comparison of the integrals of the HPLC peaks for a 
test sequence VitEp(Tp)4T and the failure sequence (Tp)4T which would 
result from a failure of [23] or [26] to couple. Using this method the 
coupling efficiencies of [23] and [26] were estimated to be >95%. In each 
final coupling cycle, the trityl-ON configuration was used. Base 
protecting groups were removed by heating to 550C in concentrated 
ammonium hydroxide for 5.5 hours. Vitamin E ODNs were found by 
HPLC to be stable in concentrated aqueous ammonia at 550C for more 
than 24hours. The crude ODNs were lyophilized to remove the 
ammonium hydroxide solution. 
13.4. Oligonucleotide Purification. 
The extreme lipophilicity of VilE ODNs greatly facilitates 
reversed-phase HPLC purification, the products eluting approximately 15 
minutes later than all failure sequences in a gradient of acetonitrile in 
aqueous ammonium acetate. As the Vitamin E moiety is introduced 
during solid-phase synthesis with high efficiency, the product is obtained 
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in high yield. Typical HPLC traces of VitE ODNs are shown in Figure 
43. The amphiphilic nature of Vitamin E-ODNs makes them behave as 
surfactants. The use of rotary evaporators for concentrating aqueous 
solutions of VitE-ODNs is not possible due to extreme foaming of the 
solution. Lyophilization was found to be a more effective, but more time-
consuming, method for concentration of VitE-ODN solutions. 
Concentration of solutions could also be achieved by passing a stream of 
argon over the solution, while heating the solution to 40°C in a heating 
block. After HPLC purification sequences were desalted on NAP-10 
columns. Sequences shorter than 12mers were desalted on a larger 
Sephadex-G 10 column. 
Approximately 10mg (6xljtmol syntheses) of 5'-VitE-p(Tp)4T was 
synthesized (using [23]) and HPLC purified. Analysis by 600MHz 1H-
NMR spectroscopy using correlated spectroscopy (COSY) indicated the 
presence of the ODN and a large number of overlapping signals 
corresponding to the alkyl protons of the Vitamin E moiety. The ODN 
signals were assigned using the COSY spectrum. However the overlap in 
the Vitamin E signals prevented the assignment of individual resonances. 
The 31P-NMR spectrum was more useful for characterisation of 5'-VitE- 
p(Tp)4T. Figure 44 clearly shows the presence of normal phosphodiester 
signals at around -2 ppm and a signal corresponding to the single 
aromatic phosphodiester linkage at -4.64 ppm. The ratio of the two 
signals is 4:1 which is the value expected for this ODN. 
13.5. Synthesis of Anti-HIV Vitamin E-Oligonucleotides. 
The anti-HIV testing of antisense ODNs in this research group was 
based on the work of Matsukura et al. 66 who found that a 
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(a) HPLC chromatogram of crude S-rev derivatised with a 5'-unspaced 
Vitamin E using [23]. 
Failure seq. 	 Product 
(b) HPLC chromatogram of crude S-rev derivatised with a 5'-







Failure seq. 	 Product 
(c) HPLC chromatogram of crude S-rev derivatised with a 3'-Vitamin E 
using Vitamin E-controlled-pore glass. 
Figure 43: Typical HPLC chromatograms of crude 28mer 
phosphorothioate S-rev derivatised with Vitamin E. 
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Figure 44: 31P-NMR spectrum of unspaced VitEp(Tp)4T in D20. 
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bases of the start codon of the rev gene of HIV-1 (strain fiB) was 
effective in inhibiting HIV replication in chronically infected H9 cells. 
This sequence is: 
S-d(TCG TCG CTG TCT CCG CIT CIT CCT GCC A), and will be 
referred to as S-rev. 
This test method is likely to give results based on sequence-
specific inhibition of HIV replication, rather than non-sequence specific 
effects which often arise in de novo infection assays. Multi-milligram 
quantities of Vitamin E derivatives of S-rev were synthesized with all 
three types of Vitamin E modification. The VitE sequences have been, or 
are being evaluated for anti-HIV activity in cell culture. 
Three 1.0 p.mole scale syntheses of each VitE-ODN were carried 
out on an Applied Biosystems 380B DNA synthesizer using the 2-
cyanoethyl phosphoramidite method. Iodine was replaced with 
tetraethylthiuram disulphide (TETD) for phosphorothioate synthesis65  
and a 15 minute sulphurization step was used. The Vitamin E 
phosphoramidite monomers [23] and [26] described above were used at a 
concentration of 0.1 M in anhydrous dichloromethane. The modified 
synthesis cycles described above were used. A normal phosphorothioate 
synthesis cycle was used for the synthesis of 3'-VitE ODNs. The Vitamin 
E derivatised-S-rev sequences were purified by reversed-phase HPLC 
(injecting one ljtmol synthesis per run), and desalted on NAP-10 
columns. Reverse-osmosis purified, UV-irradiated water was used in 
every stage of purification to ensure the absence of cytotoxic 
contaminants such as metal ions. After purification the VitE-ODNs were 
lyophilized and submitted for biological testing. All the VitE-ODNs 
synthesized were readily soluble in water and the purity of all the 
lipophilic S-rev derivatives was confirmed by denaturing polyacrylamide 
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gel electrophoresis (7M urea; 20% crosslinking). Visualisation of the 
ODNs was carried out by UV-shadowing or ethidium bromide staining. 
Single bands were observed for all the lipophilic S-rev derivatives 
(results not shown). 
AIW1ffLiiL 
Methods used previously for the attachment of cholesterol to 
ODNs are discussed in the introduction. In cell membranes, and 
presumably in lipoproteins, cholesterol is oriented with its hydroxyl 
function towards the membrane surface and the rest of the molecule 
buried in the hydrophobic core. The attachment of an ODN to the 
hydroxyl function should minimise any interference with membrane 
interactions. A cholesterol phosphoramidite has been synthesized 
previously by Dr. Calum MacKellar of this research group, by direct 
phosphitylation of the hydroxyl function of cholesterol. Due to steric 
hindrance the phosphite intermediate formed during DNA synthesis could 
not be suiphurised with TETD, and oxidation was only possible on 
prolonged treatment with iodine. This is clearly an unsatisfactory 
situation. The steric hindrance problem can be solved by the introduction 
of a spacer arm between the cholesteryl moiety and the phosphoramidite 
group. The presence of an alkyl chain attached to the hydroxyl function 
of cholesterol is unlikely to affect the normal interactions of cholesterol 
as it is often esterified with fatty acids in vivo. 
14.1. Synthesis of a Spaced Cholesterol Phosphoramidite. 
The simplest method of introducing a spacer arm onto cholesterol 
is by reaction of cholesteryl chioroformate with the amino-function of an 
amino-alcohol. The carbamate link formed is known to be stable to DNA 
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synthesis and deprotection conditions. 37,45,46  Thus cholesteryl 
chioroformate was reacted with 6-amino-hexan- 1 -ol in pyridine I 
dichioromethane / triethylamine to give the hexamethylene-spaced 
cholesteryl alcohol [31] (Scheme 10). This reaction proceeded in only 
47% yield probably due to reaction of the cholesteryl chioroformate with 
the free hydroxyl functions of both the aminohexanol and the cholesteryl 
alcohol [31]. The hydroxyl function of [31] was then phosphitylated using 
2-cyanoethyl N,N,N',N'-tetraisopropyl-phosphorodiamidite and 
diisopropylanimonium tetrazolide in dichioromethane to give the 
hexamethylene spaced cholesteryl phosphoramidite [32]. 
In order to overcome the problem of side reactions of cholesterol 
chioroformate at the free hydroxyl functions an octamethylene-spaced 
cholesteryl phosphoramidite was synthesized using 1 -amino-8 - 
tetrahydropyranyloxy-octane [19] (Scheme 11). The synthesis of this 
THP-protected amino-alcohol is described in Chapter 1 (section 9.3.). 
Thus cholesterol chioroformate was reacted with 1 -amino-8-
tetrahydropyranyloxy-octane [19] in pyridine to give the THP-protected 
cholesteryl octyl alcohol [33]. This compound was passed through a short 
silica gel chromatography column to remove polar impurities, then the 
ThP group was removed using aqueous HC1 in tetrahydrofuran. The 
resulting cholesteryl octyl alcohol [34] was obtained in 84% yield. 
Phosphitylation with 2-cyanoethyl-N,N-diisopropyl-
phosphoramidochioridite in the presence of N,N-diisopropylethylamine in 
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Scheme 11: Synthesis of an octamethylene-spaced 
cholesterol phosphoramidite. 
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14.2. Synthesis and Purification of Cholesteryl Oligonucleotides. 
The synthesis and purification conditions used were essentially the 
same as those described above for use with the Vitamin E 
phosphoramidites. The cholesteryl phosphoramidites [32] and [35] were 
used as 0. 1M solutions in anhydrous dichioromethane. Coupling 
efficiencies were >95% as estimated by HPLC. As expected the 
carbamate linkages were stable to DNA deprotection conditions. A 
typical HPLC chromatogram of a crude cholesteryl ODN is shown in 
Figure 45. 
Multi-milligram quantities of cholesteryl derivatised S-rev were 
synthesized, purified and submitted for anti-HIV assays. 
15.0. Adamantane. 
Adamantane is often used to enhance the lipophilicity of small 
molecules without introducing an excessive steric bulk. The synthesis of 
an adamantyl phosphoramidite was easy due to the commercial 
availability of 1 -(1 -adamantyl)-ethan-2-ol. This compound was 
phosphitylated using 2-cyanoethyl-N,N-diisopropylphosphoramido-
chioridite in the presence of N,N-diisopropylethylamine in 
tetrahydrofuran to give the dimethylene spaced adamantyl 
phosphoramidite [36] in 69% yield (Scheme 12). This phosphoramidite 
was used as a 0.1 M solution in anhydrous dichioromethane for DNA 
synthesis using the same conditions as used for the Vitamin E 
phosphoramidites. Coupling efficiencies were estimated to be >95% by 
HPLC analysis. As expected HPLC analysis showed that adamantyl 
ODNs were considerably less lipophilic than the corresponding 
cholesteryl- or VitE-ODNs (Figure 46). 
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Failure seq. 	 Product 
Figure 45: HPLC chromatogram of crude cholesterol derivatised S-rev 
synthesized using [32]. 
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[36] 
Scheme 12. Ethyl-spaced adamantane phosphoramidite. 
'C 
Failure seq. Product 
Figure 46: HPLC chromatogram of a preparative injection of crude 
adamantane derivatised S-rev synthesized using [36]. 
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Multi-milligram quantities of adamantyl derivatised S-rev were 
synthesized, purified and submitted for anti-HIV assays. 
16.0. Thermal Denaturation Studies. 
In order to determine if the presence of terminal lipophilic groups 
had an effect on ODN duplex stability, the UV melting temperatures of 
unmodified and VitE and Chol derivatised S-rev with a complementary 
DNA sequence with four overhanging bases at both the 3'- and 5'-ends 
were determined. The overhangs, which correspond to part of the rev 
gene, were introduced in order to give a closer approximation to the 
situation in vivo where the ODN will hybridise to a much longer mRNA 
template. It would have been preferable to use an RNA oligomer 
complementary to S-rev, however the synthesis and purification of a 
36mer oligoribonucleotide is a difficult, time consuming and expensive 
process. The sequence of the 36mer template ODN was: 
d(CCT ATG GCA GGA AGA AGC GGA GAC AGC GAC GAA GAC). 
The melting temperatures of the derivatised and underivatised S-rev with 
its 36mer template were measured over a Ca. 20-fold concentration range 
and the data obtained were used to determine thermodynamic parameters 
for each sequence. A single, sharp transition was obtained for all the 
lipophilic ODNs, indicating no gross interference with hybridisation. A 
typical UV-melting curve and its first derivative are shown in Figure 47. 
Each curve was determined in triplicate. The concentration dependence of 
the melting temperature (Tm) confirms the formation of a duplex, rather 
than a hairpin loop (which melts by unimolecular process), and allows the 
calculation of thermodynamic parameters for duplex formation.6769 For 
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a heteroduplex the relationship between T. and concentration is as 
follows: 
(1/Tm)= (H°)lfl(CI4)+(ES°/EH°) 
where i\H°=enthalpy of duplex formation, 
ZS0= entropy of duplex formation, 
C= total concentration of single strands. 
Thus a plot of 1f m versus ln(C/4) gives a straight line with gradient 
(R/H°) and intercept (LS°/EiI-I°). 
The free energy of duplex formation AGO can then be calculated using the 
relationship: 
G0=AH0 TAS0 
Van't Hoff plots of i/Tm versus ln(C/4) for S-rev and its 
derivatives are shown in Figures 49, 49 and 50. Straight lines were fitted 
to the data using a linear regression program on a BBC microcomputer. 
The data used to generate these plots are given in Appendix 2. 
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VitEoct-S-rev 	-220.6 -0.616 -36.97 341.30 
(+1164) 
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(L0.046) (+/- 2.75) 








Table 1 : Thermodynamic parameters of hybridisation of S-rev and 
derivatives with a complementary 36mer template. (Numbers in 
parentheses are errors). 
The minor differences in the thermodynamic parameters and Tm 
values are within experimental error and it is clear that terminal lipophilic 
modifications make very little difference to the duplex stability of S-rev 
with its overhanging template strand. Concentration dependent thermal 
denaturation studies were not carried out on adamantyl derivatised S-rev. 
However at a concentration of 5.5RM adamantyl derivatised S-rev 
hybridised to the 36mer template has a Tm  of 342.2K. 
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Dl 
382.80 	312.88 	322.88 	332.88 	342.88 	352.88 
1W 
Figure 47: UV thermal denaturation curve and first derivative for VitE-
S-rev hybridising to a 36mer template. (V-axis-arbitrary units). 
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Figure 48: Van't Hoff plot for unmodified S-rev. 
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(a) Unspaced VitE-S-rev. 
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Figure 50: Van 't Hoff plots for S-rev derivatives. 
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17.0. Summary. 
Spaced- and unspaced-Vitamin E phosphoramidites have been 
synthesized in reasonable yields from inexpensive starting materials. 
A Vitamin E derivatised controlled pore glass (CPG) solid-support 
has been synthesized with a loading of 24 j.tmol.g1. 
Hexa- and octa-methylene spaced cholesterol phosphoramidites have 
been synthesized in reasonable yields from inexpensive starting materials. 
An ethyl spaced adamantane phosphoramidite has been synthesized. 
Conditions have been determined to allow the attachment of Vitamin 
E, cholesterol and adamantane to ODNs during solid-phase synthesis 
using the phosphoramidites and Vitamin E CPG. 
Vitamin E, cholesterol and adamantane have been attached to both 
phosphodiester and phosphorothioate ODNs in high yields (>95%) with 
minimal changes to standard DNA synthesis conditions. 
HPLC purification of lipophilic ODNs is facile due to the increased 
lipophilicity of the desired product relative to underivatised failure 
sequences. 
The lipophilic ODNs synthesized were readily soluble in water. 
Samples of the Vitamin E phosphoramidites have been sent to Roche 
Molecular Systems Inc. to investigate the possibility of immobilisation of 
ODNs on lipophilic solid-supports. 
Multi-milligram quantities of an anti-HIV 28mer phosphorothioate 
ODN (S-rev) modified with Vitamin B, cholesterol and adamantane have 
been synthesized, purified and submitted for testing. 
All lipophilic S-rev derivatives ran as single bands on denaturing 
polyacrylamide gels. 
198 
Thermal denaturation studies indicate that there is little significant 
effect on the hybridisation properties of ODNs on cholesteryl or Vitamin 
E derivatisation. 
Vitamin E has not previously been attached to ODNs. The Vitamin 
E work described above has been published. (Will, D.W.; Brown, T. 
(1992)Tetrahedron Lett. 33, 2729-2732.) 
The work carried out on Cholesterol has been published. 
(MacKellar, C.; Graham, D.; Will, D.W.; Burgess, S.; Brown, T. (1992) 
Nucleic Acids Res. 20, 3411-3417.) 
Cambridge Research Biochemicals are carrying out trials on the 
octamethylene- spaced cholesterol phosphoramidite with a view to 
marketing it. 
18.0. Suggestions for Future Work. 
Synthesis of a variety of sequences derivatised with lipophilic groups 
to determine the sequence specificity of any antiviral activity. 
Rigorous studies on both cellular uptake and intracellular distribution 
of lipophilic ODNs are urgently required. Work carried out in 
collaboration with John Grzybowski demonstrates that fluorescently 
labelled VitE-ODNs can be synthesized (results not shown). 
The water/n-octanol partition coefficients of lipophilic ODNs should 
be measured. The possibility of solubilising lipophilic ODNs in organic 
solvents, such as tetrahydrofuran, would open many interesting avenues 
of research. 
Lipophilic methyiphosphonate ODNs should be synthesized to 
compare their antiviral and solubility properties with those of lipophilic 
phosphorothioates. 
A practical cholesteryl derivatised solid-support should be 
synthesized. Dr. Calum MacKellar of this research group synthesized 
such a derivatized CPG previously, but oxidation and suiphurisation of 
the first internucleoside linkage was highly sterically hindered. The 
synthesis of a spaced cholesteryl CPG should be facile. 
The attachment of multiple lipophilic groups to ODNs during solid-
phase synthesis should be possible using the lipophilic phosphoramidites 
in combination with the multiple hydroxyl phosphoramidite [14] 
described in Chapter 1 (section 8). 
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C. EXPERIMENTAL. 
Characterisation of compounds as previously described in Chapter 1 of 
this thesis. 
Thin Layer Chromatography. 
Thin layer chromatography (tic) was carried out on aluminium sheets, 
silica 60 F254, 0.2mm layer (Merck) using the following solvent systems: 
Hexane-ethyl acetate (80:20, v/v) 
Hexane-ethyl acetate (90:10, v/v) 
Hexane-ethyl acetate (50:50, v/v) 
Toluene-ethyl acetate (80:20, v/v) 
Dichioromethane-methanol (90:10 v/v) 
Vitamin E and Cholesteryl chloroformate were purchased from Fluka. 
Cholesterol compounds and oligonucleotides were synthesized and 
characterized in collaboration with Duncan Graham. 
DL-a-Tocopheryl-6-0-(2-cyanoethyl-N,N-di-isopropyl) 
phosphoramidite.[23]. 
DL-a-tocopherol (leq; ig; 2.32mmol) was dried by coevaporation with 
anhydrous tetrahydrofuran (3 x lOml) then dissolved in anhydrous 
tetrahydrofuran (lOmi). To this solution was added N,N-diisopropyl-
ethylamine (4eq; 9.29mmol; 1.20g; 1 .62m1) and 2-cyanoethyl-N,N-
diisopropylphosphoramidochloridite (leq; 2.32mmol; 0.55g; 0.52m1). 
After lh the reaction was quenched by the addition of ethanol (imi) and 
dichloromethane (lOOml) was added. The resulting solution was washed 
with sat. aqueous NaHCO3 (50m1) and sat. aqueous KC1 (3 x 50m1). The 
organic phase was dried (Na2SO4), filtered and solvents were removed by 
evaporation in vacuo. The residue was dissolved in hexane and applied 
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directly to a wet-flash silica gel chromatography column, eluting with a 
gradient of 0-10% ethyl acetate in hexane, to give the title compound [23] 
as a clear oil (0.8g; 55%). Rf 0.56 (solvent A). 8p(80MHz; CDCI3) 
151.44 (s). f.a.b. ms m/z 629.48111 [(M-H), C38H66N203P requires 
629.481081. 
1-(6-0-DL-(x-Tocopheryl)-(8-tetrahydropyranyloxy)-octane. [24]. 
DL-a-Tocopherol (leq; ig; 2.32mmol) was dissolved in dimethyl 
sulfoxide (25m1) and to this solution was added powdered KOH (4eq; 
9 .28mmol; 0.52g) and 1 -Bromo-8 -tetrahydropyranyloxy-octane (1 eq; 
2.32mmol; 0.68g). After stirring for 2h at 200C the reaction mixture was 
poured into water (100m!) and extracted with dichloromethane (3 x 
50m1). The resulting solution was washed with water (2 x 25m1) and sat. 
aqueous KC1 (25m1). The organic phase was dried (Na2SO4), filtered and 
solvents removed by evaporation in vacuo. The residue was dissolved in 
hexane containing 0.5% ethyl acetate and applied directly to a wet-flash 
silica gel chromatography column, eluting with a gradient of 0.5-2% ethyl 
acetate in hexane, to give the title compound [24] as a clear oil (1.084g; 
73%). Rf 0.39 (solvent B). c(50.320MHz, CDC13) 11.64 (CH3); 11.70 
(CH3); 12.58 (CH3); 19.54 (2xCH3); 20.52 (CH2); 20.89 (CH2); 22.49 
(CH3); 22.57 (CH3); 23.73 (CH3); 24.29 (CH2); 24.67 (CH2); 25.38 
(CH2); 26.07 (3xCH2); 27.83 (CH); 29.32 (CH2); 29.41 (CH2); 29.60 
(CH2); 30.19 (CH2); 30.65 (CH2); 31.16 (CH2); 32.54 (CH); 32.64 
(CH); 37.16 (CH2); 37.26 (3xCH2); 39.23 (CH2); 39.94 (CH2); 62.16 
(CH2); 67.52 (CH2); 72.94 (CH2); 74.56 (C); 98.70 (CH); 117.28 (Ar-C); 
122.59 (Ar-C); 125.65 (Ar-C); 127.69 (Ar-C); 147.49 (Ar-C); 148.29 (Ar-
C). f.a.b. ms m/z 642.55864 [Mt, C42H7404 requires 642.55868]. 
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1-(6-0-DL-a-Tocopheryl)-octan-8-oI. [25]. 
To a solution of compound [24] (leq; 1.0g; 1.56mmol) in tetrahydrofuran 
(20m1) was added cone, aqueous HC1 (5m1). After 30h at 200C the 
solvents were removed by evaporation in vacuo . Traces of water were 
removed by coevaporation with ethanol, then toluene. The residue was 
dissolved in dichloromethane and applied directly to a wet-flash silica gel 
chromatography column, eluting with a gradient of 0-20% ethyl acetate in 
dichloromethane, to give the title compound [25] as a clear oil (0.71g; 
82%). Rf 0.57 (solvent Q. 8c(50.32OMHz, CDC13) 11.65 (CH3); 11.73 
(CH3); 12.59 (CH3); 19.54 (CH3); 19.62 (CH3); 20.52 (CH2); 20.90 
(CH2); 22.51 (CH3); 22.59 (CH3); 23.75 (CH3); 24.31 (CH2); 24.68 
(CH2); 25.58 (CH2); 26.04 (CH2); 27.85 (CH); 29.27 (CH2); 29.43 
(CH2); 30.17 (CH2); 31.16 (CH2); 32.54 (CH); 32.62 (CH2) 32.67 
(CH); 37.15 (CH2); 37.26 (CH2); 37.33 (CH2); 37.44 (CH); 39.24 
(CH2); 39.93 (CH); 62.87 (CH2); 72.93 (CH2); 74.58 (C); 117.30 (Ar- 
C); 122.60 (Ar-C); 125.65 (Ar-C); 127.68 (Ar-C); 147.49 (Ar-C); 148.21 
(Ar-C). f.a.b. ms m/z 558.50120 {M+, C37H6603 requires 558.501171. 
2-cyanoethyl [1-(6-0-DL-(x-Tocopheryl)..oct-8-yI} N,N-
diisopropylamino phosphoramidite [26]. 
To a solution of compound [25] (leq; 0.62g; 1.11 mmol)  in anhydrous 
tetrahydrofuran (lOmi) was added N,N-diisopropylethylamine (4eq; 
4.44mmol; 0.57g; 0.77ml) and 2-cyanoethyl-N,N-di-isopropyl-
phosphoramidochioridite (1.05eq; 1.17mmol; 0.23g; 0.26m1). After 
10min the reaction was quenched by the addition of ethanol (0.5m1) and 
dichloromethane (lOOml) was added. The resulting solution was washed 
with sat. aqueous NaHCO3 (50m1) and sat. aqueous KC1 (3 x 50m1). The 
organic phase was dried (Na2SO4), filtered and solvents were removed by 
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evaporation in vacuo. The residue was dissolved in hexane containing 
20% ethyl acetate and applied directly to a wet-flash silica gel 
chromatography column (which had been pre-equilibrated with hexane 
containing 20% ethyl acetate and I% triethylamine), eluting with 20% 
ethyl acetate in hexane, to give the title compound [26] as a clear oil 
(0.781g; 93%) yield. Rf 0.47 (solvent A). p(80MHz; CDC13) 147.67 (s). 
f.a.b. ms m/z 758.60907 [M, C46H83N204P requires 758.609011. 
2,3-Isopropylidenedioxyprop-1-yI p-toluenesulphonate [27] 
Solketal (leq; log; 76mmol) was dissolved in anhydrous pyridine 
(lOOmi), cooled to 0°C and 4-toluene sulphonyl chloride (leq; 76mmol; 
14.43g) was added. The reaction was allowed to warm to 200G. After 2h 
the reaction was quenched with methanol (2m1), evaporated to dryness 
and the residue dissolved in dichioromethane. The resulting solution was 
washed with sat. aqueous NaHCO3 (50m1), water (2 x 50m1) and sat. 
aqueous KG! (50m1). The organic phase was dried (Na2SO4), filtered and 
solvents removed by evaporation in vacuo to give an oil which solidified 
on standing. Recrystallized from hexane afforded the title compound [27] 
as white waxy crystals (16.052g; 74%). m.p. 41-430C (lit. 41-430C); Rf 
0.49 (solvent D). H(200.130MHz, CDC13) 1.27 (3H, s, 2-H); 1.30 (3H, 
s, 2-H); 2.41 (3H, s, Ar-CH3); 3.68-4.27 (511, m, 2xCH2, CH); 7.30 (2H, 
dd, Ar-3-11, Ar-5-11, J0 j10=8.5Hz, Jmeta0.7Hz); 7.75 (2H, d, Ar-2H, 
Ar-6-H, J01-tj10=8.5Hz). c(50.320MHz, CDC13) 21.43 (CH3); 24.92 
(CH3); 26.41 (CH3); 65.89 (CH2); 69.33 (CH2); 72.69(CH); 109.81(Ar- 
C); 127.76 (2xAr-CH); 129.73 (2xAr-CH); 132.36 (C); 144.90 (C). 
f.a.b. ms m/z 287.09529 [(M+H)+, C13141905S requires 287.095311. 
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1-(6-0-DL-(x-Tocopheryl)-propan-2, 3-diol. [28]. 
DL-cx-Tocopherol (leq; Log; 2.32mmol) was dissolved in dimethyl 
sulfoxide (25m1). To this solution was added powdered KOH (4eq; 
9.28mmol; 0.52g) and compound [27] (1.leq; 2.55mmol; 0.73g). After 
24h the reaction mixture was poured into water (lOOmi) and extracted 
with dichloromethane (3 x 50m1). The resulting solution was washed with 
water (50m1) and sat, aqueous KC1 (50ml). The organic phase was dried 
(Na2SO4), filtered and solvents removed by evaporation in vacuo. The 
residue was dissolved in hexane containing 0.5% ethyl acetate and 
applied directly to a wet-flash silica gel chromatography column, eluting 
with a gradient of 0.5-2% ethyl acetate in hexane. This decolorized the 
crude product and removed polar impurities. The crude product was 
evaporated to an oil, then dissolved in tetrahydrofuran (20m1). To this 
solution was added water (2m1) and conc. aqueous HC1 (5m!). After 
45min the solvents were removed by evaporation in vacuo , and traces of 
water were removed by coevaporation with ethanol (3 x lOmi) and 
toluene (lOmi). The residue was dissolved in dichloromethane containing 
1 % methanol and applied directly to a wet-flash silica gel 
chromatography column, eluting with a gradient of 1-10% methanol in 
dichloromethane, to give the title compound [28] as a clear oil (0.63g; 
54%). Rf 0.47 (solvent E). c(50.320MHz; CDC13) 11.66 (2xCH3); 
12.53 (CH3); 19.55 (CH3); 19.62 (CH3); 20.50 (CH2); 20.89 (CH2); 
22.50 (CH3); 22.59 (CH3); 23.70 (CH3); 24.30 (CH2); 24.67 (CH2); 
27.85 (CH); 31.08 (CH2); 32.55 (CH); 32.64 (CH); 37.15-37.43 
(4xCH2); 39.23 (CH2); 39.92 (CH2); 63.99 (CH2); 70.89 (CH); 74.03 
(CH2); 74.74 (C); 117.55 (Ar-C); 122.95 (Ar-C); 125.47 (Ar-C); 127.41 
(Ar-C); 147.14 (Ar-C); 147.95 (Ar-C). f.a.b. ms m/z 504.4 1782 [Mt, 




Compound [28] (leq; 0.6g; 1.19mmol) was dried by coevaporation with 
anhydrous pyridine (3 x 5m1), then dissolved in anhydrous pyridine (7m1) 
and to this solution was added 4,4'-dimethoxytrityl chloride (leq; 
1.19mmol; 0.40g). After 2h the reaction was quenched with methanol 
(imi), and solvents were removed by evaporation in vacuo. The residue 
was dissolved in dichioromethane and the resulting solution was washed 
with sat. aqueous NaHCO3(30ml) and sat. aqueous KCI (2 x 30m1). The 
organic phase was dried (Na2SO4), filtered and solvents were removed by 
evaporation in vacuo. The residue was dissolved in hexane containing 5% 
ethyl acetate and applied directly to a wet-flash silica gel chromatography 
column, eluting with a gradient of 5-10% ethyl acetate in hexane, to give 
the title compound [29] as a pale yellow oil (0.68g; 71 %).  Rf 0.68 
(solvent Q. 6c(50.32OMHz, CDC13) 11.66 (CH3); 11.76 (CH3); 12.64 
(CH3); 19.56 (2xCH3); 20.51 (CH2); 20.92 (CH2); 22.52 (CH3); 22.61 
(CH3); 23.73 (CH3); 24.32 (CH2); 24.69 (CH2); 27.85 (CH); 31.10 
(CH2); 32.57 (CH); 32.65 (CH); 37.27 (4xCH2); 39.24 (CH2); 39.94 
(CH2); 55.04 (2xDMT-CH3) 64.27 (CH2); 70.19 (CH); 73.75 (CH2); 
74.68 (C); 86.01 (DMT-C); 112.98 (4xDMT-CH); 117.44 (Ar-C); 122.79 
(Ar-C); 125.63 (Ar-C); 126.66 (DMT-CH); 127.60 (Ar-C); 127.69 
(2xDMT-CH); 128.00 (2xDMT-CH); 129.94 (4xDMT-CH); 135.83 
(2xDMT-C); 144.69 (DMT-C); 147.41 (Ar-C); 147.79 (Ar-C); 158.35 




To a solution of compound [29] (leq; 0.476g; 0.59mmol) in anhydrous 
pyridine (lOmi) was added succinic anhydride (2.5eq; 1.48mmol; 
0.147mg) and 4-dimethylaminopyridine (0.8eq; 0.47mmol; 57mg) in 
portions over 5 days. The reaction mixture was evaporated to an oil and 
coevaporated three times with toluene. The residue was taken-up in 
dichioromethane and washed twice with ice-cold 10% aqueous citric acid. 
The organic phase was dried (Na2SO4), filtered and solvents were 
removed by evaporation in vacuo. The residue was dissolved in 
dichioromethane containing 50% ethyl acetate and 1% triethylamine and 
applied directly to a wet-flash silica gel chromatography column, eluting 
first with dichloromethane:ethyl acetate:NEt3 49.5:49.5:1 (vlv/v) to elute 
lipophilic impurities. The the triethylammonium salt of the title 
compound was then eluted from the column with 
dichloromethane:methanol:NEt3 89.5:9.5:1 (v/v/v). Rf 0.54 (solvent E). 
Procedure for the derivatisation of Long-Chain Alkyl Amino-
Controled Pore Glass (CPG) solid support with Compound [8]. 
Activation of the CPG. 
CPG (0.5g) was washed with a 10% solution of N,N- 
diisopropylethylamine in N,N-dimethylformamide (4x5ml), followed by 
N,N-dimethylformamide (5x5m1). 
Coupling the succinate on to CPG. 
To the hemisuccinate [30] (0.45 mmol), dissolved in anhydrous 
dichioromethane (2 ml) was added a solution of 4-nitrophenol (0.45 
mmol, 63mg) in anhydrous pyridine (0.1 ml) followed by N,N'-
dicyclohexylcarbodiimide (1.125 mmol, 0.23g). After a few minutes 
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dicyclohexylurea precipitated. After 2.5 h. the dicyclohexylurea was 
removed by filtration and the filtrate was added to the activated CPG (0.5 
g) suspended in N,N-dimethylformamide (2 ml). Triethylamine (0.1 ml) 
was added and the mixture was agitated with a stream of argon for 48h. 
The CPG was washed with N,N-dimethylformamide (5x5m1), 
dichioromethane (5x5m1) and diethyl ether (5x5m1) and dried in vacuo. 
Capping the CPG. 
The functionalised resin was washed with anhydrous tetrahydrofuran 
(3x5m1) then mixed with anhydrous THF (8 ml), 2M 1-methylimidazole 
in THF (1.5m1), 1M acetic anhydride in THF (3m!) and agitated for 2.5 h. 
The CPG was filtered-off, washed successively with THF, 
dichioromethane and diethyl ether then dried in vacuo overnight. 
Calculation of the loading of the CPG. 
The flinctionalised CPG (5mg) was detrity1at,k with a solution of 
trichioroacetic acid in anhydrous dichioromethane in a lOmi volumetric 
flask. After 5 mm. the absorbance of the solution at 504nm was measured 
to determine the concentration of dimethoxytrityl cations in solution and 
thus the loading on the CPG. 
c504=76mlcm-1p.mol-1  for the dimethoxytrityl cation.64 
The final loading of [30] on the CPG was 28.7pmolg4 . 
Cho1estery1-3-(carboxyamjnohexan6-oJ) [31] 
6-Aminohexan-1-ol (leq; 0.501g; 4.27mmol) was dried by coevaporation 
with anhydrous pyridine (3 x 5m1) and dissolved in anhydrous pyridine 
(7m1). To this solution was added a solution of cholesteryl chloroformate 
(1.906g; 4.24mmol) and anhydrous triethylamine (0.43g; 0.59m1; 
4.25mmol) in anhydrous dichioromethane (3m!). The reaction was stirred 
for 24hrs at 200C after which dichloromethane (50m1) was added and the 
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resulting solution washed with sat. aqueous NaHCO3(20m1), 
water(20m1) and sat. aqueous KC1 (2 x 20ml). The organic phase was 
dried (Na2SO4), filtered and solvents were removed by evaporation in 
vacuo. The residue was dissolved in hexane containing 10% ethyl acetate 
and applied directly to a wet-flash silica gel chromatography column, 
eluting with a gradient of 0-50% ethyl acetate in hexane, to give the title 
compound [31] as a white solid (1.067g; 47%) yield. Rf 0.27 (solvent Q. 
c(50.320MHz, CDC13) 11.68 (CH3); 18.54 (CH3); 19.17 (CH3); 20.85 
(CH2); 22.40 (CH3); 22.67 (CH3); 23.66 (CH2); 24.11 (CH2); 25.13 
(CH2); 26.21 (CH2); 27.84 (CH); 28.05 (2CH2); 29.82 (CH2); 31.69 
(CH, CH2); 32.38 (CH2); 35.63 (CH); 35.99 (CH2); 36.36 (C); 36.80 
(CH2); 38.40 (CH2); 39.33 (CH); 39.54 (CH2); 40.50 (CH2); 42.11(C); 
49.79 (CH); 55.92 (CH); 56.48 (CH); 62.46 (CH2); 74.02 (CH); 122.30 
(CH); 139.64 (C); 156.10 (C). f.a.b. ms mlz 530.45730 [(M+H)+, 
C34H60NO3 requires 530.45729]. 
Cholesteryl-3-carboxyaminohexyl-2-cyanoethyl,N,N.cijjsopropyl 
phosphoramidite [32] 
Cholesterol-3 -(carboxyaminohexan-6-ol) [31] (0.499g; 9.44mmol) was 
dried by coevaporation with anhydrous dichloromethane (3 x 5m1) then 
dissolved in anhydrous dichloromethane (5m1). Diisopropylammonium 
tetrazolide (0.081g; 4.72mmol) was added slowly to this solution with 
stirring until it had all dissolved before adding 2- cyanoethyl N,N,N',N'-
tetraisopropyl-phosphorodiamidite (0.3 ig; 0.33m1; 1 .O3mmol). After 24h, 
dichloromethane (SOml) was added and the resulting solution washed 
with sat, aqueous NaHCO3  (30m1) , sat. aqueous KC1 (2 x 30m1) and 
water (30ml). The organic phase was dried (Na2SO4) filtered and the 
solvent removed in vacuo to leave a clear oil. The oil was then dissolved 
MIJ 
in hexane containing 10% ethyl acetate and applied directly to a wet-flash 
silica gel chromatography column (which had been pre-equilibrated with 
hexane containing 1% triethylamine), eluting with a gradient of 0-25% 
ethyl acetate in hexane to give the title compound [32] as a clear oil 
(0.268g; 38.8%) yield. Rf 0.62 (solvent Q. öp(80MHz; CDC13) 147.67 
(s). f.a.b. ms m/z 729.55730[M, C43H76N304P requires 729.55731]. 
C holesteryl-3-(carboxyaminooctan-8-oI) [34] 
To a solution of cholesterol chioroformate (0.993g; 2.21mmol) in 
anhydrous pyridine (5m!) was added 1 -amino-8-tetrahydropyranyloxy-
octane (synthesis described in Chapter 1 experimental) (0.46g; 
2.01mmol). After 15mm. at 200C, dichloromethane (lOOml) was added 
and the resulting solution washed with sat. aqueous NaHCO3 (50m1), 
water (50m1) and sat. aqueous KC1 (2 x 25m1). The organic phase was 
dried (Na2SO4), filtered and solvents were removed by evaporation in 
vacuo . The residue was dissolved in toluene containing 10% ethyl 
acetate and applied directly to a wet-flash silica gel chromatography 
column, eluting with a gradient of 0-5% ethyl acetate in toluene, to give a 
clear oil (1.160g; 90%). A portion of this oil (0.9036g; 1.41mmo!) was 
dissolved in tetrahydrofuran (45m1) and conc. aqueous HC1 (0.5m!) and 
water (4.5m!) were added with stirring. After 24h the reaction was found 
to be incomplete. The solvent was removed in vacuo. Ethanol (2xl5ml) 
was added and removed in vacuo before adding THF(45m1), conc. 
aqueous HC1 (0.5m1) and water (4.5m1). This mixture was stirred for a 
further 30min after which the reaction was found to be complete. The 
solvent was removed in vacuo, ethanol (2x 1 5m1) added and removed in 
vacuo before adding toluene(2x15m1) which was also removed in vacuo 
to remove all traces of water and HCI. The product was then purified by 
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wet-flash silica gel chromatography eluting with a gradient of 1-50% 
ethyl acetate in hexane and dried in a vacuum dessiccator to give the title 
compound [34] as a clear glass (0.662g; 83.6%). Rf 0.40 (system C), 
c(50.320MHz, CDC13) 11.70 (CH3); 18.56 (CH3); 19.18 (CH3); 20.88 
(CH2); 22.41 (CH3); 22.67 (CH3); 23.68 (CH2); 24.13 (CH2); 25.50 
(CH2); 26.49 (CH2); 27.85 (CH); 28.03 (CH2); 28.07 (CH2); 29.03 
(CH2); 29.13 (CH2); 29.56 (CH2); 29.79 (CH2); 31.72 (CH, CH2); 32.49 
(CH2); 35.64 (CH); 36.02 (CH2); 36.39 (C); 36.83 (CH2); 38.43 (CH2); 
39.36 (CH2); 39.57 (CH2); 40.59 (CH2); 42.15 (C); 49.83 (CH); 55.97 
(CH); 56.52 (CH); 62.60 (CH2); 74.01 (CH); 122.31 (CH); 139.69 (C); 




Cholesteiyl-3-(carboxyaminooctan-8 -ol) [34] (1 eq; 0.574g; 0.995mmo1) 
was dried by coevaporation with anhydrous THF (3 x 1 5m1) then 
dissolved in anhydrous THF (15m1). To this solution was added N,N-
diisopropylethylamine (4eq; 3.98mmol; 0.513g; 0.71m1) and 2-
cyanoethyl-N,N-di-isopropylphosphoramjdochloridjte (1.1 eq; 
1.095mmol, 0.252g; 0.237m1). After 15min dichioromethane (50m1) was 
added to quench the reaction and the resulting solution washed with sat. 
aqueous NaHCO3(25m1), water (25m1) and sat. aqueous KC1 (2 x 25m1). 
The organic phase was dried (Na2SO4), filtered and the solvent removed 
in vacuo to leave a clear oil. The oil was dissolved in hexane containing 
10% ethyl acetate and applied directly to a wet-flash silica gel 
chromatography column (which had been pre-equilibrated with hexane 
containing 1 % triethylamine), eluting with a gradient of 0-10% ethyl 
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acetate in hexane to give the title compound [35] as a clear oil (0.319g; 
41%). Rf 0.76 (solvent system Q. p(80MHz; CDC13) 147.95 (s); f.a.b. 
ms m/z 757.58863 [Mt, C45H80N304P requires 757.58861]. 
2-cyanoethyl [1 -(1 -Adamantyl)-eth-2-yI] -N,N-diisopropylamino 
phosphoramidite [36] 
2-(1-Adamantyl)-ethanol (leq; 0.5g;2.77mmol) was dissolved in 
anhydrous tetrahydrofuran (lOmi) and to this solution was added N,N-
diisopropylethylamine (4eq; 0.1 imol; 1.43g; 1 .93m1) and 2-cyanoethyl-
N,N-di-isopropylphosphoramidochloridite (1.1 eq; 3 .O5mmol; 
0.72g;0.68m1). The reaction was complete after 2min and was quenched 
with anhydrous ethanol (imI), dissolved in dichloromethane and washed 
with water (40m1) and sat. aqueous KC1 (2 x 40m1). The organic phase 
was dried (Na2SO4), filtered and the solvent removed by evaporation in 
vacuo. The residue was purified by wet-flash silica gel chromatography, 
on a column which had been pre-equilibrated with hexane containing 
10% ethyl acetate and 1% triethylamine, eluting with hexane containing 
10% ethyl acetate, to give the title compound [36] as a clear liquid 
(0.721g; 69%). Rf 0.70 (solvent A). 5p(145.785MHz; CDC13) 147.21 (s). 
f.a.b. ms m/z 379.25 142 [(M-H) , C21H36N202P requires 379.25 143]. 
Synthesis of Lipophilic Oligonucleotides. 
Oligonucleotides were prepared on a 1.0 .tmole scale on an Applied 
Biosystems 380B DNA synthesizer using the cyanoethyl 
phosphoramidite method. Iodine was replaced with tetraethylthiuram 
disulphide (TETD) for phosphorothioate synthesis. A 15mm 
suiphurization step was used. The phosphoramidite monomers described 
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above were used at a concentration of 0.1 M in anh. dichioromethane. 
Slightly modified synthesis cycles were used: 
A 15 sec delivery of anhydrous dichioromethane to the synthesis 
column, before and after the coupling step for phosphoramidites [23], 
[26], [32], [35] and [36]. 
A 20 sec reverse flush and a 4 sec block flush after each 
dichioromethane wash. 
The coupling wait time was prolonged to 4 min in order to increase 
the coupling yield for phosphoramidite [23]. 
Normal synthesis cycles were used for the synthesis of 3'-Vitamin E 
oligonucleotides. 
Purification of Oligonucleotides. 
VitE and Chol-Oligonucleotides. 
Buffer A; 0.1M NFJ40Ac. Buffer B; 0.1M NH40Ac/60% MeCN. 
Gradient C. 
Adamanlyl Oligonucleotides. 
Buffer A; 0.1M NH40Ac. Buffer  B; 0.1M NH4OAc /60% MeCN. 
Gradient A. 
The final products were purified twice by gel-filtration using Sephadex 
NAP-10 columns (Pharmacia) and were then lyophilized. Pure water 
(purified by reverse osmosis) was used for the latter stages of 
purification. 
Ultraviolet Melting Studies 
The ultraviolet melting temperatures of lipophilic denvatised S-rev 
hybridised to a normal DNA template with four overhanging bases at 
both the 3'-, and 5'-end were measured. The ultraviolet melting 
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temperatures of underivatised S-rev hybridised to the same normal DNA 
template were measured at eight points over a 20-fold concentration 
range. Each point was measured in triplicate at 260nm on a Perkin-Elmer 
Lambda 15 ultraviolet spectrometer equipped with a Peltier block and 
controlled by an IBM PS2 microcomputer. A heating rate of 0.9K per 
minute was used throughout and the crude data were collected and 
processed using the PECSS-2 software package. The oligonucleotides 
were dissolved in a buffer consisting of aqueous sodium chloride (0.1 M), 
sodium dihydrogen orthophosphate (0.01M), sodium cacodylate (0.02M) 
and EDTA (1mM) which had been adjusted to pH 7.0 by the addition of 
sodium hydroxide. 
Enzyme digests carried out in this UV melting buffer led to 
incomplete digestion of the oligonucleotide as determined by HPLC. 
Concentrations of normal oligonucleotide templates were determined by 
dissolving the sample in a buffer consisting of NaCl (0.1 M) and Tns.HC1 
(10mM) at pH 8.7 and maintaining this at 37°C in the presence of 0.1 mg 
of phosphodiesterase 1 and 0.1 mg of alkaline phosphatase until complete 
digestion gave rise to maximum ultraviolet absorbance (< 1 day). 
Complete digestion was confirmed by HPLC. The published E260 values 
of the nucleosides were used as standards.70 As phosphorothioate 
oligonucleotides are resistant to enzymic digestion, their concentrations 
were estimated by measuring the U.V. absorbance of the intact 
oligonucleotide and multiplying this by a factor equivalent to the average 
proportional increase in U.V. absorbance obtained by digestion of normal 
oligonucleotides of the same sequence. 
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!! !! 4tI! 
Sequences of oligonucleotides. 
DW1 (24mer PCR primer): d(CTC GAG TAT GCC GAG ACC CCT 
AAT). 
A (26mer PCR primer): d(ATG GTF GCA GAA GAT GCC CCT GIT 
AG). 
B (25mer PCR primer): d(CAG TGC AGC ACT CCA CGA GCA GTI' 
C). 
Dl (25mer PCR primer): d(TCG TGC CGG CAG TGC CAC TGC ACA 
C). 
D2 (18mer PCR primer): d(CAG AlT GCG ACC CTC CGC). 
HC1 (40mer Epstein-Barr virus probe): d(AGC GCG TilT ACG TAA 
GCC AGA CAG CAG CCA ATF GTC AGT T). 
GW1 (24mer PCR primer): d(ATG GTT GCA GAA GAT GCC CCT 
GriT). 
OSWEL1 (23mer PCR primer): d(GTT GAC TCA GAT TGG 'TTG CAC 
IT). 
OSWEL2 (27mer PCR primer): d(CAT CAG AAT GTC 11TG GTC TTC 
CCC AlT). 
S-rev (28mer anti-HIV phosphorothioate) S-d(TCG TCG CTG TCT CCG 
CTT CYF CCT GCC A). 
S-rev overhanging template (36mer) d(CCT ATG GCA GGA AGA 
AGC GGA GAC AGC GAC GAA GAC). 
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Appendix 2. 
Relationship between melting temperature and oligonucleotide 
concentration obtained from thermal denaturation studies on lipophilic 
phosphorothioate oligonucleotides (S-rev). 
(a) Unmodified S-rev. 
------------------------------------------------------------------------------------------ 
Concentration(C) Tm 	1/Tm(x103) ln(C/4) 
/.tM 	/K 1K-1  
------------------------------------------------------------------------------------------ 
13.29 341.9 2.925 -12.615 
9.48 342.5 2.919 -12.953 
5.99 341.9 2.925 -13.412 
4.76 341.3 2.929 -13.642 
3.58 341.3 2.929 -13.926 
2.18 340.3 2.938 -14.422 
1.29 340.1 2.940 -14.947 
0.604 
------------------------------------------------------------------------ 
338.8 2.952 -15.706 
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Unspaced Vit E-S-rev. 
Concentration(C) 
------------------------------------------------------------------------------------------
Tm lfFm(x103) ln(C/4) 
/iM 
------------------------------------------------------------------------------------------
/K 1K-1  
17.05 344.2 2.906 -12.366 
14.02 343.9 2.907 -12.561 
11.44 343.9 2.908 -12.765 
8.97 343.5 2.911 -13.008 
6.14 343.2 2.913 -13.387 
3.87 342.7 2.918 -13.849 
1.89 342.0 2.924 -14.565 
1.27 341.6 2.928 -14.963 
0.604 
------------------------------------------------------------------------------------------ 
339.4 2.946 -15.706 
Octamethylene-spaced Vit E-S-rev. 
Concentration(C) 
------------------------------------------------------------------------------------------




19.3 344.5 2.902 -12.242 
15.3 343.8 2.909 -12.474 
12.5 343.8 2.909 -12.676 
9.20 343.7 2.909 -12.983 
6.55 343.4 2.912 -13.322 
4.44 342.9 2.916 -13.711 
2.29 342.1 2.923 -14.373 
0.95 
------------------------------------------------------------------------------------------ 
341.2 2.930 -15.088 
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d) 3'- Vit E-S-rev. 
Concentration(C) 
------------------------------------------------------------------------------------------
Tm 1/Tm(x103) ln(C/4) 
/j.tM 
------------------------------------------------------------------------------------------
/K 1K-1  
16.11 343.9 2.908 -12.422 
13.93 343.8 2.909 -12.568 
11.33 343.6 2.911 -12.774 
8.93 343.2 2.913 -13.012 
6.80 343.2 2.914 -13.260 
4.75 343.2 2.914 -13.644 
2.72 342.0 2.924 -14.201 
1.31 341.8 2.926 -14.932 
0.71 
------------------------------------------------------------------------------------------
339.7 2.944 -15.541 
(e) Hexamethylene-spaced Chol-S -rev. 
Concentration(C) 
------------------------------------------------------------------------------------------




15.61 342.8 2.917 -12.454 
13.43 342.8 2.917 -12.604 
9.93 342.8 2.917 -12.906 
7.83 342.4 2.920 -13.144 
5.58 342.2 2.922 -13.482 
4.16 341.7 2.927 -13.777 
1.59 
------------------------------------------------------------------------------------------
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ABSTRACT 
The synthesis of non-nucleoside-based phosphoramidites that bear the 2,4-dinitrophenyl group is 
reported. These labelled phosphoramidites, which have been used in solid-phase oligonucleotide synthesis to 
attach single and multiple dinitrophenyl groups to the 5-end of oligonucleotides, are entirely compatible 
with the normal oligonucleotide synthesis cycle. Multiple labelling can be performed readily in high yield 
and the resulting oligonucleotides can be purified readily by reversed-phase h.p.l.c. The labelled oligonucleo-
tides have been detected using monoclonal and polyclonal anti-dinitrophenyl antibodies. 
INTRODUCTION 
Non-radioactive labelling of oligonucleotides has attracted much interest in 
recent years as the number of biological and biomedical techniques that require labelled 
oligonucleotides has increased. The major drawback of non-radioactive detection has 
been its poor sensitivity relative to standard radiolabel-detection techniques. A solution 
to this problem may lie in the attachment of multiple labelling groups to the oligonucle-
otide which allow amplification of the detection signal. The attachment of multiple 
labels must not affect the hybridisation properties and solubility of the oligonucleotide, 
and it should be controllable in order to allow the optimum mumber of labels to be 
attached. The method used for multiple labelling should also be inexpensive and simple. 
The most commonly used non-radioactive labelling group is biotin, which has 
been incorporated into oligonucleotides enzymically1 '2, by reaction with 5'-amino-
functionalised oligonucleotides37, and by incorporation of biotinylated phosphorami-
dites during solid-phase synthesis8 '°. Only the last technique allows the introduction of 
multiple labelling groups in a controlled manner. The major disadvantages are that 
biotin and its analogues are expensive, the synthesis of biotinylated phosphoramidite 
monomers is made difficult by the poor solubility of biotin, and the presence of high 
levels of endogenous biotin in certain tissues makes it unsuitable for certain types of 
hybridisation in situ. Enzymic labelling of oligonucleotides with digoxigenin is also 
possible", but this technique is expensive and uncontrolled. 
* Dedicated to Professor Grant Buchanan on the occasion of his 65th birthday. 
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Labelling of oligonucleotides with fluorescent groups has also been achieved', 5 
However, detection of oligonucleotides labelled in this way requires specialised equip-
ment, which is not required in the enzyme-linked immunosorbent assay (ELISA) or 
chernilurninescent detection of immunogenically labelled oligonucleotides. 
An inexpensive labelling group which can be detected immunogenically is the 
2,4-dinitrophenyl group (DNP group). The DNP group has been introduced into 
oligonucleotides via the action of deoxynucleotidyl terminal transferase or DNA po-
lymerase on a DNP-aminohexyl derivative of ATP, and by reaction of Sanger's reagent 
(1-fluoro-2,4-dinitrobenzene) with oligonucleotides that contain an aminohexyl deriv- 
ative of 	 DNP groups have been introduced photochemically'7 and by 
reaction with brominated bases". Multiple DNP groups have been incorporated into 
oligonucleotides in a more controlled manner using a DNP nucleoside phosphorami-
dite during solid-phase synthesis'. The DNP group is unstable under the normal 
conditions for base-catalysed deprotection, but this problem can be overcome by using 
labile base-protected monomers for DNA synthesis. 
The aim of the present work is to develop simple DNP phosphoramidites for the 
mono- or poly-labelling of oligonucleotides during solid-phase synthesis. The strategy 
used involves inexpensive, readily available, non-nucleoside starting materials that can 
be functionalised in the minimum number olsteps to give the desired DNP phosphora-
midite, which can then be used in standard procedures to give the desired mono- or 
poly-labelled oligonucleotides. 
RESULTS AND DISCUSSION 
Sin thesis of a mono-labelling DNP phosphoramidite. The DNP phosphorami-
dite 3, which allows the attachment of a single DNP group to the 5'-end of oligonucleo-
tides during solid-phase synthesis, was obtained as follows. 6-Aminohexan-1-ol (1)was 
treated with Sanger's reagent in methanol to give the mono-DNP derivative 2. The 
reaction of 2 with 2-cyanoethyl N,N-di-isopropylphosphorarnidochloridite then gave 3 
(80%).  
N 	 NO2 
/\ H 
NHR 	 NO2 
HO 	 NC  
1 = H 
2 P 	DNP 
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Synthesis qf a pa/v-labelling DNP phosphoramic/ite. 	The DNP phosphorami- 
dite 7, which allows the attachment of multiple DNP groups to oligonucleotides during 
solid-phase synthesis, was obtained as follows. 3.6-Diazaoctane-1,8-diol (4) was treated 
with Sanger's reagent in methanol and the product (5, 81 %) yielded crystals that were 
suitable for X-ray diffraction analysis. The X-ray crystal structure of 5 showed that the 
DNP groups were arranged "anti" with respect to each other". If the same conforma-
tion is retained in solution, this may be advantageous, allowing the binding of an 
antibody to each of the two DNP groups, thus enhancing the detection sensitivity. The 
reaction of 5 with 4,4'-dimethoxytrityl chloride in pyridine gave 6a (3 1%). The poor 
yield was due to the equivalence of the two primary hydroxyl functions present. This 
reaction was not optimised, but 5 could be recovered by treatment of the bis(4,4'-
dimethoxytrityl) side-product 6b with acetic acid. Reaction of 6a with 2-cyanoethyl 
N,N-di-isopropylphosphoramidochloridite gave 7 (84%). One advantage of 7 is that it 
allows the attachment of two DNP groups to the oligonucleotide per synthesis cycle. 
H 
HO 	
N 	 OH 
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4R - H 
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Svn thesis of DNP-labelled oligonucleo tides. The DNP phosphorarnidites 3 and 
7 were used as 0.15m solutions in anhydrous acetonitrile and anhydrous dichioro-
methane, respectively, for the solid-phase synthesis of labelled oligonucleotides. A 
standard 0.2-mol-scale synthesis cycle was used. The coupling efficiency of 7 was 
> 97% in all syntheses. The coupling efficiency of 3 could not be measured directly, but 
was estimated by h.p.l.c. analysis to be > >90%. Oligonucleotides that had up to ten 
DNP groups (i.e., five couplings of 7) were synthesised, although, theoretically, any 
even number of DNP groups could be attached in this way. 
Stability of the labelling to basic deprotection conditions. 	The single DNP label 
introduced by the coupling of 3 to the 5'-end of the oligonucleotide was found by h.p.l.c. 
to be stable to normal base-catalysed deprotection (5 h, 550,  conc. NH4OH). However, 
the multiple labels introduced by the coupling of 7 to the 5'-end of oligonucleotides were 
unstable under these conditions. H.p.l.c. showed that there was only one degradation 
product formed, which was neither 2,4-dinitroaniline nor 2,4-dinitrophenol. This in-
stability problem was overcome by the use of commercially available phosphoramidites 
for DNA synthesis (Pharmacia "PAC"-amidites or ABI "FOD"-amidites), which bear 
base protecting groups that are removed under milder conditions (5 h in conc. NH40H 
at 20). Under such conditions, the DNP label was degraded only to a very small extent, 
and no problems arose in the purification and isolation of the labelled oligonucleotide in 
high yield. 
Purification of DNP-lahelled oligonucleotides. 	The highly lipophilic nature of 
the DNP group results in DNP-labelled oligonucleotides being eluted later than un-
labelled failure sequences on reversed-phase h.p.l.c. This difference makes the puri-
fication of DNP-labelled oligonucleotides extremely easy, as the labelled oligonucleo-
tide behaves similarly to a conventional "trityl-on" sequence. The effect of increasing 
the number of DNP labels on the time of elution is shown in Fig. 1. The labelled 
oligonucleotides are bright yellow in colour, which allows them to be distinguished 
readily from unlabelled sequences. Traces of the low-molecular-weight degradation 
product were removed when the sample was passed through a column of Sephadex G25 
during the normal purification procedure. 
Detection of DNP-labelled oligonucleotides. - Preliminary experiments con-
firmed that anti-DNP antibodies bind to DNP-labelled oligonucleotides, and that the 
antibodies can be detected both on the basis of radioactivity and by an ELISA method. 
Oligonucleotides labelled with one, two, six, and ten DNP groups were fixed on nylon 
filters in duplicate by u.v. irradiation. The filters were blocked using bovine serum 
albumin with EDTA to inhibit any DNAase activity, washed, and incubated with a 
1/200 dilution of K3 monoclonal anti-DNP antibody for 1 h. After further washing, one 
filter was treated with 1211-Protein A and then washed, and the signal was detected using 
X-ray film. The other filter was incubated with an anti-mouse-lgG-peroxidase conju-
gate for I h, washed, and detected by 4-chloro-1-naphthol and H 2O, which gave a blue 
precipitate. Further experiments are in progress. 
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Hexa-labelled 29 mer 
Unlabelled failure sequences - 
Deco-labelled 29 mer 
Fig. I. Superimposed traces from h.p.l,c. of identical 29mcrs labelled with six (upper trace) and ten (lower 
trace) DNP groups, showing the effect of the lipophilicity of the DNP groups on elution time. Buffer A, 0.1 M 
NH4OAc: buffer B, 0.IM NH40Ac/60% of acetonitrile. 
EXPERIMENTAL 
All solvents were of analytical grade. Alcohol-free anhydrous dichloromethane 
was prepared by distillation from CaH, and anhydrous tetrahydrofuran by distillation 
from sodium—benzophenone. Hexane was dried over sodium wire. Anhydrous aceto-
nitrile was supplied by Applied Biosystems Inc. H-N.m.r. spectra were recorded with 
Bruker WP-80 (80 MHz) and WP-200 (200 MHz) spectrometers. 31P-N.m.r. spectra (81 
MHz) were recorded with the latter spectrometer. F.a.b. mass spectra (positive ion, 
thioglycerol matrix) were recorded on a Kratos MS50 TC spectrometer. Oligonucleo-
tide synthesis was performed with an Applied Biosystems 381A DNA synthesiser, and 
ending procedures with an ABI 380B DNA synthesiser. 2-Cyanoethyl phosphoramidite 
monomers for DNA synthesis were supplied by Applied Biosystems and Pharmacia. 
Sephadex G-25 N.A.P. (nucleic acid purification) columns were supplied by Pharmacia. 
Flash-column chromatography was carried out on Silica Gel 60 (Fluka), and t.l.c. on 
Silica Gel 60 F2 4 (Merck), using A, toluene-ethyl acetate (1:1), 1 % of triethylamine; B, 
toluene—ethyl acetate (4:1), 1% of triethylamine; C, dichloromethane—methanol (9:1), 
l% of triethylamine; D, dichloromethane—methanol (99:1), 1% of triethylamine; E, 
dichloromethane-2-propanol (95:5), 1 % of triethylamine; F, dichloromethane—ethyl 
acetate (1:1), 1% of triethylamine. 
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6-(2,4-Dinitrophenylamino)hexan-1-ol(2). 	To a solution of 6-aminohexan-1- 
ol (0.8 g, 6.8 mmol) in methanol (20 mL) was added I -fluoro-2,4-dinitrobenzene (1.3 g, I 
equiv.). After 12 h, the solvent was evaporated in vacua and the resulting oil was washed 
with ether to leave crude 2 (1.3 g, 70%). Recrystallisation from ether-methanol gave 2 
(1.04 g, 54%), m.p. 75°, R, 0.52 (solvent Q. F.a.b. mass spectrum: m/z 284.12462 [caic. 
for C12 H1 N3O5: (M + H) ml: 284.124631. 'H-N.m.r. data (CDCl): 6 1.1-2.0 (m, 9 H,4 
CH, and OH), 3.25-3.5 (m, 2 H, H-1,1), 3.64 (t, 2 H, J 6.2 Hz, H-6,6), 6.9 (d, 1 H, Ar 
H-6), 8.25 (dd, I H, Ar H-5), 8.5 (bs, I H, NH), 9.1 (d, I H, Ar H-3). 
Anal. Cale. for C12 H17N30: C, 50.88; H, 6.01; N, 14.84. Found: C, 50.40; H, 5.78; 
N, 14.70. 
2-Cyanoethi'/ 6- (2,4-dinitrophenvlanino)hexvl N,N-di-isopropylphosphoramidite 
(3). 	To a solution of 2 (140 mg, 0.495 mmol) in anhydrous tetrahydrofuran (5 mL) 
was added anhydrous N,N-di-isopropylethylarnine (0.1 mL, 1 equiv.) and 2-cyanoethyl 
N,N-di-isopropylphosphoramidochloridite (0.132 mL, 1.2 equiv.). After I h, the reac-
tion was quenched by the addition of ethyl acetate (20 mL), and the solution was washed 
with aqueous NaHCO3 (2 x 5 mL) and brine (2 x 5 mL), dried (Na,SO4), filtered, and 
evaporated in vacua. Flash-column chromatography (dichloromethane-ethyl acetate, 
1:1) of the residue gave an oil which was dissolved in dichioromethane and precipitated 
with anhydrous hexane to give 3 (100 mg, 80%) as an oil, R 0.8 (solvent fl. 31 P-N.m.r. 
data: 5 147.54 (s). 
I-(4,4'-Dimethoxrtrit),loxi')-6- (2,4-dinitrophenylamino)hexane. -To a solution 
of 2(1 g, 3.53 mmol) in anhydrous pyridine (15 mL) was added 4,4'-dimethoxytrityl 
chloride (1 equiv., 1.2 g). The mixture was protected from moisture and the reaction was 
complete after 1 h at 203. Water (150 mL) was added and the product was extracted into 
chloroform (3 x 30 rnL). The combined extracts were dried (Na2SO4) and filtered, and 
the solvent was evaporated in vacua. The product was purified by flash-column chroma-
tography (dichloromethane + 2% of triethylamine) to give the title compound isolated 
as an oil (1.24 g, 60%), R. 0.78 (solvent C); F.a.b. mass spectrum: ml: 585.24744 (calc. 
for C3 H35N 307: in!: 585.24748). H-N.m.r. data (CDC],): 6 1.0-3.5 (m, 12 H. 6 CH,), 
3.75 (s. 6 H. 2 OMe), 6.8 (rn, 4 H, Ar). 7.2-7.5 (m, 9 H, Ar and DNP H-6),8.25 (d, I H. 
DNP H-5), 8.5 (bs, I H, NH), 9.1 (d, I H, DNP H-3). 
36-Bis(2,4-dinitrophenvl)-3,6-clia:aoctane-1,8-diol (5). 	To a solution of 3,6- 
diazaoctane-1,8-diol (4; 1.5 g, 10 mmol) in methanol (30 mL) was added triethylamine 
(2.5 equiv., 2.53 g, 3.48 mL, 25 mmol) and 1 -fluoro-2,4-dinitrobenzene (2 equiv.. 3.72 g, 
20 mmol). After 3.5 h, the mixture was cooled to 0°, and the orange precipitate was 
collected, washed with methanol (30 mL) and ether (3 x 30 mL), and dried in vacua to 
give 5(3.89g. 81%). The product was recrystallised three times from methanol to give 5 
with m.p. 149-150, R 0.38 (solvent C). F.a.b. mass spectrum: m/z 481. 'H-Nm.r. data 
(CDCI3): 63.0-4.0 (m, 12 H, 6 CH,), 4.7 (t, 2 H, 2 OH), 7.33 (d, 2 H, J5,,9.5 Hz, DNP 
H-6), 8.13 (dd, 2 H. J 5 2.8 Hz, DNP H-5), 8.47 (d, 2 H. DNP H-3). 
Anal. Cale. for C1 H20N60: C, 45.0; H, 4.16; N, 17.5. Found: C, 44.8; H, 4.18; N, 
17.4. 
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8- (4,4'-Dimethoxytritvloxy)-3,6-bis(2,4-dinitrophenyl) -3,6-diazaoc tan- 1-ol (6a). 
Anhydrous pyridine (3 x 30 mL) was evaporated from 5(3.30 g, 6.88 mmol), which 
was then dissolved in anhydrous pyridine (60 mL). To this solution was added dropwise, 
during 30 mm, a solution of 4,4'-dimethoxytrityl chloride (1.3 equiv., 3.03 g, 8.94 mmol) 
in anhydrous pyridine (100 mL). After 2 h, more 4,4'-dimethoxytrityl chloride (0.2 
equiv., 0.47 g, 1.38 mmol) in anhydrous pyridine (20 mL) was added dropwise during 20 
min and, after a further 30 mm, the reaction was quenched with methanol (20 mL) and 
the solvent was evaporated in vacuo. A solution of the residue in dichlorornethane (250 
mL) was washed with saturated aqueous NaHCO1 (50 mL) and water (3 x 50 mL). The 
organic phase was dried (Na,SO4), filtered, and concentrated in vacuo. Column chroma-
tography (solvent A) of the residue gave amorphous 6a (1.68 g, 31 %),  R1 0.29 (solvent 
D), 0.58 (solvent E), and 0.35 (solvent A). F.a.b. mass spectrum: m/z 783.26259 [calc. for 
C39H39N6012 : (M + H) ml: 783.26257]. 'H-N.m.r. data (CDCI1): d 2.0-2.25 (bs, 1 H, 
OH), 3.25-3.72 (in, 12 H, 6 CH,), 3.73 (s, 6 H, 2 OCH3), 6.65-7,23 (m, 15 H, Ar and DNP 
H-6),8.06 (dd, 1 H,J65 9.3,J36 2.7 Hz, DNP H-5), 8.13 (dd, 1 H, DNP H-5),8.52 (d, I H, 
DNP H-3), 8.55 (d, I H, DNP H-3). 
2-Cyanoethyl [8- (4,4'-dimethoxyiritvloxy)-3,6-bis(2,4-dinitrophenyl) -3,6-diaza-
octyl] N,N-di-isopropylphosp/ioramidite (7). - Anhydrous tetrahydrofuran (3 x 20 
mL) was evaporated from 6a (0.643 g, 0.822 mmol) which was then dissolved in 
anhydrous tetrahydrofuran (30 mL). To this solution was added 
N,N-di-isopropylethylamine (4 equiv., 3.29 mmol, 0.425 g, 0.573 mL) and 2-cyanoethyl 
N,N-di-isopropylphosphoramidochloridite (1.5 equiv., 1.23 rnmol, 0.291g, 0.276 mL). 
The solution was stirred at 20 for 15 mm, quenched with ethyl acetate (30 mL), washed 
with brine (4 x 100 mL), dried (Na,SO4), filtered, and concentrated in vacuo. Column 
chromatography (solvent B) of the residue gave 7 as an oil, a solution of which, in the 
minimum volume of anhydrous dichloromethane, was added dropwise to anhydrous 
hexane (750 mL) at —78. The orange precipitate which formed was collected and 
washed with anhydrous hexane to give 7 (0.678 g, 84%), R, 0.50 (solvent B). F.a.b. mass 
spectrum: m/z 983.37044 [calc. for C48H 6N8O13P: (M + H) m/z 983.37042]. 31P-N.m.r. 
data (CDCI3): d 149.12 (s). 
Synthesis of DNP-labelled oligonucleotides. - Oligonucleotide synthesis was 
performed with an Applied Biosystems 381A DNA synthesiser, using the standard 
0.2-tmol-scale synthesis cycle. For the additions to the 5'-end of oligonucleotides, a 
0.I5M solution of 3 in anhydrous acetonitrile and a 0.15M solution of 7 in anhydrous 
dichloromethane were used. Ending procedures were carried out on an Applied Bio-
systems 380B DNA synthesiser. 
Degradation of 7-CTC GAG TAT GCC GAG A CC CCTAA T with ammonia. A 
solution of 6 o.d. units (A7M)  of the title compound in distilled water (200 jzL) was added 
to conc. ammonia (1.8 mL) in a sealed vial. Every hour, an aliquot (200 jL) was 
removed, diluted with 0.1M NH4OAc (700 pL), and analysed by h.p.l.c. 
Measurement of monomer coupling efficiencies. - Coupling efficiencies were 
measured by comparison of the absorbance at 498 nm of the 4,4'-dimethoxytrityl 
cations produced in the deprotection steps of successive synthesis cycles. Each fraction 
was diluted to 25 mL with 0.1M toluene-4-sulphonic acid in acetonitrile. 
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H.p/c. 	A Gilson 303 and a Perkin—Elmer 410 system were used with ABI 
aquapore octyl reversed-phase columns. The buffer systems were varied according to 
the number of DNP labels attached to the oligonucleotide. The general buffer systems 
were A, 0.1m NH4OAc; and B, 0.1m NH40Ac/X% of acetonitrile where 
30% <X <70%. The greater the number of DNP groups present, the higher the 
percentage of acetonitrile used in buffer B. These buffers were used (flow rate, 3 
mL/min) in combination with the following gradient to achieve the optimum separation 
for the sequence being examined: 
Time (mm) 	0 	3 	4 	26 	28 	29 	32 
Buffer B(%) 0 0 15 100 100 0 0 
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Attachment of Vitamin E Derivatives to Oligonucleotides during 
Solid-Phase Synthesis. 
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Abstract: Compounds have been synthesized which allow the attachment of Vitamin E to the 5'-, and 3-ends of oligonucleotides, 
and the attachment of a Vitamin E moiety on an octamethylene spacer to the 5-end, all during solid-phase synthesis. The effects on 
cellular uptake, distribution, and antiviral activity of the attachment of the extremely lipophilic Vitamin E moiety to 
phosphorothioate antisense' oligonucleotides are now being investigated. 
The use of antisense oligonucleotides as drugs to inhibit viral replication in cells has attracted great 
interest in recent years as the potential of this strategy has become apparent1. Some of the problems inherent in 
such a strategy have been solved but many difficulties remain. One of the major problems encountered is the 
low permeability of cell membranes to large, polyionic oligonucleotides. Attempts to increase the cellular 
uptake of antisense oligonucleotides by the conjugation of lipophilic molecules are well known. Such lipophilic 
molecules fall into two main groups: 
Those known to interact specifically with cell membranes. eg. cholesterol2-5 and certain lipids6. 
Those which impart general lipophilicity to the oligonucleotide. eg. alkyl chains7'8. 
Vitamin E (a-tocopherol) is an attractive candidate as a lipophilic carrier for the following reasons: 
It is inexpensive and essentially non-toxic. 
It has only one functional group for derivatization, the rest of the molecule is chemically inert. 
It is found mainly in association with membranes of subcellular organelles9, such as the endoplasmic 
reticulum and mitochondria, rather than in the plasma membrane. This maximizes the possibility of 
intracellular transport. 
In membranes, the phytyl chain of the Vitamin E is embedded in the membrane, with the phenolic 
hydroxyl group towards the surface10'11. Thus attachment of the oligonucleotide to the phenolic 
hydroxyl group should have a minimal effect on the interactions of the Vitamin E with membranes. 
2729 
2730 
Here we describe the synthesis of molecules which allow the attachment of Vitamin E to the 5'-, and 3-ends of 
oligonucleotides, and the attachment of a Vitamin E moiety via, an octamethylene spacer to the 5-end, during 
solid-phase synthesis. In all experiments DL-ct-tocopherol was used. 
Ift, Synthesis of Vitamin E derivatives, 
This was prepared by phosphitylation of Vitamin E with 2-cyanoethyl N,N-
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Scheme 1 
(b) Octainethylene-spaced Vitamin E phosphorarnidite 3 (Scheme 2). 
Vitamin E was reacted with commercially available l-Bromo-8-tetrahydropyranyloxyoctane (Lancaster) 
in DMSO in the presence of powdered KOH 12  to form the asymmetric ether 2. The THP protecting group was 
removed by treatment with aqueous HC1 in THF, and the resulting alcohol was phosphitylated. 
0_ 	J, O(CH2)8 ° 
2 	 (i) Aqueous HCI / THF 
Cl—P






(c) Vitamin E-derivatized Controlled PoreGlass (CPG). 5 (Scheme 3) 
Solketal was reacted with 4-toluene sulphonyl chloride in pyridine. The resulting tosyl solketal was 
reacted with Vitamin E in DMSO in the presence of powdered KOH 12  to form the asymmetric ether 4. The 
2731 
acetonide protecting group was removed by treatment with aqueous HC1 in THF, and the resulting alcohol was 
reacted with dimethoxytrityl chloride in pyridine. The remaining secondary alcohol was then reacted with 
succinic anhydride/ DMAP in pyridine. The resulting tritylated-succinylated Vitamin E solketal derivative was 




Aqueous RCI / THF 
DMTrCI I pyridine 
Succinic anhydride/ DMAP/ pyridine 
DCC/ 4-nitrophenoV Long-chain 






(2) Oligo icIeotide Synthesis. 
Normal and phosphorothioate13  Vitamin E derivatised oligonucleotides were synthesized on an Applied 
Biosystems 380B DNA synthesizer. 
For 3-Vitamin E oligonucleotides: 
- standard DNA and phosphorothioate synthesis cycles were used. 
For 5-Vitamin E oligonucleotides: 
-Phosphoramidites 1 and 3 were insoluble in acetonitrile and were used as 0. IM solutions in anhydrous 
dichloromethane, 
-Minor alterations to the synthesis cycles were required (the synthesis columns were washed with 
anhydrous dichloromethane before and after the coupling reaction to prevent precipitation). 
-Coupling efficiencies were >95% estimated by HPLC. 
2732 
Vitamin E oligonucleotides were stable in conc. aqueous ammonia at 550C for >24h (HPLC analysis) 
The extreme lipophilicity of Vitamin E oligonucleotides greatly facilitates reversed-phase HPLC (RP-
HPLC) purification, the products eluting approx. 15min later than all failure sequences in a gradient of 
acetonitrile in aqueous ammonium acetate. As the Vitamin E moiety is introduced during solid-phase synthesis 
with high efficiency the product is obtained in high yield. Vitamin E oligonucleotides were characterized by 
600MHz NMR spectroscopy. 
Failure seq. 	Product 
Figure 1: RP-HPLC trace of a crude 28mer phophorothioate with a 5-octamethylene spaced Vitamin E 
attached. 
Multi-milligram quantities of derivatives of a phosphorothioate 28mer antisense to a region near the start 
codon of the rev gene of HIV 14  have been synthesized with all three types of Vitamin E modification. These 
sequences are now being evaluated for anti-HIV activity in cell culture. 
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ABSTRACT 
A number of phosphoramidite monomers have been 
prepared and used in the synthesis of antisense 
phosphorothioate oligonucleotides bearing 5'-polyalkyl 
and cholesterol moieties. Similar groups have also 
been attached to the 3'-end of oligonucleotides by 
means of functionalised CPG. Melting temperatures of 
duplexes formed between phosphorothioate 
oligonucleotides with lipophilic end-groups and 
complementary DNA strands were found to be identical 
to those formed by the equivalent unmodified 
phosphorothioates. 
INTRODUCTION 
The use of antisense oligonucleotides and their analogues as 
highly specific inhibitors of gene expression and viral replication 
has attracted great interest in recent years (1, 2, 3). It has been 
possible to demonstrate reasonable inhibition in some cases, but 
the very high activity necessary for potential drug candidates has 
proved elusive. One of the major limitations is the low 
permeability of cell membranes to large polyanionic 
oligonucleotides. Cellular uptake of oligonucleotides has been 
shown to be poor (4) and this has been improved by the 
attachment of lipophilic groups that interact specifically with cell 
membranes, ie: cholesterol (5-9), vitamin E (10) and the 
1 ,2-di-O-hexadecyl-3-glyceryl group (11); or those which impart 
general lipophilicity to the oligonucleotide, eg. hydrocarbon 
chains (12,13). In addition to the antisense effect (7,11,12,13), 
oligonucleotides (18), particularly those bearing lipophiic groups, 
have been shown to be active as antiviral agents in a non-
sequence-dependent manner (7,8,11). The origin of this 
interesting effect is not well understood, but may arise by 
interactions of oligonucleotides with polymerases such as viral 
reverse transcriptases (7,8). An alternative explanation is that 
oligonucleotides interact with the surfaces of cells or virus 
particles and interfere with the process of infection (8). Whatever 
the mechanism, there is evidence that terminal hydrophobic 
groups may stabilise certain interactions of oligonucleotides and 
thereby increase the antiviral effect (7,8,11,12,13). 
There is a great deal of interest in oligonucleotides anti-HIV 
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activity and the region around the start codon of the rev gene 
of HIV-1 is a potential target for antisense drug therapy (14). 
The phosphorothioate 28 mer oligonucleotide Srev is 
complementary to a region from the 2nd to the 29th bases of 
the rev gene of HIV-l. 
Srev:d(TCG TCG CTG TCT CCG CTT CTT CCT GCC A) 
When present at a concentration of 10 ItM it inhibits gag p24 
glycoprotein synthesis by 50% in chronically infected H9 IIIB 
cells (14). Inhibition of rev protein synthesis leads to extensive 
splicing of the full-length HIV m-RNA transcript thus causing 
a switch from the synthesis of structural proteins to regulatory 
proteins. The degree of inhibition of the normally abundant p24 
glycoprotein therefore gives a convenient measure of the efficacy 
of anti-rev antisense oligonucleotides. Cellular uptake of Srev 
is not good (4) and this is an obvious area in which significant 
improvements can be made. In general, the quest for 
oligonucleotides with improved antisense activity should take into 
account the problem of transport through cell membranes. Here 
we describe the synthesis of oligonucleotides with terminal 
lipophilic groups which are designed to improve cellular uptake. 
Ultraviolet melting studies on duplexes formed between 
phosphorothioate oligonucleotides containing lipophilic end-
groups and complementary DNA strands have been carried out 
and several compounds have been evaluated for their ability to 
inhibit the proliferation of HIV-1 in chronically infected 
lymphoblastoid T-cells. Results of anti-HIV testing will be 
reported separately. 
RESULTS AND DISCUSSION 
Synthesis of hydrophobic monomers and incorporation into 
oligonucleotides 
The solid-phase synthesis of a series of modified phosphorothioate 
oligonucleotide analogues of Srev bearing the following terminal 
hydrophobic moieties has been achieved: (i) 3'-and 5'-cholesteryl 
with and without spacer arms; (ii) 1 ,2-di-O-hexadecyl-glyceryl; 
(iii) 5'- and 3'- hexadecyl; (iv) 5'-octadecyl bearing a hydroxyl 
group on C2; and (v) the 5'-(l-adamantylethyl) group. 
Oligonucleotides bearing such groups have been studied 
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previously in various biological systems and according to 
published work (5,11,12,13) they should be taken up by cells 
more readily than standard phosphorothioates. This is particularly 
true of those containing groups (i) and (ii) which are constituents 
of cell membranes (17) and oligonucleotides bearing these groups 
may be actively transported into cells by low density lipoproteins. 
All lipophilic groups in this study were attached to the 
oligonucleotides during solid-phase synthesis by the 
phosphoramidite method. This strategy is more practical and 
convenient for large scale oligonucleotide synthesis than carbodi-
imide coupling reactions (5) or oxidative amination (7). It also 
gives higher yields than the H-phosphonate method (11). 
Cholesterol monomers 
Previously cholesterol has been attached directly to the 
5'-phosphate of oligonucleotides either post-synthetically (5) or 
during oligonucleotide synthesis using H-phosphonate chemistry 
(8). It has also been joined to the 3'-phosphate via a short 
carboxyaminoethyl linker (7) or a rigid 5-(hydroxymethyl)-(3R-
trans)-3-pyrrolidinol linker (9) or as a carbamate at the N(6)-
position of adenosine linked to CPG (6). The nature and position 
of attachment of cholesterol may influence the ability of the 
modified oligonucleotide to transverse cell membranes or to 
hybridise efficiently to mRNA. Therefore, in this study we elected 
to attach cholesterol to the 3'- and 5'-ends of oligonucleotides 
by linkers of various lengths. 
In the first example, reaction of cholesterol [la] with 
2-cyanoethyl-N ,N-diisopropylphosphoramidochloridite yielded 
the monomer [th] which was used for direct attachment of 
cholesterol to the 5'-end of oligonucleotides during solid-phase 
synthesis. Solid-phase sulphurisation of the phosphite group 
between the 5'-cholesterol and the adjacent thymidine with 
tetraethyl thiuram disulphide (TETD) was unsuccessful, 
presumably due to extreme steric hindrance. However, treatment 
with iodine in tetrahydrofuran and pyridine resulted in clean 
oxidation to give a phosphotriester linkage. The solid-phase 
synthesis of 5 '-Ch-Srev proceded smoothly and the product 
contained the correct ratio of phosphorothioate to phosphate 
groups (27:1) as confirmed by 600MHz 3 1  P n.m.r. A monomer 
was also prepared for the attachment of cholesterol to the 5'-end 
of oligonucleotides via a hexamethylene spacer. Thus, reaction 
of cholesterol-3-chloroformate [id] with aminohexanol gave the 
cholesterol derivative [id] with a carbamate linkage, a hexyl chain 
and a free terminal hydroxyl group. Phosphitylation of [id] 
yielded the phosphoramidite monomer [le] which was dissolved 
in dichloromethane and used to synthesise 5'-Ch-C6-Srev. 
Suiphurisation of the unhindered phosphite group at the 3'-side 
of this monomer proceeded smoothly. For attachment of 
cholesterol to the 3'-end of oligonucleotides, tosylation of 
cholesterol and reaction of the tosylate [if] with the sodium salt 
of solketal gave one major product, the solketal derivative of 
cholesterol [ig] in reasonable yield. The n.m.r. spectrum of [ig] 
is consistent with a diastereomeric mixture due to the use of 
racemic solketal. The spectrum also reveals that elimination of 
the tosyl group to give [ig] proceeds principally with retention 
of configuration, as the proton in the 3-position of cholesterol 
is axial, with large coupling constants (J= 11.3Hz) to 
neighbouring axial cholesterol protons. We were unable to resolve 
the diastereomers on t.l.c.. Deprotection of the acetonide gave 
[ih] which was dimethoxytritylated to give [ij] and succinylated 
to give [1k].  The succinate [1k] was used to prepare cholesterol-
CPG which was employed in the synthesis of 3'-Ch-Srev. 
Sulphurisation of the phosphite group on the 5'-side of this 
monomer during oligonucleotide synthesis was not possible, but 
prolonged oxidation with iodine (1 hour) was successful and did 
not give undesirable side-reactions. The glyceryl backbone has 
been used previously for the attachment of multiple reporter 
groups to oligonucleotides (22). 
Other lipophilic monomers 
The 1 ,2-Di-O-hexadecyl-3-glyceryl group, when attached to the 
5'-end of oligonucleotides with normal backbones has been shown 
to greatly increase oligonucleotide uptake and antiviral activity 
in L929 cells infected with VSV (11). Previously the group was 
added as an H-phosphonate monomer but in the present study 
we decided to use phosphoramidite chemistry throughout in order 
to obtain higher yields of oligonucleotides. Thus, I ,2-di-hexadecyl 
glycerol was converted to the monomer [2] for use in 
oligonucleotide synthesis. Addition of the monomer [2] to the 
5 '-terminus of the oligonucleotide chain during solid-phase 
synthesis was followed by an iodine oxidation. Thus, 
5'-(Cl6)2-Glyc-Srev was readily prepared by this method. 
Monomers bearing a Cl 6 hydrocarbon chain were prepared and 
attached to oligonucleotides as follows: The monomer [3b] was 
prepared by dimethoxytritylation and phosphitylation of I, 
2-octadecanediol and was added to the 5'-end of Srev to give 
C18-Srev. This monomer and the phosphoramidite [4b], can, 
if desired, be added at any position in an oligonucleotide chain, 
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Figure 1. Cholesterol attachment to oligonucleotides. 
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although this has not yet been done. When [4b] is incorporated 
within an oligonucleotide, the entire polyalkyl chain forms part 
of the backbone, whereas in the case of [3b] an ethylene chain 
is incorporated in the backbone and a C16 hydrocarbon chain 
extends from the side. A 3'-C16 hydrocarbon chain can be added 
to oligonucleotides using CPG functionalised with the succinate 
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prepared using [4b] and [4c]. An ethyl-spaced adamantane 
phosphoramidite [5] was prepared by phosphitylation of 
(1 -adamantane)ethan-2-ol. This was used to add an adamantyl-
ethyl group to the 5'-end of Srev to give 5'-AdaC2-Srev. It was 
apparent from reversed-phase H. P.L.C. that the adamantylethyl 
modified oligonucleotide was much less lipophilic than the other 
modified oligonucleotides prepared in this study. 
Synthesis of oligonucleotides with cleavable lipophilic groups 
Oligonucleotides attached to lipophiic groups may be sequestered 
in cell membranes and could therefore become unavailable for 
binding to viral m-RNA. To address this potential problem we 
synthesised a number of oligonucleotides attached to lipophilic 
groups by a tetrathymidine (T4) linker. Normal phosphodiester 
bonds are degraded by nuclease enzymes in cells and serum, so 
the T4 linker will be slowly cleaved to release the 
oligonucleotide from the lipophilic moiety in vivo. It is possible 
that a biodegradable linker of this type might confer certain 
advantages to antisense oligonucleotides. 
Ultraviolet oligonucleotide denaturation studies 
Terminal lipophilic groups have variously been reported to 
increase (9,16), decrease (7,11,15) or to have no effect (7) on 
oligonucleotide duplex stability. We have measured the ultraviolet 
melting temperatures of several lipophilic Srev derivatives 
hybridised to a complementary DNA template with four 
overhanging nucleotides at the 3'- and 5'-ends of the template 
corresponding to part of the rev gene. The overhangs in the 
template strand are included to give a closer approximation to 
the situation in vivo where the antisense oligonucleotide hybridises 
to a much longer strand of m-RNA. This is an important 
consideration, as the effects of the lipophilic groups cannot be 
properly evaluated unless the overhangs are present. The 
ultraviolet melting temperature of the underivatised Srev 28mer 
hybridized to the complementary DNA 36mer template was 
determined over a 20-fold concentration range and used as a 
control. In all cases we found that the stability of the duplex was 
essentially unaffected by the presence of lipophilic groups (Table 
1). The discovery that such bulky groups do not destabilise nucleic 
acid duplexes is important in the context of hybridisation to 
mRNA. 
CONCLUSION 
A number of phosphorothioate oligonucleotide derivatives of Srev 
have been synthesised with lipophilic groups covalently attached 
to their 5'- and/or 3' -termini. Several such compounds have been 
tested for their ability to inhibit the proliferation of HIV- 1 virus 
in chronically infected H9 cells and the results of these studies 
will be published shortly. 
EXPERIMENTAL 
4a. R1= DmTr 





All solvents were of analytical grade. Alcohol free 
dichloromethane was prepared by distillation from CaH2, 
anhydrous tetrahydrofuran was purified by distillation from 
sodium/benzophenone, N,N-dimethylformamide by fractional 
distillation from 4A molecular sieve and pyridine by distillation 
from CaH2. Triethylamine and N,N-diisopropylethylamine were 
dried over CaH,. Anhydrous acetonitrile was purchased from 
Applied Biosystems, 2-cyanoethyl-N,N-diisopropylphosphor-
amidochioridite from Fluka, 1 ,2-octadecanediol from Lancaster 
4c. R1=DmTr 
OH 
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Figure 5. 
dried (Na2SO4 ) and concentrated in vacuo. The product was 
purified by silica-gel flash chromatography. 
General procedure 2-Phosphoramidite monomers for DNA 
synthesis 
Anhydrous dichloromethane was twice evaporated from the 
alcohol (0.5 mmol) which was then redissolved in anhydrous 
dichloromethane (3 ml). Di-isopropylethylamine (1.5 mmol) and 
2-cyanoethyl-N , N-diisopropylphosphoramidochloridite (0.7 
mmol) were added dropwise under an atmosphere of argon and 
after stirring for 1 hour the reaction was quenched with ethyl 
acetate (40 ml), washed briefly with brine (100 nil), dried 
(Na7SO4 , concentrated in vacuo and purified by flash 
chromatography on silica gel. 
Table 1. Ultraviolet melting temperatures of hydrophobic derivatives of Srev 
hybridised to a DNA template 
Sequence 	 Melting Temperature at 5.5 AM 
Srev 341.9°K (68.9°C) 
5'-Ch-T4Srev 342.2°K (69.2°C) 
5'-ChSrev 342.0°K (69.0°C) 
5'-Ch-C6Srev 341.5°K (68.5°C) 
5'-Cl8Srev 341.5°K (68.5°C) 
5'-Cl8-T3Srev 340.8°K (67.8°C) 
5'-(C16)2-GlycSrev 342.7°K (69.7°C) 
5'-Ad-C2-Srev 342.2°K (69.2°C) 
Conditions: Details in experimental Section. 
Srev = d(TCG TCG CTG TCT CCG CTT CIT CCT 0CC A)-phosphorothioate 
DNA Template = d(CCT ATG GCA GGA AGA AGC GGA GAC AGC GAC 
GAA GAC) 
Synthesis and all other chemicals were purchased from Aldrich. 
'HNMR spectra were recorded with Brucker WP-80 (80 MHz) 
and Brucker WP-200 (200MHz) spectrometers. 31 P-NMR 
spectra (81MHz) were recorded with the latter spectrometer 
F.a.b mass spectra (positive ion, thioglycerol matrix) were 
recorded on a Kratos MS50 TC spectrometer. Oligonucleotide 
synthesis was performed with an Applied Biosystems 380B DNA 
synthesiser. Standard cyanoethyl phosphoramidite monomers for 
DNA synthesis were supplied by Cruachem Ltd and were used 
at a concentration of 0. 1M in anhydrous acetonitrile. Sephadex 
G25 NAP columns (nucleic acid purification) were supplied by 
Pharmacia. Flash column chromatography was carried out using 
silica gel 60 (Fluka) and t.I.c. on silica-gel 60 F154, (Merck) 
using (A). ethyl acetate: methanol: cone aqueous ammonia. (5:1:1) 
(B). toluene:diethyl ether(4: 1). (C). hexane:diethyl ether (1:1), 
1 % of triethylamine. (D). toluene:diethyl ether (9:1). (E). 
toluene:diethyl ether (1:1). (F). hexane:ethyl acetate (1:1). (G). 
hexane: ethyl acetate (4: 1). 
Products were visualised on t.1.c. using either ultraviolet 
absorption at 264nm or phosphomolybdic acid (10%) in ethanol 
(dark blue colour for oxidisable compounds). 
General procedure 1-DMTr protected alcohols 
Anhydrous pyridine (5 ml) was evaporated from the primary 
alcohol (3.0 mmol) which was then redissolved in anhydrous 
pyridine (5 ml). To this solution was added with stirring 
4,4'-dimethoxytrityl chloride (3.6 mmol). After 1 hour the 
reaction was quenched with methanol (10 ml) and the solvent 
was evaporated in vacuo. The residue was dissolved in 
dichloromethane (100 ml), washed with saturated KC1 (20 ml), 
General procedure 3-Derivatisation of controled pore glass 
(CPG) solid support 
Preparation of the succinate monoester. Succinic anhydride 
(1. 1 mmol) was added in portions over a period of 30 minutes 
to a stirred solution of the alcohol (1.0 mmol) in anhydrous 
pyridine (2.5 ml) containing 4-dimethylaminopyridine (0.6 
mmol). The reaction was stirred overnight, dichloromethane (15 
ml) was added and the mixture was washed with water (15 ml), 
dried (Na2SO4) and concentrated in vacuo. The product was 
purified by flash chromatography on silica gel (system A). 
Coupling the succinate on to ('PG. To a solution of the 
succinate monoester (0.39 mmol) in anhydrous dichoromethane 
(2 ml) was added a solution of 4-nitrophenol (0.39 mmol, 54 
mg) in anhydrous pyridine (0.1 ml) followed by 
dicyclohexylcarbodiimide (0.94 mmol, 193 mg). After 10 minutes 
dicyclohexylurea precipitated from the reaction mixture and after 
2.5 hours this was removed by filtration. To the filtrate was added 
triethylamine (0.1 ml) and a suspension of CPG (0.5 g) in 
dimethylformamide (2 ml). The mixture was shaken overnight 
and a bright yellow colour developed due to the release of 
4-nitrophenol. The CPG was washed with N,N-
dimethylformamide (5 x 10 nil), dichloromethane (5 x 10 ml) and 
diethyl ether (5 x 10 ml) and then dried in vacuo. 
Capping of CPG. To a suspension of the functionalised resin 
in anhydrous tetrahydrofuran (4 ml) was added a 2M solution 
of l-n-iethylimidazole in tetrahydrofuran (0.75 ml) and a 1M 
solution of acetic anhydride in tetrahydrofuran (1.5 ml). The 
mixture was shaken for 2.5 hours and the CPG was collected 
by filtration, washed successively with tetrahydrofuran (5 x 10 
ml), dichloromethane (5>< 10 ml) and diethyl ether (5 X 10 ml) 
then dried in vacuo. 
3-Cholesteryl-2-cyanoethyl N,N-diisopropylphosphoramidite 
[ib] 
This compound was prepared from cholesterol [la] and 
2-cyanoethyl-N,N-diisopropylphosphorarnidochloridite according 
to general procedure 2. Purification by flash chromatography on 
silica gel (solvent B) gave [1b] (1.09 g, 72.0%), R 0.81, 
(solvent B) F.a.b. mass spectrum: rn/z 587 (M+H). 'H-N.m.r 
data (CDCI3): d 1.14-1.15 (d, J= 2.9Hz, 6H), 1.18-1.19 (d, 
J=2.9Hz, 6H), 2.60-2.66 (t, J=5.8Hz, 2H), 3.53-3.76 (m, 
2H), 3.78-3.86 (m, 2H), all additional signals correspond to 
the cholesteryl moiety. 
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Cholesterol-3-(carboxyaminohexan-6-ol) [id] 
Cholesteryl chioroformate [ic] (1.9 g, 4.2 mmol) and anhydrous 
triethylamine (0.43 g, 0.59 ml, 4.25 mmol) were dissolved in 
anhydrous dichloromethane (3 ml) and added to aminohexanol 
(0.50 g, 4.27 mmol) which had been coevaporated three times 
with anhydrous pyridine (7 ml). After stirring for 24 hours, 
dichloromethane (50 ml) was added and the resulting solution 
was washed with saturated NaHCO3 (20 ml), saturated KC1 
(2 x 20 ml) and water (20 ml), dried (Na2 SO4), filtered and 
concentrated in vacuo . The residue was dissolved in hexane:ethyl 
acetate (9:1) and purified by flash silica gel chromatography 
eluting with a gradient of 0% to 50% ethyl acetate in hexane, 
to give [id] as a white solid. (1.07 g, 47%). R-0.27 (solvent 
F). F.a.b mass spectrum: m/z 530.45730 [caic. for C34HNO3: 
(M+H), m/z 530.45729]. 3C-N.m.r. data: (CDC13): 8 11.68 
(CH3); 18.54 (CH3); 19.17 (CH3); 20.85 (CH2); 22.40 (CH3); 
22.67 (CH3); 23.66 (CH2); 24.11 (CH2); 25.13 (CH2); 26.21 
(CH2); 27.84 (CH); 28.05 (2CH2); 29.82 (CH2); 31.69 (CH, 
CH2); 32.38 (CH2); 35.63 (CH); 35.99 (CH2); 36.36 (C); 36.80 
(CH2); 38.40 (CH2); 39.33 (CH); 39.54 (CH); 40.50 (CH2); 
42.11 (C); 49.79 (CH); 55.92 (CH); 56.48 (CH); 62.46 (CH); 
74.02 (CH); 122.30 (CH3);  139.64 (C); 156.10 (C) 
Cholesteryl-3-carboxyaminohexyl-2-cyanoethyl N,N-
diisopropylphosphoramidite [le] 
Anhydrous dichloromethane (5 ml) was evaporated twice from 
cholesterol-3-carboxyaminohexan-6-ol (0.5 g; 9.44 mmol) which 
was then dissolved in anhydrous dichloromethane (5 ml). 
Diisopropylammonium tetrazolide (0.08 g; 4.72 mmol) was 
added slowly with stirring and when this had dissolved 
2-cyanoethyl N, N,N' ,N'-tetraisopropylphosphordiamidite 
(0.31 g; 0.33 ml; 1.03 mmol) was added. After 24 hours 
dichloromethane (50 ml) was added and the solution washed with 
saturated NaHCO3 (20 ml), saturated KCI (2x20 ml) and water 
(20 ml), dried (Na2SO4) filtered and concentrated in vacuo. The 
residual oil was dissolved in hexane:ethyl acetate (9:1) and 
purified on a silica gel flash chromatography column which had 
been pre-equilibrated with hexane:ethyl acetate: triethylamine 
(100:10:1). Elution with a gradient of 0% to 25% ethyl acetate 
in hexane gave [le] as a clear oil (0.27 g, 39%). Rf 0.62 
(solvent F). F.a.b. mass spectrum: m/z 729.55730 [calc. for 
C41H76N304P: (Mt) m/z 729.55731]. 31P N.m.r data (CDC13) 
d 147.67 (s). 
Cholesterol-3-(4-toluenesulphonate) [If] 
4-Toluenesulfonyl chloride (0.30 mol, 57 g) and cholesterol (0.21 
mol, 80 g) were dissolved in anhydrous chloroform (150 ml) and 
cooled in an ice bath. Anhydrous pyridine (1.0 mol, 80.6 g, 82.1 
ml) was added with stirring to maintain the temperature between 
0° and 3°C and the reaction was stirred for 16 hours at room 
temperature. A mixture of ice (200 g) and concentrated HCl (70 
ml) was then added and the organic phase was washed with water 
(100 ml), dried (Na2SO4) and concentrated in vacuo. The 
product was twice purified by silica gel flash chromatography 
eluting with toluene:hexane (8:3) to give [If] (61.4 g, 54%). Rf  
0.87 (solvent B). F.a.b. mass spectrum: m/z 539 (Mt). 
3-(2,3-Isopropylidene-1-glyceryl) cholesterol [ig] 
A mixture of rac-solketal (0.24 mol, 30 ml), 
cholesterol-3-(4-toluenesulphonate) (0.013 mol, 7.3 g), and 
sodium (0.065 mol, 1.5 g) in toluene (10 ml) was heated at 
120°C for 4 hours and stirred for a further 16 hours at 
room temperature. The solution was then washed with water 
(50 ml), dried (Na2SO4) and concentrated in vacuo. The 
residue was purified by flash chromatography on silica gel 
(solvent D) to give [ig] (3.65 g, 56.2%). Rf 0.41 (solvent D). 
F.a.b. mass spectrum: m/z 499 (Mt). 'H-N.m.r. data (CDC13): 
d 1.35 (s, 3H); 1.41 (s, 3H); 3.13-3.21 (tt, J=11.3Hz, ax-ax, 
ax-ax, J=4.4Hz, ax-eq, ax-eq, 1H, 3-chol); 3.40-3.45, 
(dd + dd, J jj =9.7Hz, Jj2'=6.OHz, 1H, Hi'); 3.55-3.60 
(dd+dd, Jj1 =9.7Hz, J j2 =5.6Hz, 1H, 112'); 3.70-3.74 
(dd+dd, J33 =8.2Hz, J32 =6.3Hz, 1H, H3'), 4.03-4.07 
(dd, J33 =8.2Hz, J3 ' 2.=6.3Hz, 1H, H3"), 4.19-4.26 
(quin, J21.133 =6.OHz, lH, H2'), all additional signals 
correspond to cholesteryl moiety. Compound is a mixture of 
diastereomers due to the use of racemic solketal. 
3-(1-glyceryl) cholesterol [lh] 
3-(2,3-Isopropylidene-1-glyceryl) cholesterol (2.92 mmol, 1.46 
g) was dissolved in 2N HCI:tetrahydrofuran (1:1) (30 ml) and 
set aside at room temperature for 2 hours. Absolute ethanol (12 
ml) was then added and the solvent was removed in vacuo. The 
residue was redissolved in absolute ethanol (12 ml) and 
concentrated in vacuo to give [lh] (1.11 g, 83%), Rf 0.13 
(solvent E). 'H-N.m.r data: 6 3.45-3.70 (m, 6H), 3.76-3.83 
(m, lH), all additional signals correspond to the cholesteryl 
moiety. 
3-[1-(4,4'-dimethoxytrityl)-3-glyceryl] cholesterol [lj] 
This compound was prepared by reaction of dimethoxytrityl 
chloride with [lh] according to general procedure 1 and was 
purified by flash chromatography on silica gel eluting with 
hexane:diethyl ether (2:3) with 1% triethylamine added. (1.49 
g, 81.3%). Rf 0.41 (solvent Q. mass spectrum: m/z 762 
(M+H))H-N.m.r data (CDC13) d 3.42-3.77 (m, 5H, 
glyceryl H-i and H-3, cholesteryl H-3), 3.78 (s, 6H, OMe), 
3.79-3.88 (m, lH, glyceryl H-2), 6.77-6.86 (m, 4H, trityl), 
7.15-7.34 (m, 7H, trityl), 7.39-7.45 (m, 211, trityl), all 
additional signals correspond to the cholesteryl moiety. 
Derivatisation of CPG with 3-[1-(4,4'-diinethoxytrityl)-2-
succinyl-3-glyceryl]cholesterol [1k] 
This coupling was achieved by reaction of [lj] with succinic 
anhydride according to general procedure 3 to yield 
3-[ 1 -(4,4'-dimethoxytrityl)-2-succinyl-3-glyceryl] cholesterol 
[1k]: 0.43 g (50.3%), Rf O.46 (solvent A). H-N.m.r. (CDC13): 
6 1.75-1.80(m, 2H), 2.67-2.70(m, 2H), 3.20-3.24(m, 2H), 
3.76 (s,314), 3.78 (s, 3H), 6.78-6.85 (m, 4H), 7.14-7.33 (m, 
711), 7.40-7.45 (m, 214), all additional signals correspond to 
the cholesteryl moiety. 
After coupling the amount of nucleoside covalently linked to 
CPG was found by dimethoxytrityl analysis to be 23.3 /Lmol/g 
2-cyanoethyl (1 ,2-di-O-hexadecyl-rac-3-glyceryl)-N,N-di-
isopropylphosphoramidite [2] 
This compound was prepared according to general procedure 2 
and was purified by flash chromatography on silica gel (solvent 
B) to give [2] (0.20 g, 58.9%). Rf O.82 (solvent B). F.a.b. mass 
spectrum: m/z 741 (M+H). 1 H-N.m.r data (CDC13) d 
0.83-0.90 (t, Jr=6.2 Hz, 6H), 1.15-1.16 (d, J= 1.3 Hz, 6H), 
1.18-1.19 (d, J=l.3 Hz, 611), 1.24(s, 30 H), 2.59-2.63 (t, 
J=5.9 Hz, 2H), 3.39-3.64 (m, 7H), 3.80-3.85 (m, 2H). 
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1-(4,4'-dimethoxytrityloxy) octadecan-2-oI [3a] 
This compound was prepared from I ,2-octadecanediol and 
4,4'-dimethoxytrityl chloride according to general procedure 1 
and was purified by flash chromatography on silica gel eluting 
with system C. (5.58 g , 90.4%). Rf O.S1 (solvent Q. F.a.b. 
mass spectrum m/z 588(M).'H-N.m.r. data (CDC13): ô 
0.92-0.98 (t, J=5.8 Hz, 311), 1.34 (s, 30 H), 2.58 (s, 1H), 
3.06-3.26 (m, 3H), 3.79 (s, 6H), 6.85-6.90 (d, J=8.9 Hz, 
4H), 7.22-7.42 (m, 7H), 7.49-7.50 (m, 211). 
2-Cyanoethyl [1-(4,4'-dimethoxytrityloxy) octadec-2-yl] N,N-
di-isopropylphosphoramidite [3b] 
This compound was prepared from 1-(4,4'-dimethoxytrityl-
oxy)octadecan-2-ol and 2-cyanoethyl-N,N-diisopropylphosphor-
amidochloridite according to general procedure 2 and was purified 
by flash chromatography on silica gel eluting with anhydrous 
hexane:toluene (1:1) with 1% triethylamine. Further purification 
was performed on a flash column eluting with anhydrous 
hexane:diethyl ether (1:1). 
Yield: 1.14 g (85.0%), T.l.c. (system C), Rf 0.58, 
200MHz-'H-NMR, d: 0.84-0.91 (t, J=6.iHz, 3H), 
1.03-1.20(m, 12H), 1.25(s, 30H), 2.35-2.41(t, J=6.7Hz, 2H), 
2.57-2.63(t, J=6.lHz, 211), 3.10-3.16(m, 3H), 3.54-3.77(m, 
211), 3.78(s, 6H), 3.79-3.87(m, 2H), 6.77-6.85(dd, J=8.9Hz, 
J=3.9Hz, 411), 7.18-7.36(m, 7H), 7.43 —7.48(m, 2H). Mass 
Spectrum (+FAB), m/z 789(M). 
1-(4,4'-dimethoxytrityloxy) hexadecan-16-ol [4a] 
This compound was prepared according to general procedure 1 
but with 5 equivalents of 1,1 6-hexadecanediol and 1 equivalent 
of dimethoxytrityl chloride. 
The product was purified by flash chromatography on silica 
gel eluting with hexane:diethyl ether (1:4) with 1 % triethylamine 
to give [4a] (0.58g, 70.1%). R1 0.l8 (solvent Q. F.a.b. mass 
spectrum: m/z 560 (Mt). 'H-N.m.r data (CDC13):  d 1.24 (s, 
28 H), 2.98-3.02 (m, 2H), 3.62-3.64 (m, 2H), 3.76 (s, 3H), 
3.78, (s, 3H), 6.77-6.83 (m, 4H), 7.22-7.34 (m, 
7H),7.41-7.47, (m, 2H). 
2-Cyanoethyl [1-(4,4'-dimethoxytrityloxy) hexadec-16-yl] N,N-
di-isopropylphosphoramidite [4b] 
This compound was prepared according to general procedure 2 
and was purified by flash chromatography on silica gel eluting 
with anhydrous hexane:diethyl ether (1:1) with 1% triethylamine. 
A second purification was performed eluting with hexane:diethyl 
ether (1:1) to give [4b] (0.41g, 68.2%). R1 O.52 (system Q. 
F.a.b. mass spectrum ,n/z 761 (M+H). 'H-NMR data 
(CDC13): a 1.24 (s, 28 H ,CH2), 1.56 (s, 12H, CH3), 
2.61-2.67 (m, 2H, cyanoethyl H-i), 2.98-3.05 (m, 2H, i-Pr 
CH), 3.51-3.68 (m, 4H, H-i, H-16), 3.78 (s, 6H, OMe), 
3.81-3.88 (m, 2H, cyanoethyl H-2), 6.79-6.94 (m, 4H, trityl), 
7.18-7.34 (m, 7H, trityl), 7.41 —7.45 (m, 2H, trityl). 
Derivatisation of CPG with 1-(4,4'-dimethoxytrityloxy) 
hexadecyl-16-succinate ['Ic] 
This coupling was achieved according to the general procedure 
3 to give ['Ic] (0.13 g, 55.5%). R10.43 (solvent A). F.a.b. mass 
spectrum: m/z 659 (Mt). 'H-N.m.r data (CDC13): d 1.24 (s, 
28H), 1.59-1.61 (m, 211), 2.62-2.65 (m, 2H), 2.98-3.05 (t, 
J=6.5 Hz, 2H), 3.78 (s, 6H), 4.04-4.11 (t, J=6.7 Hz, 2H), 
6.79-6.85 (m, 4H), 7.18-7.35 (m, 7H), 7.41-7.46 (m, 2H). 
After coupling, the amount of nucleoside covalently linked to 
CPG was found by dimethoxytrityl analysis to be 24.6 zmoI/g 
1-Adamantylethyl-2-cyanoethyl N,N-diisopropylphosphor-
amidite [5] 
To a solution of i-adamantylethan-2-ol (0.5 g, 2.77 mmol) in 
anhydrous tetrahydrofuran (1 Omi) was added N,N-diisopropyl-
ethylamine (4 equiv., 0.11 mol, 1.43 g, 1.93 ml) and 2-cyano-
ethyl-N,N-diisopropylphosphoramidochloridite (1.1 equiv., 3.05 
mmol, 0.72 g, 0.68 ml). After 5 minutes the reaction was 
quenched with anhydrous ethanol (1 ml) and dichloromethane 
(15 ml) was added. The mixture was washed with water (20 ml) 
and saturated KCI (2x20 ml), dried (Na2SO4), filtered and 
concentrated in vacuo. The product was purified by flash silica 
gel chromatography, on a column which had been pre-
equilibrated with hexane : ethyl acetate: triethylamine (100: 10: 1) 
Elution with hexane ethyl acetate (9:1) gave [5] as a clear liquid 
(0.72 g, 69%). Rf O.7O (solvent G). F.a.b. mass spectrum: m/z 
379.25142 calc. for C71H36N20,P (M+H) ,n/z 379.25143]. 
31P N.m.r data (CDC13): d 147.21 (s). 
Oligonucleotide synthesis 
Three 1.0 mmole scale syntheses were performed for each 
oligonucleotide using cyanoethyl phosphoramidite chemistry on 
an ABI 380B DNA synthesiser. For phosphorothioate 
oligonucleotide synthesis iodine was replaced by tetraethyl 
thiuram disulphide (TETD) (19). All lipophilic phosphoramidite 
monomers were used as 0.1M solutions in anhydrous 
dichloromethane. In order to increase the coupling yields of 
phosphoramidite monomers [ib], [2] and [3b] above 75%, 
coupling times were increased from the standard 40 seconds to 
4 minutes. In all cases an additional dichloromethane column 
wash before and after the coupling step was included in the 
synthesis cycle to prevent precipitation of the monomer and 
blockage of reagent lines. Sulphurisation was unsuccessful for 
compounds [ib], [2] and [3b], and for 3'-cholesterol 
oligonucleotides, so the suiphurisation step was replaced with 
an iodine oxidation step lasting 10 mm. The trityl-ON 
configuration was used throughout and all oligonucleotides were 
obtained in quantities in excess of 10 mg after full purification. 
Oligonucleotide purification 
After deprotection with concentrated ammonium hydroxide, 
oligonucleotides were dried under a stream of argon, dissolved 
in H.P.L.C. buffer A (below) and purified by reversed-phase 
H.P.L.C. using a Brownlee Aquapore Octyl reverse phase 
column (10 min x250 mm) with a flow rate of 3 ml/minute and 
the following gradient: 








Buffer A: 0.IM NH40Ac. Bu'r B: 0.IM NH40Ac with 60% acetonitrile. 
*For oligonucleotides containing the adamantaneethyl group the step at 19 minutes 
was omitted to produce a shallower gradient. 
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The desired products elute at 100% B, several minutes after 
the failure sequences. Where appropriate the H.P.L.C. purified 
oligonucleotides were detritylated in 80% acetic acid for 30 
minutes. After evaporation to remove the solvent, 
oligonucleotides were further purified twice by gel-filtration using 
Sephadex NAP-10 columns (Pharmacia) and were then 
lyophilised. Purified water (purified by reverse osmosis) was used 
for all stages of purification after H.P.L.C. 
Ultraviolet melting studies 
Ultraviolet melting temperatures were determined at 260 nm on 
a Perkin-Elmer Lambda 15 ultraviolet spectrometer equipped with 
a Peltier block and controlled by an IBM PS2 microcomputer. 
A heating rate of 0.9 K per minute was used throughout and the 
crude data were collected and processed using the PECSS-2 
software package. The oligonucleotides were dissolved in a buffer 
consisting of aqueous sodium chloride (0.1 M), sodium 
dihydrogen orthophosphate (0.01 M), sodium cacodylate (0.02 
M) and EDTA (1 mM) adjusted to pH 7.0 by the addition of 
sodium hydroxide. Concentrations of normal oligonucleotide 
templates were determined by dissolving the sample in a buffer 
consisting of NaCl (0.1 M) and Tris.HCI (10 mM) at pH 8.7 
and maintaining this at 37°C in the presence of 0.1 mg of 
phosphodiesterase I and 0.1 mg of alkaline phosphatase until 
complete digestion gave rise to maximum ultraviolet absorbance 
(< 1 day). Published E260 values of the nucleosides were used 
as standards (21). As phosphorothioate oligonucleotides are 
resistant to enzymic digestion, their concentrations were estimated 
by measuring the U.V. absorbance of the intact oligonucleotide 
and multiplying this by a factor equivalent to the proportional 
increase in U.V. absorbance obtained by digestion of a normal 
oligonucleotide of the same base sequence. Melting temperatures 
of lipophilic derivatives of Srev hybridised to a normal DNA 
template with four overhanging bases at both the 3'-, and 5 '-end 
were measured and compared with the ultraviolet melting 
temperature of underivatised Srev hybridised to the same DNA 
template. The T. of Srev was measured at eight points over a 
20-fold concentration range (each point measured in triplicate) 
and thermodynamic parameters were determined by standard 
methods (20). 
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